



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Deferasirox for managing iron overload in people with thalassaemia (Review)

Bollig C, Schell LK, Rucker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ

Bollig C, Schell LK, Rucker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.  
Deferasirox for managing iron overload in people with thalassaemia.  
*Cochrane Database of Systematic Reviews* 2017, Issue 8. Art. No.: CD007476.  
DOI: [10.1002/14651858.CD007476.pub3](https://doi.org/10.1002/14651858.CD007476.pub3).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER .....	1
ABSTRACT .....	1
PLAIN LANGUAGE SUMMARY .....	2
SUMMARY OF FINDINGS .....	4
BACKGROUND .....	14
OBJECTIVES .....	15
METHODS .....	15
RESULTS .....	19
Figure 1. ....	20
Figure 2. ....	24
Figure 3. ....	25
DISCUSSION .....	36
AUTHORS' CONCLUSIONS .....	39
ACKNOWLEDGEMENTS .....	39
REFERENCES .....	40
CHARACTERISTICS OF STUDIES .....	50
DATA AND ANALYSES .....	87
Analysis 1.1. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 1 Mortality at any time point. ....	88
Analysis 1.2. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 2 AEs. ....	88
Analysis 1.3. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 3 Discontinuations due to serious AEs. ....	89
Analysis 2.1. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 1 Mortality at any time point. ....	99
Analysis 2.2. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 2 LVEF (%): least squares mean change from baseline. ....	100
Analysis 2.3. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 3 LVEF (# participants affected). ....	101
Analysis 2.4. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 4 Incidence of thyroid disease at end of study. ....	101
Analysis 2.5. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 5 ALT (# participants affected): improvement from abnormal to normal range. ....	101
Analysis 2.6. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 6 ALT (U/L) at end of study. ....	101
Analysis 2.7. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 7 AST (U/L) at end of study. ....	101
Analysis 2.8. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 8 Serum creatinine (mg/dL) at end of study. ....	102
Analysis 2.9. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 9 Blood urea (mg/dL): mean at end of study. ....	102
Analysis 2.10. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 10 Serum ferritin (ng/mL): mean change from baseline and at end of study. ....	102
Analysis 2.11. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 11 Sensitivity analysis: serum ferritin (ng/mL): mean change from baseline. ....	103
Analysis 2.12. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 12 Liver R2* (Hz): mean change from baseline. ....	104
Analysis 2.13. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 13 LIC (mg/g) evaluated by MRI (R2/R2*): mean change from baseline. ....	104
Analysis 2.14. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 14 LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline. ....	104
Analysis 2.15. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 15 Responder analysis I (responder: fall in LIC > 10%). ....	105
Analysis 2.16. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 16 Responder analysis II (responder: LIC 1 to < 7 mg Fe/g dw). ....	105

Analysis 2.17. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 17 Myocardial T2* (ms): mean change from baseline. ....	106
Analysis 2.18. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 18 Myocardial iron concentration derived from T2* value (mg Fe/g dw): change from baseline. ....	106
Analysis 2.19. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 19 Myocardial T2* (# participants affected). ....	106
Analysis 2.20. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 20 Iron excretion-intake ratio. ....	107
Analysis 2.21. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 21 Any serious AEs (# participants affected). ....	108
Analysis 2.22. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 22 Serious AEs. ....	108
Analysis 2.23. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 23 Any AE (# participants affected). ....	110
Analysis 2.24. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 24 AEs. ....	110
Analysis 2.25. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 25 Any drug-related AE (# participants affected). ....	116
Analysis 2.26. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 26 Drug-related AEs. ....	116
Analysis 2.27. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 27 Satisfaction with treatment (very satisfied or satisfied). ....	118
Analysis 2.28. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 28 Convenience (good or very good). ....	118
Analysis 2.29. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 29 Willingness to continue treatment. ....	119
Analysis 2.30. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 30 Time lost from normal activities due to treatment (hours/month): participants treated previously with DFO. ....	119
Analysis 2.31. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 31 Adherence (% of planned dose). ....	120
Analysis 2.32. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 32 Discontinuations. ....	120
Analysis 2.33. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 33 Dose adjustments and dose interruptions. ....	121
Analysis 2.34. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 34 Dose interruptions (interrupted at least once). ....	121
Analysis 2.35. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 35 Dose reduction (at least once). ....	122
Analysis 2.36. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 36 Dose adjustments (# participants affected). ....	122
Analysis 2.37. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 37 Dose interruptions due to an AE (# participants affected). ....	122
Analysis 2.38. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 38 Haemoglobin (g/dL): mean change from baseline and at end of study. ....	122
Analysis 2.39. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 39 Transfusion index (mL/kg/year): mean at end of study. ....	123
Analysis 2.40. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 40 Transferrin saturation (%): mean at end of study. ....	123
Analysis 2.41. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 41 Platelet count ( $\times 10^3/\text{mm}^3$ ): mean at end of study. ....	123
Analysis 2.42. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 42 Absolute neutrophilic count ( $/\text{mm}^3$ ): mean at end of study. ....	123
Analysis 3.1. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 1 Mortality at any time point. ....	125
Analysis 3.2. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 2 Incidence of thyroid disease at end of study. ....	126
Analysis 3.3. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 3 ALT (U/L): mean change from baseline. ....	126

Analysis 3.4. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 4 AST (U/L): mean change from baseline. ....	126
Analysis 3.5. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 5 Urea (mg/dL): mean change from baseline. ....	127
Analysis 3.6. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 6 Creatinine (mg/dL): mean change from baseline. ....	127
Analysis 3.7. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 7 Neutrophil (count per mm <sup>3</sup> ): mean change from baseline. ....	127
Analysis 3.8. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 8 Serum ferritin (ng/mL): mean change from baseline and at end of study. ....	127
Analysis 3.9. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 9 LIC (mg/g) evaluated by MRI (R <sup>2</sup> *): mean change from baseline. ....	128
Analysis 3.10. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 10 Myocardial T2* (ms): mean change from baseline. ....	128
Analysis 3.11. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 11 Any AE (# participants affected). ....	128
Analysis 3.12. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 12 AEs. ....	128
Analysis 3.13. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 13 Discontinuations (# participants affected). ....	129
Analysis 3.14. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 14 Discontinuation due to an AE (# participants affected). ....	130
Analysis 3.15. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 15 Transferrin saturation (%): mean at end of study. ....	130
Analysis 3.16. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 16 Haemoglobin (g/dL): mean at end of study. ....	130
Analysis 3.17. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 17 Transfusion index (mL/kg/year): mean at end of study. ....	130
Analysis 3.18. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 18 ALP (U/L): mean change from baseline. ....	130
Analysis 6.1. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 1 Mortality at any time point. ....	131
Analysis 6.2. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 2 Neutrophil (µg/L): mean at end of study. ....	131
Analysis 6.3. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 3 ALT (g/dL): mean at end of study. ....	132
Analysis 6.4. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 4 AST (g/dL): mean at end of study. ....	132
Analysis 6.5. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 5 Serum ferritin: mean at end of study (ng/mL). ....	132
Analysis 6.6. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 6 Discontinuations. ....	132
Analysis 6.7. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 7 Haemoglobin (g/dL): mean at end of study. ....	132
Analysis 6.8. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 8 ALP (g/dL): mean at end of study. ....	133
Analysis 7.1. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 1 Mortality at any time point. ....	135
Analysis 7.2. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 2 Serum ferritin (ng/mL): mean change from baseline. ....	135
Analysis 7.3. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 3 LIC (mg/g) evaluated by MRI (R <sup>2</sup> *): mean change from baseline. ....	135
Analysis 7.4. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 4 Myocardial T2* (ms): mean change from baseline. ....	135
Analysis 7.5. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 5 Serious AE (# participants affected). ....	135

Analysis 7.6. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 6 Serious drug-related AE (# participants affected). . . . .	136
Analysis 7.7. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 7 Serious non-related drug AE. . . . .	136
Analysis 7.8. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 8 AEs. . . . .	136
Analysis 7.9. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 9 Drug-related AEs (# participants affected). . . . .	136
Analysis 7.10. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 10 Drug-related AEs. . . . .	136
Analysis 7.11. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 11 Non-related drug AEs (# participants affected). . . . .	137
Analysis 7.12. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 12 Non-related drug AEs. . . . .	137
Analysis 7.13. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 13 Mild elevation of hepatic transaminases at start of therapy (# participants affected). . . . .	138
Analysis 7.14. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 14 Initial gastrointestinal manifestations (# participants affected). . . . .	138
Analysis 7.15. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 15 Quality of life (%) (measured by SF-36): mean change from baseline. . . . .	138
Analysis 7.16. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 16 Adherence: actual dose/total prescribed dose. . . . .	138
Analysis 7.17. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 17 Discontinuations. . . . .	138
Analysis 7.18. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 18 Serious AE resulting in study discontinuation or interruption. . . . .	139
Analysis 8.1. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 1 Mortality at any time point. . . . .	143
Analysis 8.2. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 2 Serum ferritin (ng/mL): mean change from baseline. . . . .	144
Analysis 8.3. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 3 LIC (mg Fe/g dw) evaluated by MRI R2: least squares mean change from baseline. . . . .	144
Analysis 8.4. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 4 LIC (mg Fe/g dw) evaluated by MRI R2: mean change from baseline. . . . .	145
Analysis 8.5. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 5 LIC: decrease of $\geq 3$ mg Fe/g dw (# participants affected). . . . .	146
Analysis 8.6. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 6 LIC: $\geq 30\%$ reduction Fe/g dw (# participants affected). . . . .	146
Analysis 8.7. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 7 LIC: shift to lower iron burden range (# participants affected). . . . .	147
Analysis 8.8. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 8 LIC: achieve LIC $< 5$ mg Fe/g dw (# participants affected). . . . .	147
Analysis 8.9. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 9 Drug-related serious AEs (# participants affected). . . . .	148
Analysis 8.10. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 10 Drug-related serious AEs (# participants affected). . . . .	148
Analysis 8.11. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 11 Any AE (# participants affected). . . . .	148
Analysis 8.12. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 12 Mild AE (# participants affected). . . . .	149
Analysis 8.13. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 13 Moderate AE (# participants affected). . . . .	149
Analysis 8.14. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 14 Severe AE (# participants affected). . . . .	149
Analysis 8.15. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 15 AEs. . . . .	149
Analysis 8.16. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 16 Drug-related AEs. . . . .	150

Analysis 8.17. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 17 Adherence (# participants taking the planned study dose). .....	151
Analysis 8.18. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 18 Discontinuations. .	151
Analysis 8.19. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 19 Discontinuing study due to AE (# participants affected). .....	151
Analysis 8.20. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 20 Dose increase. ....	152
Analysis 8.21. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 21 Dose interruption (at least once). .....	152
Analysis 8.22. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 22 Dose reduction. ...	153
Analysis 8.23. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 23 Dose reduction due to AE. ....	153
Analysis 8.24. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 24 Haemoglobin (g/L): mean change from baseline. ....	154
Analysis 8.25. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 25 Transferrin saturation (%): mean change from baseline. ....	154
APPENDICES .....	155
WHAT'S NEW .....	163
HISTORY .....	164
CONTRIBUTIONS OF AUTHORS .....	164
DECLARATIONS OF INTEREST .....	165
SOURCES OF SUPPORT .....	165
DIFFERENCES BETWEEN PROTOCOL AND REVIEW .....	165
INDEX TERMS .....	165

[Intervention Review]

# Deferasirox for managing iron overload in people with thalassaemia

Claudia Bollig<sup>1</sup>, Lisa K Schell<sup>2</sup>, Gerta Rücker<sup>3</sup>, Roman Allert<sup>4</sup>, Edith Motschall<sup>5</sup>, Charlotte M Niemeyer<sup>6</sup>, Dirk Bassler<sup>7</sup>, Joerg J Meerpohl<sup>1</sup><sup>1</sup>Cochrane Germany, Medical Center – Univ. of Freiburg, Faculty of Medicine, Univ. of Freiburg, Freiburg, Germany. <sup>2</sup>Cologne, Germany.<sup>3</sup>Institute for Medical Biometry and Statistics, Faculty of Medicine and Medical Center – University of Freiburg, Freiburg, Germany.<sup>4</sup>Department of Obstetrics and Gynaecology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany. <sup>5</sup>Center for Medical Biometry and Medical Informatics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.<sup>6</sup>Pediatric Hematology & Oncology, Center for Pediatrics & Adolescent Medicine, University Medical Center Freiburg, Freiburg, Germany.<sup>7</sup>Department of Neonatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland**Contact address:** Joerg J Meerpohl, Cochrane Germany, Medical Center – Univ. of Freiburg, Faculty of Medicine, Univ. of Freiburg, Breisacher Straße 153, Freiburg, 79110, Germany. [meerpohl@cochrane.de](mailto:meerpohl@cochrane.de), [joerg.meerpohl@uniklinik-freiburg.de](mailto:joerg.meerpohl@uniklinik-freiburg.de).**Editorial group:** Cochrane Cystic Fibrosis and Genetic Disorders Group.**Publication status and date:** New search for studies and content updated (no change to conclusions), published in Issue 8, 2017.**Citation:** Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ. Deferasirox for managing iron overload in people with thalassaemia. *Cochrane Database of Systematic Reviews* 2017, Issue 8. Art. No.: CD007476. DOI: [10.1002/14651858.CD007476.pub3](https://doi.org/10.1002/14651858.CD007476.pub3).

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.

## ABSTRACT

### Background

Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long-term complications.

Both deferoxamine and deferiprone are effective; however, a review of the effectiveness and safety of the newer oral chelator deferasirox in people with thalassaemia is needed.

### Objectives

To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload.

### Search methods

We searched the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 12 August 2016.

We also searched MEDLINE, Embase, the Cochrane Library, Biosis Previews, Web of Science Core Collection and three trial registries: ClinicalTrials.gov; the WHO International Clinical Trials Registry Platform; and the Internet Portal of the German Clinical Trials Register: 06 and 07 August 2015.

### Selection criteria

Randomised controlled studies comparing deferasirox with no therapy or placebo or with another iron-chelating treatment.

### Data collection and analysis

Two authors independently assessed risk of bias and extracted data. We contacted study authors for additional information.

### Main results

Sixteen studies involving 1807 randomised participants (range 23 to 586 participants) were included. Twelve two-arm studies compared deferasirox to placebo (two studies) or deferoxamine (seven studies) or deferiprone (one study) or the combination of deferasirox and deferoxamine to deferoxamine alone (one study). One study compared the combination of deferasirox and deferiprone to deferiprone

in combination with deferoxamine. Three three-arm studies compared deferasirox to deferoxamine and deferiprone (two studies) or the combination of deferasirox and deferiprone to deferiprone and deferasirox monotherapy respectively (one study). One four-arm study compared two different doses of deferasirox to matching placebo groups.

The two studies (a pharmacokinetic and a dose-escalation study) comparing deferasirox to placebo ( $n = 47$ ) in people with transfusion-dependent thalassaemia showed that deferasirox leads to net iron excretion. In these studies, safety was acceptable and further investigation in phase II and phase III studies was warranted.

Nine studies (1251 participants) provided data for deferasirox versus standard treatment with deferoxamine. Data suggest that a similar efficacy can be achieved depending on the ratio of doses of deferoxamine and deferasirox being compared. In the phase III study, similar or superior efficacy for the intermediate markers ferritin and liver iron concentration (LIC) could only be achieved in the highly iron-overloaded subgroup at a mean ratio of 1 mg of deferasirox to 1.8 mg of deferoxamine corresponding to a mean dose of 28.2 mg per day and 51.6 mg per day respectively. The pooled effects across the different dosing ratios are: serum ferritin, mean difference (MD) 454.42 ng/mL (95% confidence interval (CI) 337.13 to 571.71) (moderate quality evidence); LIC evaluated by biopsy or SQUID, MD 2.37 mg Fe/g dry weight (95% CI 1.68 to 3.07) (moderate quality evidence) and responder analysis, LIC 1 to < 7 mg Fe/g dry weight, risk ratio (RR) 0.80 (95% CI 0.69 to 0.92) (moderate quality evidence). The substantial heterogeneity observed could be explained by the different dosing ratios. Data on mortality (low quality evidence) and on safety at the presumably required doses for effective chelation therapy are limited. Patient satisfaction was better with deferasirox among those who had previously received deferoxamine treatment, RR 2.20 (95% CI 1.89 to 2.57) (moderate quality evidence). The rate of discontinuations was similar for both drugs (low quality evidence).

For the remaining comparisons in people with transfusion-dependent thalassaemia, the quality of the evidence for outcomes assessed was low to very low, mainly due to the very small number of participants included. Four studies (205 participants) compared deferasirox to deferiprone; one of which (41 participants) revealed a higher number of participants experiencing arthralgia in the deferiprone group, but due to the large number of different types of adverse events reported and compared this result is uncertain. One study (96 participants) compared deferasirox combined with deferiprone to deferiprone with deferoxamine. Participants treated with the combination of the oral iron chelators had a higher adherence compared to those treated with deferiprone and deferoxamine, but no participants discontinued the study. In the comparisons of deferasirox versus combined deferasirox and deferiprone and that of deferiprone versus combined deferasirox and deferiprone (one study, 40 participants), and deferasirox and deferoxamine versus deferoxamine alone (one study, 94 participants), only a few patient-relevant outcomes were reported and no significant differences were observed.

One study (166 participants) included people with non-transfusion dependent thalassaemia and compared two different doses of deferasirox to placebo. Deferasirox treatment reduced serum ferritin, MD -306.74 ng/mL (95% CI -398.23 to -215.24) (moderate quality evidence) and LIC, MD -3.27 mg Fe/g dry weight (95% CI -4.44 to -2.09) (moderate quality evidence), while the number of participants experiencing adverse events and rate of discontinuations (low quality evidence) was similar in both groups. No participant died, but data on mortality were limited due to a follow-up period of only one year (moderate quality evidence).

### Authors' conclusions

Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload. Based on the available data, deferasirox does not seem to be superior to deferoxamine at the usually recommended ratio of 1 mg of deferasirox to 2 mg of deferoxamine. However, similar efficacy seems to be achievable depending on the dose and ratio of deferasirox compared to deferoxamine. Whether this will result in similar efficacy and will translate to similar benefits in the long term, as has been shown for deferoxamine, needs to be confirmed. Data from randomised controlled trials on rare toxicities and long-term safety are still limited. However, after a detailed discussion of the potential benefits and risks, deferasirox could be offered as the first-line option to individuals who show a strong preference for deferasirox, and may be a reasonable treatment option for people showing an intolerance or poor adherence to deferoxamine.

## PLAIN LANGUAGE SUMMARY

### Deferasirox for managing iron overload in people with thalassaemia

#### Background

Thalassaemia is a hereditary anaemia due to a defect in the production of haemoglobin. Regular red blood cell transfusions are needed, particularly for the severe form of the disease, thalassaemia major. This results in iron overload. Since the human body has no means of actively getting rid of excessive iron, drug treatment (iron-chelating drugs) is needed. Several years ago, a newer oral iron chelator, deferasirox, was introduced.

#### Review question

Does deferasirox offer advantages compared to placebo or to the other iron chelators deferoxamine or deferiprone in people with thalassaemia with regard to effectiveness and safety?

#### Study characteristics

### Deferasirox for managing iron overload in people with thalassaemia (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



The evidence is current to 12 August 2016. This updated review includes 16 randomised controlled studies (1807 participants) containing 20 comparisons of deferasirox versus another treatment.

In people with transfusion-dependent thalassaemia, two studies compared deferasirox with placebo and nine studies (1251 participants) compared deferasirox with standard treatment of deferoxamine. Four studies (205 participants) compared deferasirox to deferiprone. One study each compared deferasirox and deferiprone respectively to deferasirox and deferiprone combination therapy (40 participants), deferasirox and deferoxamine combination therapy to deferoxamine alone (94 participants) and deferasirox and deferiprone combination therapy to deferiprone and deferoxamine combination therapy (96 participants).

In people with non-transfusion dependent thalassaemia (individuals not requiring regular blood transfusions), one study (166 participants) compared deferasirox to placebo. The duration of the included studies ranged from 12 days to two years.

### Key results

Two studies comparing deferasirox with placebo in people with transfusion-dependent thalassaemia showed that deferasirox was effective at removing iron. Nine other studies compared deferasirox with standard treatment of deferoxamine. Similar effectiveness seems possible, depending of the doses of the two drugs compared. It needs to be confirmed whether this leads to similar improvements in patient-important outcomes in the long run. The safety of deferasirox was acceptable; however, rarer adverse events or long-term side effects could not be adequately investigated due to the limited number of participants and the relatively short duration of the studies. Patient satisfaction was significantly better with deferasirox among those who had previously been treated with deferoxamine. The rate of discontinuations was similar for both drugs. Deferasirox may be an alternative for those individuals who do not tolerate, or have poor adherence with, deferoxamine. In people with a strong preference to deferasirox, potential benefits and risks should be discussed.

One study (41 participants) reported that more individuals with transfusion-dependent thalassaemia experienced joint pain when treated with deferiprone than with deferasirox, but due to the large number of different types of adverse events reported and compared, this result may be due to chance. One study revealed that adherence to treatment was higher when both oral iron chelators, deferasirox and deferiprone are used than the combination of deferiprone and deferoxamine, but no participant discontinued the study. We found no evidence for any differences comparing deferasirox or deferiprone alone to combined deferasirox and deferiprone treatment or deferasirox and deferoxamine combination to deferoxamine alone, but the numbers of people in the studies were small and available data were very limited.

One study in people with non-transfusion-dependent thalassaemia found deferasirox was better at reducing serum ferritin and liver iron concentration compared to placebo. However, there is no evidence on the impact on patient-important outcomes or long-term safety data in this population.

### Quality of the evidence

The quality of included studies comparing deferasirox to deferoxamine in people with transfusion-dependent thalassaemia was moderate to low, mainly due fact that the investigators and participants knew which interventions had been assigned to which participants, the small number of participants included in the studies and the use of a surrogate markers (measures used in place of a hard clinical end point) instead of patient-important outcomes. For the comparison of deferasirox to placebo in people with non-transfusion-dependent thalassaemia, the quality of the evidence was moderate to very low based on only one small study. For the other comparisons, the quality of the evidence was low to very low, mainly due to the inclusion of even fewer participants. Ideally, further randomised studies looking at patient-important, long-term outcomes and rarer adverse events, should be conducted.

## SUMMARY OF FINDINGS

### Summary of findings for the main comparison. Deferasirox compared to deferoxamine in people with transfusion-dependent thalassemia

#### Deferasirox compared to deferoxamine in people with transfusion-dependent thalassemia

**Patient or population:** people with transfusion-dependent thalassemia

**Setting:** outpatient care

**Intervention:** deferasirox

**Comparison:** deferoxamine

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with deferoxamine	Risk with deferasirox				
Mortality at any time point	Study population		RR 0.48 (0.09 to 2.63)	1170 (8 RCTs)	⊕⊕⊕⊖ LOW <sup>12</sup>	
	7 per 1.000	3 per 1.000 (1 to 18)				
Responder analysis II (responder: LIC 1 to less than 7 mg Fe/g dw)	Study population		RR 0.80 (0.69 to 0.92)	553 (1 RCT)	⊕⊕⊕⊖ MODERATE <sup>134</sup>	
	664 per 1.000	531 per 1.000 (458 to 611)				
Serum ferritin (ng/mL): mean change from baseline and at end of study		MD 454.42 higher (337.13 higher to 571.71 higher)	-	1002 (6 RCTs) <sup>5</sup>	⊕⊕⊕⊖ MODERATE <sup>134</sup>	
LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline		MD 2.37 higher (1.68 higher to 3.07 higher)	-	541 (1 RCT)	⊕⊕⊕⊖ MODERATE <sup>134</sup>	
Satisfaction with treatment (very satisfied or satisfied): participants previously treated with DFO assessed with: questionnaire follow up: mean 52 weeks	Study population		RR 2.20 (1.89 to 2.57)	571 (1 RCT)	⊕⊕⊕⊖ MODERATE <sup>1</sup>	
	1.330 per 1.000	1000 per 1.000 (1.000 to 1.000)				
Adherence: discontinuations	Study population		RR 0.95 (0.60 to 1.50)	1211 (8 RCTs)	⊕⊕⊕⊖ LOW <sup>16</sup>	
	54 per 1.000	52 per 1.000 (33 to 82)				

AE: investigations - isolated serum creatinine increase above ULN

Study population	
137 per 1.000	353 per 1.000 (258 to 482)

RR 2.57  
(1.88 to 3.51)      657  
(2 RCTs)      ⊕⊕⊕⊕  
LOW<sup>1 7</sup>

\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**AE:** adverse events; **CI:** confidence interval; **DFO:** deferiprone; **dw:** dry weight; **FE:** iron LIC: liver iron concentration; **MD:** mean difference; **RR:** risk ratio; **SQUID:** superconducting quantum interference device; **ULN:** upper limit of normal.

#### GRADE Working Group grades of evidence

**High quality:** we are very confident that the true effect lies close to that of the estimate of the effect

**Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low quality:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

- 1 Serious risk of bias: studies that carry large weight for the overall effect estimate rated as high risk of bias due to lack of blinding and selective reporting.
- 2 Serious imprecision: wide confidence interval including both clinically relevant benefit as well as harm.
- 3 Serious inconsistency: differing ratio of drugs between subgroups of one study.
- 4 Upgrade due to dose-response gradient: observed for both drugs. Effects therefore depending on ratio of drugs used in comparisons.
- 5 A sensitivity analysis without the results from four studies which were calculated according to [Wan 2014](#) showed similar results.
- 6 Serious imprecision: Wide confidence interval, including less discontinuations with deferoxamine treatment.
- 7 Serious indirectness: Surrogate of creatinine used for patient-important outcome of kidney failure.

## Summary of findings 2. Deferasirox compared to deferiprone in people with transfusion-dependent thalassemia

### Deferasirox compared to deferiprone in people with transfusion-dependent thalassemia

**Patient or population:** people with transfusion-dependent thalassemia

**Setting:** outpatient care

**Intervention:** deferasirox

**Comparison:** deferiprone

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with deferiprone	Risk with deferasirox				
Mortality at any time point	Study population		not estimable	146 (3 RCTs)	⊕⊕⊕⊕ VERY LOW <sup>1 2</sup>	
	0 per 1.000	0 per 1.000				

	(0 to 0)			
Responder analysis	Not measured			NA
Serum ferritin (ng/mL): mean change from baseline and at end of study	MD 229.99 ng/mL higher (403.14 lower to 863.11 higher)	-	83 (2 RCTs)	⊕⊕⊕⊕ VERY LOW <sup>3 4</sup>
LIC (mg/g) evaluated by MRI R2*: mean change from baseline	MD 0.8 mg/g lower (2.75 lower to 1.15 higher)	-	45 (1 RCT)	⊕⊕⊕⊕ VERY LOW <sup>3 4</sup>
Satisfaction	Not measured			NA
Adherence: discontinuations	Study population	RR 0.16 (0.01 to 2.99)	179 (3 RCTs)	⊕⊕⊕⊕ LOW <sup>2 5</sup>
	32 per 1.000 5 per 1.000 (0 to 95)			
Renal failure	Study population	not estimable	38 (1 RCT)	⊕⊕⊕⊕ VERY LOW <sup>1 6</sup>
	0 per 1.000 0 per 1.000 (0 to 0)			

\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **LIC:** liver iron concentration; **MD:** mean difference; **MRI:** magnetic resonance imaging; **NA:** not applicable **RCT:** randomised controlled trial; **RR:** risk ratio.

#### GRADE Working Group grades of evidence

**High quality:** we are very confident that the true effect lies close to that of the estimate of the effect

**Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low quality:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

<sup>1</sup> Very serious imprecision: only very few number of included participants.

<sup>2</sup> Serious risk of bias: selective reporting: Results from [Elalfy 2015a](#) for 60 participants not reported.

<sup>3</sup> Serious risk of bias: no blinding assumed, selective reporting: Results from [Elalfy 2015a](#) for 60 participants not reported.

<sup>4</sup> Very serious imprecision: very wide confidence interval including both relevant benefit as well as harm.

<sup>5</sup> Serious imprecision: wide CIs including both benefit as well as harm.

<sup>6</sup> Serious risk of bias: no blinding assumed.

### Summary of findings 3. Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion-dependent thalassemia

#### Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion-dependent thalassaemia

**Patient or population:** people with transfusion-dependent thalassaemia

**Setting:** outpatient care

**Intervention:** deferasirox

**Comparison:** deferasirox and deferiprone

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with deferasirox and deferiprone	Risk with deferasirox				
Mortality at any time point	Not reported <sup>1</sup>				NA	
Responder analysis	Not measured <sup>1</sup>				NA	
Serum ferritin (ng/mL)	Not reported <sup>1</sup>				NA	
LIC (mg Fe/g dry weight)	Not reported <sup>1</sup>				NA	
Satisfaction with treatment	Not measured <sup>1</sup>				NA	
Adherence	Not reported <sup>1</sup>				NA	
AE: serum creatinine increase	Not measured <sup>1</sup>				NA	

\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**AE:** adverse events; **CI:** confidence interval; **LIC:** liver iron concentration; **MD:** mean difference; **RCT:** randomised controlled trial; **RR:** risk ratio.

#### GRADE Working Group grades of evidence

**High quality:** we are very confident that the true effect lies close to that of the estimate of the effect

**Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low quality:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

<sup>1</sup> One RCT (40 participants) contributed to this comparison, but no relevant outcome data to this table are available ([Kakkar 2014](#)).

## Summary of findings 4. Combined deferasirox and deferiprone compared to deferiprone alone in people with transfusion-dependent thalassemia

### Combined deferasirox and deferiprone compared to deferiprone alone in people with transfusion-dependent thalassaemia

**Patient or population:** people with transfusion-dependent thalassemia

**Setting:** outpatient care

**Intervention:** deferasirox and deferiprone

**Comparison:** deferiprone

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with deferasirox and deferiprone	Risk with deferasirox				
Mortality at any time point	Not reported <sup>1</sup>				NA	
Responder analysis	Not measured <sup>1</sup>				NA	
Serum ferritin (ng/mL)	Not reported <sup>1</sup>				NA	
LIC (mg Fe/g dry weight)	Not reported <sup>1</sup>				NA	
Satisfaction with treatment	Not measured <sup>1</sup>				NA	
Adherence	Not reported <sup>1</sup>				NA	
AE: Serum creatinine increase	Not measured <sup>1</sup>				NA	

\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**AE:** adverse events; **CI:** confidence interval; **LIC:** liver iron concentration; **MD:** mean difference; **RR:** risk ratio.

#### GRADE Working Group grades of evidence

**High quality:** we are very confident that the true effect lies close to that of the estimate of the effect

**Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low quality:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

<sup>1</sup> One RCT (40 participants) contributed to this comparison, but no relevant outcome data to this table are available ([Kakkar 2014](#)).

## Summary of findings 5. Deferasirox and deferoxamine compared to deferoxamine in people with transfusion-dependent thalassemia

### Deferasirox and deferoxamine compared to deferoxamine in people with transfusion-dependent thalassemia

**Patient or population:** people with transfusion-dependent thalassemia

**Setting:** outpatient care

**Intervention:** deferasirox and deferoxamine

**Comparison:** deferoxamine

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with deferoxamine	Risk with deferasirox and deferoxamine				
Mortality at any time point	Study population		not estimable	94 (1 RCT)	⊕⊕○○ LOW <sup>1</sup>	
	0 per 1.000	0 per 1.000 (0 to 0)				
Responder analysis	Not measured				NA	
Serum ferritin (ng/mL) - mean at end of study		MD 87.84 ng/mL higher (612.23 lower to 787.91 higher)	-	94 (1 RCT)	⊕○○○ VERY LOW <sup>2 3</sup>	
LIC	Not measured				NA	
Satisfaction with treatment	Not measured				NA	
Adherence: Discontinuations	Study population		not estimable	94 (1 RCT)	⊕○○○ VERY LOW <sup>1 2</sup>	
	0 per 1.000	0 per 1.000 (0 to 0)				
AE: serum creatinine increased	Not reported				NA	Serum creatinine was measured in Molavi 2014, but no results were reported.

\*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**AE:** adverse events; **CI:** confidence interval; **LIC:** liver iron concentration; **MD:** mean difference; **NA:** not applicable; **RR:** risk ratio.

**GRADE Working Group grades of evidence**

**High quality:** we are very confident that the true effect lies close to that of the estimate of the effect

**Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low quality:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

<sup>1</sup> Very serious imprecision: only very few participants included.

<sup>2</sup> Serious risk of bias: assumed lack of blinding.

<sup>3</sup> Very serious imprecision: very wide confidence interval including both benefit as well as harm.

## Summary of findings 6. Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion-dependent thalassemia

### Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion-dependent thalassemia

**Patient or population:** people with transfusion-dependent thalassemia

**Setting:** outpatient care

**Intervention:** deferasirox and deferiprone

**Comparison:** deferiprone and deferoxamine

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with deferiprone and deferoxamine	Risk with deferasirox and deferiprone				
Mortality at any time point	Study population		not estimable	96 (1 RCT)	⊕⊕⊕⊕ LOW <sup>1</sup>	"All the included patients continued till the end of study with no patients were lost follow-up." (Elalfy 2015b)
	0 per 1.000	0 per 1.000 (0 to 0)				
Responder analysis	Not measured				NA	
Serum ferritin (ng/mL): mean change from baseline		MD 315.9 ng/mL lower (1046.26 lower to 414.46 higher)	-	96 (1 RCT)	⊕⊕⊕⊕ VERY LOW <sup>2 3</sup>	
LIC evaluated by MRI R2*: mean change from baseline		MD 0.62 mg/g lower (2.25 lower to 1.01 higher)	-	96 (1 RCT)	⊕⊕⊕⊕ LOW <sup>2 4</sup>	
Satisfaction	Not reported				NA	"Compared to baseline, patient-reported satisfac-



tion associated with ICT was significantly higher in group B [DFX and DFP] compared to group A [DFP and DFO] ( $p < 0.01$ )" (Elalfy 2015b)

Adherence: Discontinuations	Study population		not estimable	96 (1 RCT)	⊕⊕⊕⊕ VERY LOW <sup>1 2</sup>
	0 per 1.000	0 per 1.000 (0 to 0)			
Drug-related AE: serum creatinine increased ( $\geq 33\%$ ) above baseline in 2 consecutive occasions	Study population		RR 3.00 (0.32 to 27.83)	96 (1 RCT)	⊕⊕⊕⊕ VERY LOW <sup>2 3</sup> 5
	21 per 1.000	63 per 1.000 (7 to 580)			

\*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

AE: adverse events; CI: confidence interval; LIC: liver iron concentration; MD: mean difference; MRI: magnetic resonance imaging; NA: not applicable; RR: risk ratio.

#### GRADE Working Group grades of evidence

**High quality:** we are very confident that the true effect lies close to that of the estimate of the effect

**Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low quality:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

<sup>1</sup> Very serious imprecision: very few participants included.

<sup>2</sup> Serious risk of bias: no blinding, selective reporting; no data for 18 months follow-up.

<sup>3</sup> Very serious imprecision: very wide confidence interval including both benefit as well as harm.

<sup>4</sup> Serious imprecision: wide confidence interval including both benefit as well as harm.

<sup>5</sup> Serious indirectness: surrogate of creatinine used for patient-important outcome of kidney failure.

### Summary of findings 7. Deferasirox compared to placebo in people with non-transfusion-dependent thalassemia

#### Deferasirox compared to placebo in people with non-transfusion-dependent thalassemia

**Patient or population:** people with non-transfusion-dependent thalassemia

**Setting:** outpatient care

**Intervention:** deferasirox

**Comparison:** placebo



Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with deferasirox				
Mortality at any time point	Study population		not estimable	148 (1 RCT)	⊕⊕⊕⊖ MODERATE <sup>1</sup>	"No deaths occurred during the study in any group" (Taher 2012)
	0 per 1.000	0 per 1.000 (0 to 0)				
Responder analysis	Not measured				NA	
Serum ferritin (ng/mL): mean change from baseline		MD 306.74 ng/mL lower (398.23 lower to 215.24 lower)	-	154 (1 RCT)	⊕⊕⊕⊖ MODERATE <sup>1</sup>	
LIC (mg Fe/g dry weight) evaluated by MRI R2: least squares mean change from baseline		MD 3.27 mg Fe/g dry weight lower (4.44 lower to 2.09 lower)	-	159 (1 RCT)	⊕⊕⊕⊖ MODERATE <sup>1</sup>	
Satisfaction with treatment	Not measured				NA	
Adherence: Discontinuations	Study population		RR 1.32 (0.50 to 3.52)	166 (1 RCT)	⊕⊕⊖⊖ LOW <sup>2</sup>	
	89 per 1.000	118 per 1.000 (45 to 314)				
AE: abnormal serum creatinine (post-baseline)	Study population		RR 3.59 (0.19 to 68.40)	166 (1 RCT)	⊕⊖⊖⊖ VERY LOW <sup>2 3</sup>	
	0 per 1.000	0 per 1.000 (0 to 0)				

\*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

AE: adverse events; CI: confidence interval; LIC: liver iron concentration; MD: mean difference; NA: not applicable; RR: risk ratio.

#### GRADE Working Group grades of evidence

**High quality:** we are very confident that the true effect lies close to that of the estimate of the effect

**Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low quality:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

- 1 Serious imprecision: only few patients included.
- 2 Very serious imprecision: very wide confidence interval, including both benefit as well as harm.
- 3 Serious indirectness: surrogate of creatinine used for patient-important outcome of kidney failure.

## BACKGROUND

### Description of the condition

Thalassaemia, first described by Cooley and Lee in 1925 (Cooley 1925), is a hereditary anaemia resulting from a defect in haemoglobin production (Weatherall 2000). The disruption in the synthesis of either the  $\alpha$ - or  $\beta$ -chains of haemoglobin, classified in  $\alpha$ - and  $\beta$ -thalassaemia, leads to an ineffective erythropoiesis (i.e. the process by which red blood cells are produced) (Rund 2005). The worldwide birth rate for symptomatic thalassaemia is about 0.44 per 1000 births (Angastiniotis 1998) summing up to more than 40,000 newborns per year (Modell 2008). An estimated number of one to two million people with thalassaemia major, the severe form of the condition, need regular blood transfusions worldwide (Modell 2008; Weatherall 2000) of which only approximately 100,000 are treated as required (Modell 2008). The high frequency of thalassaemia genes can be explained by a protective effect of thalassaemia trait against malaria (Richer 2005; Weatherall 1998).

Due to various mutations in the different genes for the  $\alpha$ - and  $\beta$ -chain genes and other modifying factors, there is a broad spectrum of clinical symptoms ranging from intrauterine death through to severe anaemia with the need for regular red blood cell transfusions and to asymptomatic anaemia (Olivieri 1999). Diagnosis is usually confirmed by either using electrophoretic techniques or molecular analysis. According to the clinical severity, the  $\beta$ -thalassaemia syndromes can be classified into thalassaemia major, thalassaemia intermedia and thalassaemia minor.

Whereas carriers with thalassaemia minor are often asymptomatic, those with thalassaemia intermedia may need occasional red blood cell transfusions (Peters 2013). To achieve sufficiently high haemoglobin levels for adequate growth and development, children with thalassaemia major usually are transfusion-dependent, starting within their first year of life. Several studies have shown that a haemoglobin level above 9 to 10 g/dL is required to successfully suppress ineffective erythropoiesis and to prevent hepatosplenomegaly, as well as bone deformities due to extramedullary hematopoiesis (Olivieri 1999; Rund 2005; Weatherall 2000).

Iron overload in people with thalassaemia is mainly the result of the additional iron load of up to 10 g per year by regular blood transfusions (Kushner 2001). Particularly in people with thalassaemia intermedia, iron overload is also due to increased intestinal iron absorption (Taher 2006). Since the human body has no means of effectively excreting excess iron apart from gastrointestinal mucosal shedding, loss via sweat or through any bleeding (e.g. menstrual loss), iron chelation therapy is essential for these people. Without iron chelation therapy, iron-mediated free radical damage causes liver fibrosis, endocrine failure and myocardial damage (Borgna-Pignatti 2005).

### Description of the intervention

Deferasirox (4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazole-1-yl)benzoic acid) also known as CGP 72670, ICL670, Exjade®, Osveral®, Desirox®, Defrijet®, Asunra®, Desifer® or Jadenu™ is an oral chelator available for routine use. It is approved for the treatment of secondary iron overload by the US Food and Drug Administration (FDA) (FDA 2005) and the European Medicines Agency (EMA) (EMA 2007).

Adverse effects (AEs) known from experiences in people with thalassaemia include gastrointestinal disturbances (nausea, stomach pain or diarrhoea) that have generally been mild and a diffuse rash being more common at higher doses (Cappellini 2006). More rarely, fever, headache and cough have been encountered. The main AE with the use of deferasirox seems to be a mild to moderate elevation of the creatinine level in approximately a third of individuals. Elevations of liver enzyme levels have also been described with a lower incidence (5.6%) (Cappellini 2006). As with standard therapy (deferroxamine), hearing loss and ocular disturbances including cataracts and retinal disorders have been reported with a very low incidence (less than 1%).

With wider use outside of clinical studies, other more severe AEs have been reported, such as cytopenias, Fanconi syndrome and renal failure (Grange 2010; Rafat 2009; Yew 2010), liver failure and gastrointestinal bleeding, which resulted in a boxed warning by the FDA (FDA Boxed Warning 2010).

Deferoxamine (DFO, Desferal®), a further iron chelator, which was reviewed in detail in a Cochrane Review (Fisher 2013a), has been the treatment of choice for iron overload for the last 40 years. Due to its long availability it is the only chelating agent for which a profound effect on the long-term survival of a large cohort of people with thalassaemia has been shown (Borgna-Pignatti 2004; Brittenham 1994; Gabutti 1996; Zurlo 1989). To be clinically effective, deferoxamine has to be administered as a subcutaneous, or less often an intravenous, infusion over 8 to 12 hours, five to seven days per week. This regimen has been demonstrated to reduce the body iron load, prevent the onset of iron-induced complications and even reverse some of the organ-damage due to iron (Davis 2004; Olivieri 1994). But the arduous schedule of overnight subcutaneous infusions often leads to reduced adherence (Cappellini 2005a; Modell 2000; Olivieri 1997). Another problem concerns the toxicity of deferoxamine, particularly at higher doses. Toxicities beside local skin reactions include ophthalmologic (optic neuropathy, retinal pigmentation) and hearing problems (high frequency sensorineural hearing loss). Rare AEs, such as growth retardation, renal impairment (Koren 1991), anaphylactic reactions and pulmonary fibrosis (Freedman 1990) have been reported. The high cost of deferoxamine (approximately USD 10,000 per year) (Delea 2008) and the consumables required (e.g. balloon infusers, which imply additional costs) as well as its complicated mode of administration limit its use in low- and middle-income countries.

Oral preparations have been highly sought after for many years. In 1987 two studies showed that the orally active iron chelator deferiprone (1,2 dimethyl-3-hydroxypyrid-4-1, also known as L1, CP20, Ferriprox® or Kelfer) could achieve effective short-term iron chelation (Kontoghiorghes 1987a; Kontoghiorghes 1987b). However, doubts on the efficacy to reduce liver iron and prevent liver damage arose due to individuals with progression to overt liver fibrosis (Olivieri 1998). However, the hypothesis of direct liver toxicity of deferiprone could not be confirmed (Wanless 2002; Wu 2006). In the meantime, several studies have shown the efficacy of deferiprone for iron chelation (Ceci 2002; Maggio 2002) and in particular its benefit on cardiac iron and cardiac morbidity (Peng 2008). Adverse effects include gastrointestinal disturbances, arthropathy, neutropenia and agranulocytosis (Hoffbrand 1989). Studies on combination therapy of deferoxamine and deferiprone have been performed, most of which showed additive rather

than synergistic effects (Farmaki 2006; Galanello 2006; Kattamis 2003; Kolnagou 2008; Origa 2005; Tanner 2007). An extensive Cochrane Review on the effectiveness of deferiprone in people with thalassaemia was updated in 2013 (Fisher 2013b).

### How the intervention might work

Deferasirox is an oral iron chelator which is rapidly absorbed after administration and has a bioavailability of about 70%. Safety and tolerability were shown to be reasonable in a randomised dose escalation study in people with  $\beta$ -thalassaemia in 2003 (Nisbet-Brown 2003). The elimination half-life of 8 to 16 hours allows a once daily administration after the tablets have been added to water or juice. A newer formulation approved in 2015 in the USA (Jadenu™) (Novartis 2015) and in 2016 in the European Union (Exjade® film-coated tablets) (EMA 2016) allows people to swallow the tablets with water directly. Containing the same active ingredient with comparable pharmacokinetics, the formulation was approved based on safety and efficacy studies investigating the original tablet for suspension (Chalmers 2016).

As deferasirox is a tridentate chelator, two molecules of deferasirox are needed to bind one molecule of iron. The excretion of the bound iron is mainly via faeces.

### Why it is important to do this review

Deferoxamine necessitates serious commitment from the user and due to its AEs, deferiprone is only approved as second-line therapy in some countries. Thus, much hope is being placed in the newer oral chelator deferasirox which apparently offers a promising line of treatment due to its iron chelation properties and safety and tolerability profile (Cappellini 2007). Therefore, an update of our previous Cochrane Review of the effectiveness and safety of deferasirox according to state of the art Cochrane standards is needed in the light of several studies being recently published (Meerpohl 2012).

## OBJECTIVES

To evaluate the effectiveness and safety of oral deferasirox for management of iron overload in people with thalassaemia.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

Randomised controlled studies (RCTs) were considered for this review.

#### Types of participants

People with thalassaemia regardless of age, type of thalassaemia (e.g. thalassaemia major, thalassaemia intermedia) and setting (e.g. country, primary or secondary care), who have developed iron overload (defined as ferritin levels of over 1000 ng/mL on at least two occasions in individuals with transfusion-dependent thalassaemia and over 300 ng/mL in those with non-transfusion-dependent thalassaemia). People with thalassaemia who have undergone stem cell transplantation (SCT) are excluded.

### Types of interventions

For oral deferasirox (all schedules and doses) the following comparisons were considered:

1. deferasirox compared with no therapy or placebo in people with transfusion-dependent thalassaemia;
2. deferasirox compared with no therapy or placebo in people with non-transfusion-dependent thalassaemia;
3. deferasirox compared with another iron-chelating treatment (i.e. deferoxamine or deferiprone or any combination thereof) in people with transfusion-dependent thalassaemia;
4. deferasirox compared with another iron-chelating treatment (i.e. deferoxamine or deferiprone or any combination thereof) in people with non-transfusion-dependent thalassaemia.

However, the necessity of chelation therapy in iron-overloaded people is well-established and, if at all, only short-term (e.g. pharmacokinetic studies) would be ethically justifiable. Longer-term studies with no therapy or placebo in people with transfusion-dependent thalassaemia would not suffice the paradigm of equipoise.

### Types of outcome measures

#### Primary outcomes

1. Overall mortality measured at any point in time

#### Secondary outcomes

1. Reduced end-organ damage due to iron deposition
  - a. cardiac failure (necessitating medical treatment)
  - b. endocrine disease (necessitating substitution hormone therapy or treatment of diabetes)
  - c. histological evidence of hepatic fibrosis
  - d. pathological surrogate markers of end-organ damage (i.e. elevated liver enzymes, elevated fasting glucose or pathological oral glucose tolerance test (OGTT), pathological measures (e.g. ejection fraction in echocardiography)
2. Measures of iron overload
  - a. serum ferritin (ng/mL)
  - b. iron levels in biopsies of liver and other tissue (mg/g liver dry weight)
  - c. tissue iron assessment by superconducting quantum interference device (SQUID) (mg/g liver wet weight)
  - d. tissue iron assessment by magnetic resonance imaging (MRI) (ms)
  - e. responder analysis (deletion of body iron, depending on study definition)
3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)

4. Any AEs
  - a. raised levels of creatinine or kidney failure (above upper normal limit or rise of more than 20% above baseline level)
  - b. skin rash
  - c. gastrointestinal disturbances
  - d. neutropenia or agranulocytosis (absolute neutrophil count (ANC) less than 1000/ $\mu$ L or less than 500/ $\mu$ L)
  - e. raised levels of liver enzymes (above upper normal limit or rise of more than 20% above baseline level) or progression to liver fibrosis
  - f. hearing loss
  - g. eye problems (e.g. retinal toxicity)
  - h. unanticipated AEs as reported in the primary studies
5. Participant satisfaction (measured e.g. by a validated questionnaire) and adherence to chelation treatment (measured by the number of people in each arm that show adequate level of adherence to treatment (intake or application of iron chelator on five or more days per week))
6. Cost of intervention per year

Data from outcomes not defined a priori but which have arisen from the review were also collected, if the outcome was considered to be of clinical relevance.

Data were extracted at longest follow-up.

### Search methods for identification of studies

No language restriction was applied.

#### Electronic searches

We searched for relevant studies in the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms: (thalassaemia OR haemoglobinopathies general) AND ICL670(A).

The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and quarterly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group's [website](#).

Date of most recent search of the Group's Haemoglobinopathies Trials Register: 12 August 2016.

We also searched:

- Cochrane Database of Systematic Reviews (2015, Issue 8); Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7); Database of Abstracts of Reviews of Effect (DARE; 2015, Issue 2); Health Technology Assessment Database (2015, Issue 3); NHS Economic Evaluation Database (2015, Issue 2); Cochrane Methodology Register (2012, Issue 3) in the Cochrane Library [www.thecochranelibrary.com](http://www.thecochranelibrary.com) (searched 6 August 2015);

- MEDLINE OvidSP (2010 to July Week 5 2015);
- MEDLINE OvidSP in Process and Other Non-Indexed Citations (searched 05 August 2015);
- MEDLINE OvidSP Daily Update (searched 05 August 2015)
- Embase OvidSP (2010 to 05 August 2015);
- PubMed [www.pubmed.com](http://www.pubmed.com) [limited to MEDLINE subset "supplied by publisher"] (1946 to 06 August 2015);
- Web of Science Core Collection via Thomson Reuters (2010 to 04 August 2015);
- Biosis Previews via Thomson Reuters (2010 to 04 August 2015);
- Google [www.google.com](http://www.google.com) – searched for "Osferal" and also "Osveral" (searched 07 January 2016)

An RCT filter was used for searches in MEDLINE, Embase, Biosis Previews and Web of Science Core Collection. In MEDLINE, we used the "Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); Ovid format" (Lefebvre 2011), but we replaced "randomized" with "randomi#ed". For Embase, Biosis Previews and Web of Science Core Collection, we devised the search for RCTs and used textwords from the Cochrane RCT Filter we used for the MEDLINE search. For details of the search strategies see [Appendix 1](#).

Regarding the search with Google, we screened the first 50 results of both searches. Every link which was suspected to obtain a relevant study was looked at.

Since research into deferasirox treatment is ongoing, we searched the following trial registers for all years available in all possible fields using the basic search function (using separately the following keyword terms: "deferasirox", "ICL670", "ICL 670", "exjade", "desirox" and "jadenu"):

1. ClinicalTrials.gov: [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (searched 07 August 2015);
2. ICTRP: [www.who.int/ictrp/en/](http://www.who.int/ictrp/en/) (searched 07 August 2015);
3. German Clinical Trial Register: [www.drks.de](http://www.drks.de) (searched 07 August 2015).

For the previous version of this review, several databases and ongoing trials registers were searched from 24th June to 1st July 2010. Please see [Appendix 2](#) for full details.

#### Searching other resources

Additionally, reference lists of all identified primary papers were screened to identify other potentially relevant citations.

Contact was made with selected experts in the field as well as the manufacturer of deferasirox (Novartis) to request information on any unpublished studies that involved deferasirox.

### Data collection and analysis

#### Selection of studies

One author (JM; for the update: CB or LS) screened all titles and abstracts of papers identified by the search strategies for relevance. We only excluded citations which were clearly irrelevant at this stage. We obtained full copies of all potentially relevant papers. At this stage two review authors (JM and DB; for the update: CB and RA or LS and JM) independently screened the full papers, identified relevant studies and assessed eligibility of studies for inclusion.

We resolved any disagreement on the eligibility of studies through discussion and consensus or if necessary through a third party (GA; for the update: JM). We excluded all irrelevant records and recorded details of the studies and the reasons for exclusion.

### Data extraction and management

In addition to details relating to the risk of bias of the included studies, we extracted two sets of data.

1. Study characteristics: place of publication; date of publication; population characteristics; setting; detailed nature of intervention; detailed nature of comparator; and detailed nature of outcomes. A key purpose of this data was to define unexpected clinical heterogeneity in included studies independently from the analysis of the results.
2. Results of included studies with respect to each of the main outcomes indicated in the review question. We carefully recorded reasons why an included study did not contribute data on a particular outcome and considered the possibility of selective reporting of results on particular outcomes.

Two review authors (JM, DB; for the update: CB and RA or LS and JM) independently undertook data extraction using a data extraction form developed by the authors (except for one Chinese study which was extracted by one Chinese reviewer only). The review authors resolved any disagreements by consensus or through discussion with a third review author (GA ; for the update: JM). Once we had resolved disagreements, we recorded the extracted data on the final data extraction form. One review author (JM; for the update: CB or LS) transcribed these into RevMan 5.3 (Review Manager 2014). Another review author (DB; for the update: JM) verified all data entry for discrepancies. We extracted data primarily from full publications of studies; however, if additional abstracts or results records in clinicaltrials.gov were available, these data were also considered. When only abstracts were available, we extracted data therefrom as far as possible.

### Assessment of risk of bias in included studies

Two review authors (JM, DB; for the update: CB, RA or LS, JM) assessed every study using a simple risk of bias form and following the domain-based evaluation as described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a).

We assessed the following domains as having either a low, unclear, or high risk of bias:

1. randomisation;
2. concealment of allocation;
3. blinding (of participants, personnel and outcome assessors);
4. incomplete outcome data;
5. selective outcome reporting;
6. other sources of bias.

We reviewed the assessments and discussed any inconsistencies between the review authors in the interpretation of inclusion criteria and their significance to the selected studies. We resolved any disagreements through discussion with a third author (GA or JM). We did not automatically exclude any study as a result of a rating of 'unclear risk of bias' or a 'high risk of bias'. We presented

the evaluation of the risk of bias in included studies in tabular form in the [Results](#) section of the review.

### Measures of treatment effect

We analysed extracted data using the most up-to-date version of the RevMan 5 software available at the time of analysis (Review Manager 2014).

We planned to extract hazard ratios (HR) with their 95% confidence intervals (CI) for the time-to-event outcomes mortality and end-organ damage. If reports did not provide HRs, we planned to use indirect estimation methods described by Parmar and Williamson to calculate them (Parmar 1998; Williamson 2002).

If we were unable to either extract these data from the study reports or receive the necessary information from the primary investigators, alternatively we used, where appropriate, the proportions of participants with the respective outcomes measured at certain time points (i.e. three months, six months, then six-monthly intervals) to be able to calculate risk ratios (RR). We also extracted data from other time points if available.

We expressed any results for binary outcomes as RR with 95% CIs as measures of uncertainty. Continuous outcomes were expressed as mean differences (MD) with 95% CIs as measures of uncertainty.

Outcomes were not described as means and standard deviations (SD) in all studies, therefore, in order to enter and analyze as many data in RevMan as possible, we undertook further calculations wherever possible. If studies only reported median and range, CI or interquartile range, we estimated means and SDs as described by Wan (Wan 2014). If studies only reported standard error (SE) of the mean (SEM), we used the following calculation:  $SD = SEM \times \sqrt{n}$ . If studies provided P values, n and mean, we calculated the SD with the calculator integrated in RevMan 5 (Review Manager 2014). If studies provided Z values, we calculated the SD for the change from baseline. For heavily skewed data, analysis based on means is not appropriate. Although the study authors did not always explain the reasons, means were presented as geometric means (Gmeans) in some cases. We therefore analysed the data on a log scale and report these data as the ratio of Gmeans.

Reporting of results was ambiguous in some studies, so we had to make the following assumptions.

- One study reported the percentage of participants with dose reductions and interruption and the values for adherence, but the number of participants included for each outcome was not clear (Pennell 2014). For our analysis we assumed that all those who had received the study drug were included.
- Where results of individual studies were displayed only graphically and we considered estimation to be reasonable, we estimated values visually from the graphs.
- We assumed that the values of means and SD in neutrophil, alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) levels were confused in one study (Molavi 2014) so we used corrected values for our meta-analysis.
- A further study reported different P values for the same outcome "QoL (end of study-baseline)" in the same journal publication (Elalfy 2015b). We calculated the SD for change from baseline using the most conservative P values given.

- When the P value was reported as  $P < 0.001$ , we used  $P = 0.001$  for our calculation of SD.
- One study lost three participants across the term of the study (Elalfy 2015a). For calculating change from baseline, we included all 30 participants for our conservative analysis.
- Sometimes we realised discrepancies in results reported in journal publications and in abstracts or trial registers. In these cases, we usually extract results from full journal publications.
- For some outcomes, a possible perception of the comparison might be whether deferiasirox is not inferior to standard treatment with deferoxamine. Therefore, for these outcomes a per protocol analysis might be chosen.

### Unit of analysis issues

We found two three-armed studies comparing the three different iron chelation monotherapies deferiasirox, deferiprone and deferoxamine (Chirico 2013; Elalfy 2015a). To include the results in our meta-analysis, we divided the number of participants in the deferiasirox arms as suggested in chapter 16 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011b).

One four-arm study compared two different doses of deferiasirox to equivalent placebos, but results of both placebo groups were not reported individually, so we split the placebo group for both comparisons (Taher 2012).

We did not include any cross-over studies in this review. However, for future updates, we plan to use the methods recommended by Elbourne for combining results from such studies (Elbourne 2002). We will use the methods described by Curtin to combine results from parallel and cross-over studies (Curtin 2002a; Curtin 2002b; Curtin 2002c).

The study investigators planned that the included phase III study would be a non-inferiority study (Cappellini 2005b). Therefore, they did not report efficacy outcomes based on an intention-to-treat (ITT) analysis. For our review, we used the data as presented, i.e. per protocol.

We did not use any of the below mentioned strategies outlined by Witte (Witte 2004) in this version of the review, because only a few studies could be pooled per outcome. However, for future updates we will consider applying one of these strategies according to the data available.

1. If all studies report only an ITT analysis (or all studies report only a per protocol analysis), we will perform a non-inferiority meta-analysis based on Witte's 'perfect case' proposal.
2. If some studies report only an ITT analysis and others only a per protocol analysis (exclusively), we will perform meta-regression with analysis type as a covariate.
3. If some studies report only an ITT analysis and others only a per protocol analysis, whilst others report both, we will undertake a sensitivity analysis.
4. If all studies give enough information to do both analyses, we will analyse data using a bivariate model.

To interpret results according to a non-inferiority scenario, we will use the following definitions.

For time-to-event data, non-inferiority is given, if the relative difference in HRs is less than 10%. For RRs, non-inferiority is defined

as a relative RR difference of less than 10% in treatment failures compared to standard therapy. For the continuous outcomes of "measures of iron overload and iron excretion" as well as "costs", a relative difference of less than 10% is considered equivalent.

### Dealing with missing data

We contacted the original investigators to clarify some methodological issues and to request additional data from two studies during the development of the previous review version (Galanello 1999; Nisbet-Brown 2001); however, to date, we have not received any additional data to that presented in the primary reports. For this version of the review, we contacted investigators of 11 studies (Chirico 2013; Elalfy 2015a; Elalfy 2015b; Habibian 2014; Hagag 2015; Kakkar 2014; Kakkar 2015; Molavi 2013; Molavi 2014; Pennell 2014; Taher 2012) and the manufacturer of deferiasirox regarding two studies (Pennell 2014; Taher 2012). We could clarify some issues and the original investigator confirmed that our list of included studies is complete. However, additional data on investigator-sponsored studies have to be requested via a data request platform in most cases. We plan to request available data via this platform for all manufacturer sponsored studies for a future update.

### Assessment of heterogeneity

Where feasible, we considered clinical heterogeneity by presenting results of subgroups according to differences in dose of intervention and baseline measures of iron overload. We examined statistical heterogeneity in the results of studies using the  $I^2$  and  $Chi^2$  statistics (Higgins 2002; Higgins 2003).

### Assessment of reporting biases

We made a great effort to identify unpublished studies and minimise the impact of possible dissemination bias by using a comprehensive search strategy and contacting the manufacturer of deferiasirox for the previous version. We did not use funnel plots to assess dissemination bias, since asymmetry is difficult to detect with a small number of studies (i.e. less than 10) and we could only include 16 studies overall in this review, with no more than eight studies per outcome. If in future we are able to include more than 10 studies for a given outcome in the review, we will use funnel plots to graphically assess the likelihood of dissemination bias. We took care in translating the results of the included studies into recommendations for action by involving all review authors in drawing conclusions.

### Data synthesis

While extracting data, we had to take the following decisions. Although we would have preferred to consistently present data separately for the different dose groups, we decided to pool safety data of the different dose groups from the Nisbet-Brown study, since splitting the placebo group ( $N = 5$ ) did not seem reasonable due to the small size (Nisbet-Brown 2001). Due to the huge amount of different AE types reported, we decided to pool AEs for the different dose groups for three studies rather than presenting the various subgroups for all AEs (as in the previous version of this review) (Cappellini 2005b; Piga 2002; Taher 2012).

We conducted meta-analyses of pooled data from all contributing studies using a fixed-effect model. We took heterogeneity of the pooled data into account by using subgroup analysis or the



random-effects model (or both) (see [Effects of interventions](#) for specific details).

### 'Summary of findings' tables

We created 'Summary of findings' tables for each comparison apart from deferasirox versus placebo in people with transfusion-dependent thalassemia, because abstaining from iron chelation treatment in this patient group is ethically not justified and therefore not patient-relevant.

The following outcomes were selected for presentation in the 'summary of findings' tables because we considered these outcomes most relevant for decision-making given the limitations of the available evidence:

1. overall mortality measured at any point in time;
2. responder analysis (deletion of body iron, depending on study definition);
3. serum ferritin (ng/mL);
4. iron levels in liver measured by biopsies (mg/g liver dry weight) or SQUID (mg/g liver wet weight) or MRI (ms);
5. adherence to chelation treatment (measured by the number of people in each arm that show adequate level of adherence to treatment (intake or application of iron chelator on five or more days per week, or number of patients who discontinued as form of adherence));
6. participant satisfaction (measured e.g. by a validated questionnaire);
7. AEs: raised levels of creatinine or kidney failure (above upper normal limit or rise of more than 20% above baseline level).

We used the five Grading of Recommendations Assessment, Development and Evaluation (GRADE) considerations (risk of bias, inconsistency, indirectness, imprecision and publication bias) to assess the quality of the body of evidence as it relates to the studies that contributed data to the meta-analyses as described in chapters 11 and 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We used footnotes to justify all decisions to down- or upgrade the quality of evidence and we made comments to aid readers' understanding of the review where necessary. We generated 'Summary of findings' tables using the Gradepro software (GRADEpro GDT 2015).

### Subgroup analysis and investigation of heterogeneity

If data were available, we presented subgroups according to baseline measures of iron overload or doses of intervention as

they were reported in the studies. If relevant, other subgroup analysis as defined in study publications are presented. Due to the amount of reported adverse events, we merged AEs for different subgroups. For future updates of this review, we will assess clinical heterogeneity, if possible, in addition by examining differences due to:

- age of participants (e.g. zero to two years, three to five years, 6 to 11 years; 12 to 17 years, 18 years or older);
- age at commencement of the intervention (e.g. zero to two years, three to five years, 6 to 11 years, 12 to 17 years, 18 years or older).

Additional subgroup analyses are planned for different:

- subtypes of thalassaemia (e.g. thalassaemia major, thalassaemia intermedia, haemoglobin E thalassaemia) where applicable.

### Sensitivity analysis

We were only able to include a maximum of nine published studies for each of our comparisons and no additional unpublished studies nor studies with a low risk of bias were identified. Due to missing data regarding SD, we did some calculations according to Wan and undertook sensitivity analysis (Wan 2014). For future updates of this review, we plan to perform additional sensitivity analyses based on assessment of risk of bias (evaluating only studies of low risk of bias) and publication status (unpublished and published studies).

## RESULTS


### Description of studies

#### Results of the search


##### Updated searches

The updated searches for this current version of the review (last search ran in August 2016) identified 1211 citations, including 477 duplicates (Figure 1). The title and abstract screening of the remaining 734 citations identified 71 as potentially eligible for this review. After screening of the full texts, eight new studies (described in 23 references) and a reference to a previously included study were included in the updated version of this review. Four additional studies (reported in five references) were identified through Google-searches resulting overall in a total of 16 included studies.

**Figure 1. Study flow diagram.**



**Figure 1. (Continued)**



**Previous searches**

For the previous version of this review, the last search was run in November 2011 (see Figure 1). Altogether, 2171 citations, including 1195 duplicates, were identified. After title and abstract screening of the 976 unique citations, 687 citations could be excluded. A total of 289 full texts were screened and four RCTs (described in 33 references) were identified (Cappellini 2005b; Galanello 1999; Nisbet-Brown 2001; Piga 2002).

The search of the three trial registers (last run on 30 June 2010) identified 49 unique references to studies. One ongoing RCT was identified, which has now been published and was therefore included in this updated review (Pennell 2014).

**Included studies**

Sixteen studies met the inclusion criteria (Characteristics of included studies) including 1807 randomised participants (range 23 to 586 per study). Twelve studies included two treatment arms comparing deferasirox to placebo (Galanello 1999; Nisbet-Brown 2001) or deferoxamine (Cappellini 2005b; Habibian 2014; Hassan 2016; Molavi 2013; Peng 2013; Pennell 2014; Piga 2002;) or deferiprone (Sanjeeva 2015) or comparing the combination of deferasirox and deferoxamine to deferoxamine alone (Molavi 2014). One study compared the combination of deferasirox and deferiprone to deferiprone in combination with deferoxamine (Elalfy 2015b). Three studies included three treatment arms comparing deferasirox to deferoxamine and deferiprone (Chirico 2013; Elalfy 2015a) or the combination of deferasirox and deferiprone to deferiprone and deferasirox monotherapy respectively (Kakkar 2014). One study included four treatment arms, comparing two different doses of deferasirox to matching placebo groups (Taher 2012). One identified abstract is a report of a previously included study (Cappellini 2005b).

**1. Transfusion-dependent thalassaemia: deferasirox versus placebo**

The two relevant studies comparing deferasirox to placebo are short-term studies examining mainly safety and pharmacokinetic outcomes while on deferasirox therapy (Galanello 1999; Nisbet-Brown 2001).

The first study was reported in one full article and one abstract (Galanello 1999). Twenty-four individuals were allocated to three groups: all groups received two single doses of deferasirox at an interval of at least seven weeks. Group 1 received single doses of 2.5 mg/kg and 20 mg/kg, Group 2 single doses of 5 mg/kg and 40 mg/kg and Group 3 single doses of 10 mg/kg and 80 mg/kg. In each treatment period, two of eight participants received placebo in such a way that a given participant did not receive placebo more than once. Usual deferoxamine and transfusion therapy was given in the interval between the two doses. This study by Galanello on deferasirox focused on safety, tolerability and pharmacokinetics.

The second study was reported in one full article and two abstracts (Nisbet-Brown 2001). It was designed as a dose-escalation study focusing on effectiveness and safety; treatment duration was 12 days. A total of 23 individuals were randomly assigned to placebo (n = 5), 10 mg/kg/day of deferasirox (n = 5), 20 mg/kg/day of deferasirox (n = 6) and 40 mg/kg/day of deferasirox (n = 7). Primary objectives included assessment of safety and tolerability (measured by adverse events and clinical laboratory monitoring), pharmacokinetics (measured as drug and drug-iron complex), and cumulative net iron excretion (measured by faecal and urine output minus food input).

**2. Transfusion-dependent thalassaemia: deferasirox versus deferoxamine**

One of the seven studies comparing deferasirox to deferoxamine was reported in one full article and four abstracts (Piga 2002). This is a randomised open-label phase II study including 71 people with  $\beta$ -thalassaemia aged over 18 years from four centres in Italy. The primary objective was to determine the safety and tolerability of deferasirox at daily doses of 10 and 20 mg/kg in comparison with a standard dose of deferoxamine 40 mg/kg in individuals with transfusional haemosiderosis. Secondary objectives included evaluation of the effects of deferasirox on liver iron concentration (LIC), serum ferritin, serum iron, transferrin and transferrin saturation. The ITT principle was used for analyses.

Results from the second study were reported in five full articles, 19 abstracts (and two responses to letters) (Cappellini 2005b). This phase 3 open-label randomised study was planned as a non-inferiority study with a predefined delta of 15% (two-sided 95% CI). There were 591 participants actually randomised, but five withdrew consent prior to any study medication; 586 participants were included in the study, of which 541 completed one year of therapy. After randomisation, stratified by three age groups, people were assigned to a treatment dose of either deferasirox or deferoxamine according to baseline LIC; the mean ratio of doses between deferasirox and deferoxamine varied from 1:5.5 to 1:1.8. The primary endpoint was maintenance or reduction of LIC. Secondary criteria for response included evaluation of the change in serum ferritin levels over time and evaluation of net body iron balance.

A third study, a randomised, controlled study in Iran, was reported in one journal article (Molavi 2013). A total of 138 people with thalassaemia major and intermedia with serum ferritin more than 1000 ng/mL and older than two years were randomised to 20 mg/kg oral Osveral® (Iranian generic product of deferasirox) daily or 40 mg/kg to 50 mg/kg subcutaneous Desferal® (deferoxamine) for six nights a week. Due to the different administration routes, we assumed that no blinding took place. Primary outcome was serum ferritin, secondary outcomes were serum levels of ALT, AST, creatinine, haemoglobin and drug side effects (leukopenia, thrombocytopenia).

A further study (reported in one full article in Chinese) compared deferasirox to deferoxamine and was a single-centre RCT in China (blinding not mentioned) (Peng 2013). A total of 24 people with severe  $\beta$ -thalassaemia were randomised to oral deferasirox 40 mg/kg daily or deferoxamine 50 mg/kg at least five days a week. During the 12 month follow up, serum ferritin and liver R2\* were assessed.

A larger multi-centre, open-label study was reported in two full articles and two abstracts (Pennell 2014). A total of 197 people with  $\beta$ -thalassaemia major (aged 10 years and over) were randomised to 40 mg/kg/day oral deferasirox or deferoxamine 50 mg/kg/day to 60 mg/kg/day as subcutaneous infusion over eight to 12 hours, five to seven days a week. Regarding the primary outcome, change in myocardial T2\* during one year follow-up, the study was designed as a non-inferiority study with a non-inferiority margin of 90%. Secondary endpoints were change in left ventricular ejection fraction (LVEF), LIC and serum ferritin. Adverse events and adherence were also reported. Data from the one-year extension phase were not included in this review due to the high number of individuals who did not continue with deferoxamine therapy after the core phase.

A small study including 30 people with thalassaemia major was only reported in a conference abstract (Habibian 2014). After 12 months, serum ferritin was measured. More information regarding dosing or other outcomes was not reported.

One study, reported in a journal publication, investigated 60 individuals with thalassaemia major (Hassan 2016). Participants were randomised to receive deferasirox (single oral daily dose of 20 to 40 mg/kg/day) or deferoxamine (20 to 50 mg/kg/day via a subcutaneous infusion over 8 to 10 hours, five days a week) for one year. Serum ferritin, ALT, AST, blood urea, serum creatinine, neutrophilic and platelet counts and some adverse events were reported.

### **3. Transfusion-dependent thalassaemia: deferasirox versus deferiprone**

One single randomised study compared deferasirox 20 mg/kg/day to deferiprone 75 mg/kg/day divided in three doses (Sanjeeva 2015). The study included 41 regularly transfused children with ferritin over 1000 ng/mL who were not on chelation therapy previously. Serum ferritin level (primary outcome) and AEs (secondary outcomes) were assessed during a follow up of 12 months. The study was reported as a journal article and a doctoral thesis.

### **4. Transfusion-dependent thalassaemia: deferasirox and deferoxamine versus deferoxamine**

The combination of deferasirox (20 mg/kg to 40 mg/kg) and deferoxamine (50 mg/kg, three times a week) was compared to deferoxamine monotherapy in one study, reported in one journal article (Molavi 2014). A total of 100 people with thalassaemia major were randomised to one of the groups at a medical centre in Iran. Six participants were excluded after randomisation but before start of the study. Serum ferritin, liver enzymes, ALP, neutrophils, creatinine and haemoglobin were measured.

### **5. Transfusion-dependent thalassaemia: deferasirox and deferiprone versus deferiprone and deferoxamine**

One randomised study included two treatment arms and compared two combination regimes: the first group received oral deferiprone 75 mg/kg/day divided into two doses and deferoxamine 40 mg/kg/day by subcutaneous infusion over 10 hours for six days a week, the second group received in addition to deferiprone (75 mg/kg/day) deferasirox 30 mg/kg/day for seven days a week (Elalfy 2015b). The open-label study was reported in one full article and two abstracts. A total of 96 people with thalassaemia major were randomised into two equal groups. Primary outcomes were change in serum ferritin, LIC and cardiac MRI, secondary outcomes were AEs, serious AEs (SAEs), participant's adherence, participant's satisfaction and health-related quality of life.

### **6. Transfusion-dependent thalassaemia: deferasirox versus deferoxamine versus deferiprone**

Two studies compared all three iron-chelators against each other (Chirico 2013; Elalfy 2015a).

The first study was published as one full article and one abstract (Chirico 2013). The full study had a duration of eight years, but only the last two years were designed as a randomised controlled study. A total of 37 individuals who had not developed a thyreopathy under treatment with deferoxamine in the last six years were randomised to either deferasirox (n = 12), deferoxamine (n = 13) or deferiprone (n = 12) monotherapy. The number of participants with thyroid disease and serum ferritin after two years of follow-up were reported.

The other study comparing the three iron chelator monotherapies was reported in one full-text and two abstracts (Elalfy 2015a). The aim of this study was to investigate the effects of vitamin C as an adjuvant therapy to iron chelation in a factorial study with six arms. Therefore, 180 people with iron-overloaded thalassaemia major with serum ferritin from 1000 ng/mL to 2500 ng/mL and vitamin C deficiency were randomised in a 1:1:1 ratio to deferoxamine 40 mg/kg/day (five days a week), deferiprone 75 mg/kg/day or deferasirox 25 mg/kg/day. Participants were further equally randomised either to receive vitamin C supplementation (100 mg daily) or not. The primary efficacy endpoint was change of serum ferritin, LIC and cardiac MRI T2\* during one year of follow-up. The occurrence of any adverse effects was a secondary outcome measure.

### **7. Transfusion-dependent thalassaemia: deferasirox versus deferiprone versus deferasirox and deferiprone**

In one study, 40 people were randomised to deferasirox 30 mg/kg/day to 40 mg/kg/day (n = 10), deferiprone (75 mg/kg/day to 100 mg/kg/day) (n = 10), or both drugs administered sequentially every alternate week (n = 20) (Kakkar 2014). Cardiac and liver MRI, serum ferritin, complete blood count (CBC), liver enzymes and renal function tests were performed. Duration of follow-up was not reported. The study was only reported as a conference abstract.

### **8. Non-transfusion-dependent thalassaemia: deferasirox compared to placebo**

One study included participants with non-transfusion-dependent thalassaemia with iron overload (Taher 2012). We identified no other RCT evaluating people with non-transfusion-dependent thalassaemia. A total of 166 individuals were randomised in a 2:1:2:1 ratio to starting doses of 5 or 10 mg/kg/day or matching

placebos. The primary efficacy endpoint was the change in LIC during the 52-week treatment duration. Secondary endpoints were change in serum ferritin, correlation of serum ferritin and LIC, AEs and adherence. The study lasted for one year and was published in two journal publications and six abstracts.

### Excluded studies

#### Updated searches

Several reports of the extension phases of studies were not included, since after completion of the core first year, cross-over to deferasirox treatment took place during the extension phase (Cappellini 2005b; Taher 2012). Therefore, data collected during the extension phase represent observational data on a large cohort of deferasirox-treated individuals; there is no longer a comparison group and participants were not analysed according to their initially assigned group. Due to a high number of participants who did not continue in the deferoxamine treatment group after the core phase, the extension phase of the Pennell study was also excluded (Pennell 2014).

Overall, the reasons for exclusion of 44 reports were:

- included people with disease other than thalassaemia (n = 3);
- included people with thalassaemia who had received curative stem cell transplantation (n = 5);
- review/other, no primary data containing articles (n = 3);
- intervention/comparison other than deferasirox (n = 2);
- pharmacokinetic studies (n = 2);
- non-randomised data on participants with thalassaemia (n = 29)
  - extension phases of core studies (n = 13)
  - other non-randomised data (n = 16).

#### Previous searches:

256 references were excluded. Reasons for exclusion were:

- included people with disease other than thalassaemia
  - \* only sickle cell disease (n = 16)
  - \* only myelodysplastic syndrome (n = 53)
  - \* other condition (n = 9);
- review article, editorial or comment (n = 49);
- intervention other than deferasirox (n = 2);
- cost-effectiveness analysis (n = 8);
- non-randomised data on people with thalassaemia (n = 119) (for selected references see [Characteristics of excluded studies](#))

- EPIC study (n = 16)
- ESCALATOR study (n = 13)
- extension phases of core studies (n = 21)
- other non-randomised data (n = 69).

### Studies awaiting classification and ongoing studies

Three studies identified through searches in electronic databases were classified as 'awaiting classification', because it was not clear if randomisation of participants really took place in two studies (Hagag 2015; Ansari 2015;) and the conference abstract of another study did not mention the number of included participants (Kakkar 2015). Authors of all studies were contacted for clarification; however, we have not yet received any further information.

The searches in trial registers identified four ongoing studies (Cutino 2009; DEEP-2 2012; NCT02125877; NCT02435212) as well as two unpublished completed studies (EUCTR2010-023217-61-GB; NCT02198508). The Google search also revealed a registry entry of an RCT in the Iranian Registry of Clinical Trials, which met our inclusion criteria and was added as study awaiting classification (IRCT201110087677N1).

We contacted the investigators of unpublished completed studies (as far as contact addresses could be identified) to request information on study results. If these studies are published within two years of this update (as per the standard Cochrane updating guidelines), this will trigger an earlier update of this review.

### Risk of bias in included studies


The risk of bias for the 16 included studies in this review was classified as previously described ([Assessment of risk of bias in included studies](#)).

The three blinded studies comparing deferasirox to placebo were judged overall as having an 'unclear' risk of bias (Galanello 1999; Nisbet-Brown 2001; Taher 2012). These assessments were mainly based on the inadequate reporting of several of the criteria that are considered to be important in the evaluation of methodological rigour in terms of study design and conduct.

All other included studies were predominantly classified as having an overall 'high' risk of bias, mainly due selective reporting of secondary outcomes and lack of blinding.

For further details see the risk of bias tables in [Characteristics of included studies](#), the risk of bias graph (Figure 2) and the risk of bias summary (Figure 3).

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**



**Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding (performance bias and detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Cappellini 2005b	?	?	-	?	?	+
Chirico 2013	?	?	-	+	-	?
Elalfy 2015a	+	+	-	+	-	?
Elalfy 2015b	+	+	-	+	-	+
Galanello 1999	?	?	+	+	?	+
Habibian 2014	?	?	-	?	-	?
Hassan 2016	?	?	-	+	+	+
Kakkar 2014	?	?	-	?	-	?
Molavi 2013	?	?	-	+	-	+
Molavi 2014	?	?	-	+	-	+
Nisbet-Brown 2001	?	?	+	+	?	+
Peng 2013	?	?	-	+	-	+
Pennell 2014	+	?	-	-	-	+
Piga 2002	+	?	-	+	?	+
Sanjeeva 2015	+	?	-	-	-	+
Taher 2012	?	+	?	?	-	+

**Allocation**

The methods to generate the allocation sequence were not described in 11 studies (Galanello 1999; Habibian 2014; Hassan 2016; Nisbet-Brown 2001; Cappellini 2005b; Chirico 2013; Kakkar 2014; Molavi 2013; Molavi 2014; Peng 2013; Taher 2012). Three studies used computer-generated randomisation sequences and were therefore assessed as low risk of bias (Elalfy 2015a; Elalfy 2015b; Sanjeeva 2015). One study used a "validated system that generates an automated random assignment of numbers to treatment groups" (Piga 2002). One study described randomisation

based on permuted blocks which was considered as low risk of bias (Pennell 2014).

Since no details were given in the reports with regard to allocation concealment, it remains unclear whether allocation concealment was achieved in 12 studies (Cappellini 2005b; Chirico 2013; Galanello 1999; Habibian 2014; Hassan 2016; Kakkar 2014; Molavi 2013; Molavi 2014; Peng 2013; Pennell 2014; Piga 2002; Sanjeeva 2015). One study reported using sealed envelopes but it was unclear if these were opaque and numbered (Nisbet-Brown 2001). Three studies were assessed as low risk of bias regarding allocation concealment. One Elalfy study used opaque and numbered sealed

envelopes (Elalfy 2015a), a second ensured allocation concealment through assigning participants to treatment groups by telephone contact from the co-ordinating centre (Elalfy 2015b). In one study the investigator had to contact an interactive voice system to obtain the linked randomisation number (Taher 2012).

### Blinding

Blinding was done in the three placebo-controlled studies (Galanello 1999; Nisbet-Brown 2001; Taher 2012), although in the Taher study blinding with regard to the different doses used was not done (Taher 2012).

The remaining 12 studies were open-label, the reason being the obvious difference in application mode, deferasirox and deferiprone being orally taken, while deferoxamine needs to be applied subcutaneously over several hours and the different frequency of intake regarding both oral iron chelators. One study reported that "patients, physicians, laboratory staff and the epidemiologist who analysed the data were not aware of the intervention for each group" (Chirico 2013). However, no placebo treatment was mentioned, so we assumed that no adequate blinding took place.

### Incomplete outcome data

Since the Cappellini and Pennell studies were planned as non-inferiority studies, efficacy data were not consistently reported on an ITT basis (Cappellini 2005b; Pennell 2014). In the Pennell study, the provided ITT analysis did not include all randomised participants (Pennell 2014). Two studies did not address how many participants reached the end of the study (Habibian 2014; Kakkar 2014). One study reported three dropouts due to AEs; a per protocol analysis was done for most of the outcomes, which was assessed as having a high risk of bias (Sanjeeva 2015). One of the Elalfy studies reported discontinuing participants in an abstract publication, whereas in a later full publication, all participants apparently reached the end of the study (Elalfy 2015b). One study reported that "efficacy was assessed for the full analysis set (all randomised patients)" in the journal publication, but the data set on clinicaltrials.gov states a lower number of analysed participants (Taher 2012). The author confirmed that the change could only be calculated for participants with both a baseline and at least one post-baseline value. The remaining nine studies fully reported or addressed adequately incomplete outcome data (Chirico 2013; Elalfy 2015a; Galanello 1999; Hassan 2016; Molavi 2013; Molavi 2014; Nisbet-Brown 2001; Peng 2013; Piga 2002).

### Selective reporting

Only one study was assessed as low risk of bias regarding selective reporting (Hassan 2016). Data on a broad spectrum of AEs were usually collected. However, only limited AE data were reported, often only qualitatively. Commonly, laboratory parameters were apparently measured but not reported. However, end of study results for the primary outcome were reported in all studies.

Evidence of publication bias could not be detected.

### Other potential sources of bias

Four studies were assessed as unclear, because no or limited information on baseline characteristics was provided (Chirico 2013; Elalfy 2015a; Habibian 2014; Kakkar 2014).

### Support and sponsorship

Six studies were conducted with support and involvement of the producer of deferasirox (Novartis) (Cappellini 2005b; Galanello 1999; Nisbet-Brown 2001; Pennell 2014; Piga 2002; Taher 2012). Also, many authors of these studies were affiliated with Novartis. The relevance of these conflicts of interest is open to interpretation. Four studies declared to have no conflicts of interest (Chirico 2013; Elalfy 2015b; Elalfy 2015a; Hassan 2016), whereas conflicts of interest were not reported at all in five other studies (Kakkar 2014; Sanjeeva 2015; Molavi 2013; Molavi 2014; Habibian 2014). One study was funded by a public grant (Peng 2013).

### Effects of interventions

See: [Summary of findings for the main comparison Deferasirox compared to deferoxamine in people with transfusion-dependent thalassemia](#); [Summary of findings 2 Deferasirox compared to deferiprone in people with transfusion-dependent thalassemia](#); [Summary of findings 3 Deferasirox alone compared to combined deferasirox and deferiprone in people with transfusion-dependent thalassemia](#); [Summary of findings 4 Combined deferasirox and deferiprone compared to deferiprone alone in people with transfusion-dependent thalassemia](#); [Summary of findings 5 Deferasirox and deferoxamine compared to deferoxamine in people with transfusion-dependent thalassemia](#); [Summary of findings 6 Deferasirox and deferiprone compared to deferiprone and deferoxamine in people with transfusion-dependent thalassemia](#); [Summary of findings 7 Deferasirox compared to placebo in people with non-transfusion-dependent thalassemia](#)

#### 1. Transfusion-dependent thalassaemia: deferasirox compared to placebo

Two studies compared deferasirox to placebo (Galanello 1999; Nisbet-Brown 2001). Due to both its design and the presentation of results in the paper, data could not be extracted quantitatively from the Galanello study (Galanello 1999). Regarding safety data, it was not clear whether participants contributed more than one episode to the count of one AE (such as headache) since safety parameters were assessed after each dose. So, a single participant could theoretically contribute more than one episode of an event such as headache. For this reason, we do not present these data in a forest plot. We have contacted the authors but have not yet been able to clarify all details. Therefore, we decided to report important information in a narrative manner as done by Galanello (Galanello 1999).

#### Primary outcomes

##### 1. Overall mortality measured at any point in time

No deaths were observed during these two short-term studies (47 participants) (Galanello 1999; Nisbet-Brown 2001) (Analysis 1.1).

#### Secondary outcomes

##### 1. Reduced end-organ damage due to iron deposition

No data on end-organ damage were available from either study.

##### 2. Measures of iron overload

Efficacy was not a focus of the Galanello study and no consistent trend on serum iron and transferrin could be observed (as expected after single-dose administration) (Galanello 1999). Other measures of efficacy were not reported.



For the Nisbet-Brown study, ferritin levels were reported at baseline and end of study for each group (Nisbet-Brown 2001). However, since no SD was given for mean change of ferritin and since we were

unable to obtain these data from the authors, the mean ferritin levels ( $\mu\text{g/L}$ ) and SDs at baseline and end of study are presented here (as reported in the primary study):

Serum ferritin (mean (SD) [ $\mu\text{g/L}$ ])	Placebo	10 mg/day	20 mg/day	40 mg/day
Baseline	4265 (3882)	2452 (869)	4753 (3168)	2644 (1320)
End of study	5215 (5430)	2344 (1606)	4872 (2511)	1756 (793)

We decided against estimating SDs because imputation from another study would require studies similar in design and conduct which are not available (due to the fact that we are dealing here with an early phase dose escalation study). We decided against use of post-treatment values only, since there were large, clinically relevant differences between groups at baseline due to small sample size despite randomisation.

### 3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)

In the Galanello study, the authors note that the majority of iron is excreted in the faeces; however, data are only given for urinary iron excretion (Galanello 1999). These data are presented as urinary iron excretion over 24-hour intervals for each dose. To minimize the influence of outliers, medians and ranges are given (see table).

Iron excretion over 24 hours: median (range) (mg/kg/24 hours)						
Placebo	2.5 mg de-ferasirox	5 mg deferasirox	10 mg de-ferasirox	20 mg de-ferasirox	40 mg de-ferasirox	80 mg de-ferasirox
0.017	0.009	0.010	0.010	0.016	0.193	0.391
(0.006 - 0.629)	(0.005 - 0.031)	(0.006 - 0.028)	(0.004 - 0.014)	(0.006 - 0.119)	(0.053 - 0.508)	(0.121 - 0.842)

Therefore, we were unable to extract these data to include them in the RevMan graphs. We are trying to obtain additional data on faecal iron excretion.

The Nisbet-Brown study measured net iron excretion (Nisbet-Brown 2001). Since the actual data were not given in the publications and we have not received these from the authors, we estimated the values from the figures of the paper and performed an analysis of variance for the three dose groups using the placebo group as reference (Software: R). The mean and SE (mg Fe/kg/day) are 0.03 (0.10) for placebo, 0.12 (0.14) for 10 mg/day deferasirox, 0.31 (0.14) for 20 mg/day and 0.47 (0.13) for 40 mg/day.

### 4. Any adverse events

Galanello reported that "Adverse events were infrequent and of mild intensity. The most frequently reported adverse event was headache, with no association to the dose level (four participants at 2.5 mg/kg, one participant at 20 mg/kg, and one participant at placebo). Nausea and diarrhoea occurred in the 80-mg/kg group only (three of eight participants, all from one centre), suggesting that these symptoms were either drug related or possibly related to the dense oral suspension administered. Single occurrences of influenza, joint pain, and vertigo were not dose associated and were not suspected to be drug related. No consistent effect on individual laboratory values was observed. In single cases, hematological, biochemical, and special kidney parameters were outside the normal range, including at baseline, but no correlation with treatment could be observed. Notable parameters outside the

normal ranges (and order of magnitude) were as follows: bilirubin, alanine aminotransferase, and aspartate aminotransferase (up to 1.5- to 3-fold increase); alkaline phosphatase (up to 1.5-fold increase); and creatinine kinase (0.3- to 0.6-fold decrease). A couple of creatinine values were just below the normal ranges (with the exception of a single value observed at screening, which was below the lower limit by a factor of 0.8). Abnormally low hematocrit, haemoglobin, and erythrocytes were frequent but had no association to the dose level, while other hematological parameters were abnormally high, such as platelet, eosinophils, lymphocytes, monocytes, and neutrophils, with an order of magnitude of 1.2 to 1.5. These findings are suspected to be caused by the underlying disease and by frequent blood sampling during the study. As expected in this study population, all patients had elevated ferritin values prior to the study, ranging from 1422 to 4780 ng/mL. No notable change in the levels of the trace elements was observed (zinc, copper, magnesium, and calcium). Among the special kidney function parameters, values of  $\alpha$ -glutathione-S-transferase and  $\beta$ 2- microglobulin were in single instances above the range of the normal values by a factor of 2- to 5-fold (including at baseline) and, in the extreme case, by a factor of more than 10- and 30-fold, respectively, for each parameter. The urinalysis sometimes showed pH values up to 6.5 to 7, as well as traces of urine bilirubin, glucose, ketones, leukocytes, and protein." (Galanello 1999).

Some data reported by Nisbet-Brown regarding AEs (23 participants) (Analysis 1.2) could be extracted (Nisbet-Brown 2001). Other safety and tolerability data are only available descriptively.

"No clinically relevant changes in any safety variable were seen between ICL670 and placebo groups. Specifically, no relevant changes were reported in haematological variables, mean concentrations of serum calcium, phosphorus, magnesium, uric acid, creatinine, urea nitrogen, albumin, creatine kinase, triglycerides, or total cholesterol. No abnormalities of renal sediment were noted. Further, no relevant changes from baseline in electrocardiographic, audiometric, or ophthalmologic examinations were noted, with the exception of one patient in whom a myelinated fibre bundle or retinal infarct was seen after seven days of treatment with ICL670 at 20 mg kg<sup>-1</sup> day<sup>-1</sup>. This patient was reviewed by an independent ophthalmologist, and the change was thought to be secondary to his underlying diabetes mellitus. No significant changes between ICL670 and placebo were seen in copper or zinc concentrations in blood over the study period, indicating thus that ICL670 was highly selective for iron." (Nisbet-Brown 2001).

## 5. Participant satisfaction and adherence

Only data on discontinuations due to serious adverse events could be extracted (Analysis 1.3). Nisbet-Brown reported that nine participants in total discontinued treatment for serious AEs, eight of which were receiving deferasirox (24 participants) (Nisbet-Brown 2001) (Analysis 1.3). However, two participants did not complete a single treatment day and only three discontinuations due to rash were deemed to be drug-related.

## 6. Cost of intervention per year

No data on costs of intervention were available from either study (Galanello 1999; Nisbet-Brown 2001).

## 7. Other additional outcomes

No other additional outcomes were reported.

## 2. Transfusion-dependent thalassaemia: deferasirox compared to deferoxamine

Seven studies compared deferasirox to deferoxamine (Cappellini 2005b; Habibian 2014; Hassan 2016; Molavi 2013; Peng 2013; Pennell 2014; Piga 2002). Two additional studies compared all three iron chelators (Chirico 2013; Elalfy 2015a). To include data in the comparison of deferasirox and deferoxamine as well as deferasirox and deferiprone, the number of participants in the deferasirox group was split for each comparison.

While mainly earlier studies which specified the treatment used lower deferasirox doses (Cappellini 2005b: 5 to 30 mg/kg/day, Molavi 2013: 20 mg/kg/day, Piga 2002: 10 or 20 mg/kg/day, Elalfy 2015a: 25 mg/kg/day), newer studies extended the upper limit of doses to 40 mg/kg/day (Hassan 2016: 20 to 40 mg/kg/day, Peng 2013: 40 mg/kg/day, Pennell 2014: 40 mg/kg/day). Higher doses might affect safety and cause higher costs.

For the Cappellini study, discrepancies between those who discontinued (n = 29) or those who died (n = 4), who were not included in the primary efficacy population (n = 33) and those who did not complete one year of study (n = 45 according to the primary report and n = 29 according to the report on patient-reported outcomes) were not clearly addressed (Cappellini 2005b). The success rate analysis (Analysis 2.16) was based on the primary efficacy population (n = 553), while changes in ferritin were based on n = 563 (Analysis 2.10), and both changes in LIC and iron

excretion to intake ratio were based on those only who compared one year of study (n = 541) (per protocol analysis) (Analysis 2.14; Analysis 2.20). In the Elalfy study, participants were randomised twice: to three iron chelators and to treatment with vitamin C or no treatment with vitamin C, but results are only reported for those who received vitamin C (Elalfy 2015a).

## Primary outcomes

### 1. Overall mortality measured at any point in time

Mortality was reported in eight studies (Cappellini 2005b; Hassan 2016; Molavi 2013; Elalfy 2015a; Pennell 2014; Chirico 2013; Peng 2013; Piga 2002). Piga 2002 reported mortality for both 10 and 20 mg/kg/day subgroups. There was no significant difference in mortality observed; data were pooled despite range from eight months to two years (1170 participants) (Analysis 2.1). However, the number of participants and in particular the number of events was limited. Cappellini reported that all four deaths were felt to be unrelated to the administration of the study drug by the independent Program Safety Board (Cappellini 2005b) (Analysis 2.1).

## Secondary outcomes

### 1. Reduced end-organ damage due to iron deposition

One study assessed LVEF (%) (172 participants) (Pennell 2014) (Analysis 2.2). Data for mean change from baseline was extracted from clinicaltrials.gov as least squares mean and SEM, SD was calculated. LVEF remained stable in both groups, showing no significant difference between both groups after one year. No significant difference was also seen in the number of individuals for both subgroups with improvement from abnormal LVEF at baseline to normal range (21 participants) (Analysis 2.3) and from normal LVEF at baseline to below lower limit of normal at end of study (151 participants) (Analysis 2.3).

The incidence of thyroid disease was assessed in one study (19 participants) (Chirico 2013) (Analysis 2.4). No difference was observed after two years of treatment, but the included population was very small.

Two studies reported detailed information on ALT levels and creatinine clearance (Hassan 2016; Pennell 2014). Overall mean (SD) ALT levels had decreased in both treatment groups after one year (deferasirox: -3.5 (80.4) U/L; deferoxamine: -18.9 (35.5) U/L) in the Pennell study, but due to missing number of included participants, we were not able to include these data in our meta-analysis (Pennell 2014). Among participants with abnormal baseline ALT, levels had improved to within the normal range in a similar number of participants in both groups (119 participants) (Analysis 2.5). In the Hassan study, AST (U/L) and ALT (U/L) levels were significantly different at end of study (Hassan 2016), but values were already significant different at baseline. While ALT levels increased (60 participants), AST levels decreased in both treatment groups (60 participants) during the study (Analysis 2.6; Analysis 2.7). Another study reported, that 32% of participants had increased ALT at baseline, but most participants had normal AST at baseline (Piga 2002). The authors assume liver damage due to chronic viral hepatitis and/or iron overload. No participant had consistent or progressive elevations in transaminase levels during the study.

Hassan reported serum creatinine at end of study (Hassan 2016). The difference between both treatment groups was not significantly different (60 participants) (Analysis 2.8). In the Pennell study, mean (SD) creatinine clearance had decreased in both groups after one year of treatment (deferasirox: -37.0 (42.9) mL/min; deferoxamine: -23.1 (36.6) mL/min), but the number of included participants was not mentioned (Pennell 2014). One study reported, that blood urea was significantly higher in the deferasirox group at end of study (60 participants), MD 7.10 (95% CI 4.01 to 10.19) (Hassan 2016) (Analysis 2.9).

## 2. Measures of iron overload

### a. Serum ferritin concentration

In the Cappellini study the mean ratio of deferasirox to deferoxamine varied between the predefined subgroups according to iron overload measures at baseline and different effects were seen in the different subgroups accordingly (Cappellini 2005b). Data from Cappellini showed a clear dose-response effect for serum ferritin levels (Analysis 2.10). At a ratio of less than 1:2.2 of deferasirox to deferoxamine, the latter was statistically more effective; similar efficacy was achieved only in the highly iron-overloaded subgroup at a mean ratio of 1:1.8.

One study reported serum ferritin as mean change from baseline (Molavi 2013). For the following studies we used the methods as described by Wan to calculate the means and SDs for our analysis (Wan 2014). One study reported median change and range (Pennell 2014). The Peng study reported median and range at end of the study; additionally Z values for change from baseline were given for both treatment groups, so we were able to calculate change from baseline values (Peng 2013). A further study reported median and interquartile ranges at end of study (Elalfy 2015a). A sixth study reported median and range at end of study; due to a given P value for change from baseline ( $P < 0.001$ ), SD for change from baseline could be calculated (Hassan 2016).

Combined evidence from the meta-analysis of all six studies showed a significant difference between treatment arms, favouring deferoxamine, MD 454.42 (95% CI 337.13 to 571.71) (1002 participants) (Analysis 2.10). Heterogeneity was very high ( $I^2 = 92%$ ), likely due to different baseline iron overload and different chelation doses. Using the random-effects model, results remained statistically significant, MD 743.14 (95% CI 263.18 to 1223.09).

A sensitivity analysis was undertaken for serum ferritin without all values which were calculated according to Wan (Wan 2014) (701 participants) (Analysis 2.11). The results of the Cappellini and Molavi studies were pooled and remained statistically significant, favouring deferoxamine, MD 418.94 (95% CI 297.23 to 540.65) (Cappellini 2005b; Molavi 2013).

In the Piga study, data for serum ferritin are presented only in a figure giving means and SDs at various time points; since no information was given with regard to change in mean serum ferritin with respective SDs, we were unable to extract data on ferritin (Piga 2002). In the Chirico study, data on serum ferritin could not be extracted as it was unclear if mean or median, range or interquartile range were reported (Chirico 2013). The authors stated, that they did not find statistical differences between serum ferritin changes in all treatment groups after therapy. Although Habibian measured serum ferritin, no data were presented that would allow for inclusion in our meta-analysis (Habibian 2014).

The authors reported that "mean ferritin level was alike between two groups except for third month follow up that was significantly higher in Osveral<sup>®</sup> group ( $P < 0.03$ ).". Data from Elalfy were only available for half of the participants receiving adjuvant vitamin C, but data on participants without vitamin C supplementation was missing and could not be included in our meta-analysis (Elalfy 2015a). The author only describes that serum ferritin was significantly improved in iron chelation subgroups receiving vitamin C compared to those receiving no vitamin C.

### b. Liver iron concentration (LIC)

LIC was measured in one study (Peng 2013) by R2\* after 12 months of treatment (24 participants) (Analysis 2.12). Based on given median and range at end of study, mean and SD could be calculated as stated in our methods. Due to given Z values for change from baseline, mean change and SDs could be calculated. No significant difference was observed, but the study included only a small population of 24 participants.

Change in LIC measured by MRI (R2) was significantly different favouring deferoxamine in one study (Pennell 2014). Elalfy also presented MRI R2\* measurements at end of study for those participants receiving vitamin C, (SDs for change could be calculated from P values (both given as  $< 0.001$ )), but no difference in LIC was observed between both groups (Elalfy 2015a). When data from the two studies were pooled, the change in LIC was not significantly different between the two groups, but heterogeneity was very high ( $I^2 = 79%$ ) (217 participants) (Analysis 2.13). No significant difference was observed when the analysis was repeated using the random effects model. In the Elalfy study, data for the iron chelation subgroups not receiving vitamin C were not given, but the author describes that LIC was significantly improved compared to those who didn't receive vitamin C (Elalfy 2015a).

In most participants in the Cappellini study, the LIC was measured by biopsy ( $n = 454$ ) and only in a minority by SQUID ( $n = 87$ ) (Cappellini 2005b). According to the authors, SQUID measurement underestimated LIC; however, since this applies to both groups and data were not completely given for all relevant outcomes, we did not examine these data for the subgroups separately, but rather decided to extract the data on LIC for the combined group measured by either biopsy or SQUID (Analysis 2.14). At a ratio of 1:1.8 deferasirox showed a significantly better efficacy than deferoxamine in the subgroup of highly iron-overloaded people, while deferoxamine showed higher efficacy in the other three subgroups at ratios of 1:2.2, 1:3.6 and 1:5.5 (541 participants), MD 2.37 (95% CI 1.68 to 3.07) (Analysis 2.14). For both drugs a clear dose-effect relation was shown. The primary objective of the Cappellini study was to investigate if deferasirox is non-inferior to deferoxamine regarding success rate in LIC (Cappellini 2005b). Across all dose groups, non-inferiority was not achieved, because the lower limit of the 95% CI was less than -15% (predefined by authors, less conservative than our definition of non-inferiority).

Two studies also did special responder analysis (Cappellini 2005b; Piga 2002). Responder-definition varied between the studies (decrease in LIC more than 10% in the Piga study (67 participants) (non-significant result) (Analysis 2.15). The Cappellini study (553 participants) used a definition of LIC ranging from 1 to less than 7 mg Fe/g dry weight after one year, significantly favouring deferoxamine, RR 0.80 (95% CI 0.69 to 0.92) (Analysis 2.16).

Results for mean change in LIC could not be included in the analysis from the Piga study due to missing SDs (Piga 2002). However, results for mean change in LIC were reported: -0.4 mg Fe/g dry weight for the 10 mg/kg/day deferasirox dose group, -2.1 mg Fe/g dry weight for the 20 mg/kg/day dose group and -2.0 mg Fe/g dry weight for the 40 mg/kg/day deferoxamine group.

### c. Myocardial iron concentration

Two studies measured cardiac T2\* (Elalfy 2015a; Pennell 2014).

One study measured myocardial T2\* after one year of treatment (Pennell 2014). Results are presented as geometric means and coefficients of variance (%) for both groups in the journal publication, so it was not possible to calculate means and SDs for inclusion in our meta-analysis. Efficacy is reported as ratio of the Gmeans of deferasirox versus deferoxamine. For the ITT-population, which only included 180 of 197 randomised participants, the ratio was 1.055 (repeated 95% CI, 0.999 to 1.129). Analysing the per protocol population, a ratio of 1.056 (repeated 95% CI, 0.998 to 1.133) was calculated. Both analyses showed no significant difference between the two treatment arms. The Pennell study was designed as a non-inferiority study regarding myocardial iron removal (Pennell 2014). The authors defined a non-inferiority margin of 90% (as we did in our review). The results for myocardial T2\* revealed that the lower bound of the 95% CI was greater than prespecified margin of 0.9, which demonstrated non-inferiority of deferasirox compared to deferoxamine.

The second study reported myocardial T2\* for participants receiving vitamin C also after one year (Elalfy 2015a). We were able to calculate the change from baseline due to given P values for change from baseline. Meta-analysis revealed no significant difference between the two groups (Analysis 2.17, 45 participants). In the Elalfy study, data are not given for participants not receiving vitamin C, but the author describes that cardiac MRI T2\* was increased compared to groups not receiving vitamin C (Elalfy 2015a).

The Pennell study authors derived myocardial iron concentration from myocardial T2\* values based on a formula described by Carpenter (Carpenter 2011) (Pennell 2014). No significant difference was seen for all participants and for the subgroups of participants with myocardial T2\* < 10 ms and ≥ 10 ms at baseline (Analysis 2.18, 172 participants). Improvement in myocardial T2\* was defined as increase from a range of 6 to < 10 milliseconds at baseline to 10 to 20 ms at end of study. Worsening of myocardial iron was defined as decrease from a range of 10 ms to ≤ 20 ms at baseline to 6 to < 10 ms. Significantly more participants treated with deferasirox reached normalized myocardial T2\* than participants with deferoxamine, RR 2.85 (95% CI 1.09 to 7.43) (Analysis 2.19, 172 participants). No significant difference was found for improvement and worsening between the two groups (Analysis 2.19).

### d. Other measures of iron overload

One study evaluated the iron excretion-intake ratio (Cappellini 2005b). The results reflect the dose-response and ratio effect seen for ferritin, MD -0.18 (95% CI -0.24 to -0.12) (Analysis 2.20, 541 participants). Deferoxamine showed higher efficacy at ratios of 1:2.2, 1:3.6 and 1:5.5, while deferasirox at a ratio of 1:1.8 showed significantly higher efficacy in the subgroup of highly iron-overloaded people.

### 3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)

No data on iron excretion were available from any study.

### 4. Adverse events

Five studies reported in a detailed manner on AEs (Cappellini 2005b; Molavi 2013; Piga 2002; Pennell 2014; Hassan 2016). In the Cappellini study, it is not clearly stated whether all 586 participants were included in this analysis; however, since discontinuations are reported, we assume that all 586 participants were included (Cappellini 2005b). From the Piga phase II study reports, some safety data were reported by dose group. Our intention was to pool the data with the results of other studies, so we summed the number of AEs of both dose subgroups. Only common (observed in ≥ 5% of participants) adverse events of the Pennell study were reported in the journal publication. On clinicaltrials.gov more adverse events were reported, but due to unexplained differences between journal publication and register entry in the numbers of some adverse events, we extracted the data from the peer-reviewed journal publication.

Two studies reported the number of participants affected by SAEs (773 participants) (Cappellini 2005b; Pennell 2014) (Analysis 2.21). The pooled results revealed no significant difference between both treatment groups. One study reported SAEs in detail (Pennell 2014). No significant differences were seen in all SAE between the two groups (187 participants) (Analysis 2.22).

No statistically significant difference was found between deferasirox and deferoxamine with regard to the number of participants experiencing "any adverse events" (Pennell 2014; Piga 2002, 258 participants); heterogeneity was high ( $I^2 = 74%$ ) (Analysis 2.23). No significant difference was observed using random-effects model. Different types of AEs were reported, but only isolated increases of creatinine occurred significantly more often while on deferasirox treatment compared to deferoxamine (657 participants) (Analysis 2.24). However, likelihood for a false-positive finding is high due to the large number of AEs reported and compared. All other reported AEs such as thrombocytopenia, agranulocytosis, neutropenia, leukopenia, cardiac AEs, hearing loss, lens and retinal abnormalities, different gastrointestinal disorders, asthenia, influenza-like illness, pyrexia, allergic conjunctivitis, bronchitis, upper respiratory tract infection, urinary tract infection, increased ALT, elevated ALT (> 2 x ULN), increased AST, increased blood creatinine, increased platelet count, arthralgia, back pain, osteoporosis, headache, vertigo, proteinuria, cough, influenza, nasopharyngitis, oropharyngeal and pharyngolaryngeal pain, pharyngitis, rhinitis and rash were either not observed at all or at frequencies that were not statistically different between both treatments (Analysis 2.24). Heterogeneity regarding the pooled data for diarrhoea was high ( $I^2 = 53%$ ), but results remained not statistically significant using a random-effects model.

Cappellini describes mild, dose-dependent increases in serum creatinine in 38% deferasirox participants, mostly in the 20 and 30 mg/kg/day groups in those participants with the highest decreases in LIC and serum ferritin (Cappellini 2005b). Increases were sometimes transient and generally within the normal range. The increases never exceeded 2x ULN. 14% of participants in the deferoxamine group experienced similar increases. Eight participants in the deferasirox and seven participants in the

deferoxamine group experienced deafness, neurosensory deafness or hypoacusis. For two participants in the deferasirox group and five participants in the deferoxamine group, cataracts or lenticular opacities were reported. Electrocardiograms were performed for 258 participants in the deferasirox group and 245 participants in the deferoxamine group. The authors reported that no cardiac safety concerns regarding deferasirox were identified and a similar percentage of participants receiving deferasirox (5.1%) and deferoxamine (6.9%) experienced cardiac AEs.

Pennell assessed drug-related AEs and reported the ones affecting  $\geq$  two participants (Pennell 2014). Hassan also reported different kinds of drug-related AEs, but not in a systematic way (Hassan 2016). As far as possible, these were included in the analyses; no significant differences were observed regarding the number of participants experiencing drug-related AEs (Analysis 2.25, 187 participants) or the different kinds of drug-related AEs (Analysis 2.26, 247 participants). In the Cappellini study, the authors describe the most common AEs with an apparent relationship to deferasirox were transient gastrointestinal events (15.2% of participants) and skin rash (10.8%) (Cappellini 2005b). Median duration of the gastrointestinal events were eight days or less, therefore dose adjustment or discontinuation of deferasirox was rarely required. Two participants receiving deferasirox developed ALT levels  $> 2x$  ULN, which was felt by the investigator to be drug-related. Of the participants experiencing deafness, neurosensory deafness or hypoacusis, these symptoms were considered drug-related in one participant receiving deferasirox and five participants receiving deferoxamine. Cataracts or lenticular opacities were reported in one participant receiving deferasirox and four participants receiving deferoxamine. There was no drug-related agranulocytosis reported in this study.

### 5. Participant satisfaction and adherence

Satisfaction with, convenience of and willingness to continue treatment was significantly higher in the group receiving deferasirox who had previously been treated with deferoxamine, although differences were not as marked in the small group of deferoxamine-naive participants (Analysis 2.27; Analysis 2.28; Analysis 2.29) (even when those who did not respond to the questionnaire were counted as not satisfied or unwilling to continue treatment). Time lost from normal activities due to treatment was significantly less with deferasirox (Analysis 2.30, 187 participants). For the outcomes "willingness to continue" (Analysis 2.29) and "time lost from normal activities" (Analysis 2.30), the number of participants who responded at end of study were not given; however, to incorporate these data, we assumed that all participants provided this information.

Adherence was evaluated in one study and defined as percentage of the planned dose taken by participants (Pennell 2014). No significant difference was seen between both groups (Analysis 2.31, 187 participants).

Another study measured adherence by either pill or vial count, but no results were reported (Elalfy 2015a). Five participants in the deferoxamine subgroup did not continue till the end of study because of poor adherence, but it was unclear if participants actively discontinued the study or were excluded by the investigators.

One study reported, that all participants were adherent, but adherence was not defined (Hassan 2016).

The number of participants who discontinued the study was not statistically significant different between both groups in eight studies (Analysis 2.32, 1211 participants). In the Piga study, two participants each in the deferasirox 20 mg/kg/day and deferoxamine groups were withdrawn prematurely from the study (Piga 2002). One participant in the deferasirox 20 mg/kg/day group was excluded due to unsatisfactory therapeutic effect and QTc prolongation. The other three participants were excluded due to adverse events. The AEs of one participant in the deferoxamine group (arthralgia, headache and fever) were considered to be study drug-related by the investigator. In the Elalfy study, five participants in the deferoxamine treatment group discontinued because of poor compliance (Elalfy 2015a). It remains unclear if participants left the study deliberate or were excluded by investigators.

One study reported the number of participants with dose adjustments or dose interruptions, but no significant difference between both treatments was observed (586 participants) (Cappellini 2005b) (Analysis 2.33); approximately 5% of people discontinued, while dose adjustments were required in approximately one third of people.

Another study evaluated number of participants with at least one dose interruption (187 participants) (Analysis 2.34) or dose reduction (187 participants) (Analysis 2.35) separately (Pennell 2014). No significant differences between both groups were observed. The main reason for interruption (deferasirox: 21/96; deferoxamine: 19/91) and dose reduction (deferasirox: 24/96; deferoxamine: 21/91) was an AE. One study reported the number of participants with dose adjustments (71 participants) (Piga 2002); there were significantly more participants with dose adjustments in the deferasirox group, RR 3.23 (95% CI 1.28 to 8.16) (Analysis 2.36). However, there was no significant difference in the number of participants with dose interruptions due to an AE in this study (71 participants) (Analysis 2.37).

### 6. Cost of intervention per year

No data on costs of intervention were available from any study.

### 7. Other reported outcomes not predefined

In the Elalfy study, also transfusion index, haemoglobin, iron, total iron binding capacity, transferrin saturation and vitamin C at baseline and end of study are reported (Elalfy 2015a). We included transfusion index, haemoglobin and transferrin saturation in our analysis. Due to missing P values, we were not able to calculate the SD for change from baseline. Haemoglobin at end of study was significant higher in the deferoxamine group, MD -0.70 (95% CI -1.33 to -0.07) (Analysis 2.38). In the Molavi study, change in haemoglobin levels from beginning to end of study were significant, MD -0.46 (95% CI -0.81 to -0.11) (Molavi 2013). Pooled results of both studies showed a significant lower hemoglobin in the deferasirox group, MD -0.52 (95% CI -0.82 to -0.21) (180 participants) (Analysis 2.38). No significant difference was observed for either transfusion index or transferrin saturation at end of the Elalfy study (42 participants) (Elalfy 2015a) (Analysis 2.39; Analysis 2.40). This study provides only data on participants receiving vitamin C, but the author describes, that improvement in transfusion index, serum iron, T<sub>sat</sub> and hemoglobin was significant improved in those receiving vitamin C compared to those not receiving vitamin C.

Hassan reports no significant difference regarding platelet count ( $\times 10^3/\text{mm}^3$ ) and absolute neutrophilic count ( $/\text{mm}^3$ ) (Hassan 2016) (Analysis 2.41; Analysis 2.42).

In the Piga study, all treatment groups had transient and low grade ( $< 10$ -fold above the ULN) elevations of urinary b-2 microglobulin, but the elevations were more frequent in those receiving deferasirox 20 mg/kg/day (Piga 2002). The elevations tended to normalize, although the study drug was continued in most cases. In three participants in the deferasirox group, treatment was discontinued and values normalized within seven to 10 days. Two participants in the deferasirox 20 mg/kg/day group had the highest evaluations, the dose was reduced to 10 mg/kg/day which resulted in a normalization of the b-2 microglobulin levels. Moreover, Piga reported that there were no consistent changes in urinary N-acetyl-beta-glucosaminidase levels (Piga 2002).

Serum copper and zinc levels fluctuated in participants in the Piga study, but no progressive decreases occurred (Piga 2002). In the Cappellini study, the authors describe that zinc and copper levels at the end of the study were comparable in both treatment groups (Cappellini 2005b).

Growth and development was described as normally within children who were receiving deferasirox (Cappellini 2005b).

### 3. Transfusion-dependent thalassaemia: deferasirox compared to deferiprone

One study compared deferasirox to deferiprone (Sanjeeva 2015). Two additional studies compared all three iron chelation monotherapies (Chirico 2013; Elalfy 2015a). A further study compared deferasirox to deferiprone monotherapy and combination of both (Kakkar 2014). To include data from these multi-armed studies into meta-analysis, deferasirox groups were split.

#### Primary outcomes

##### 1. Overall mortality measured at any point in time

No deaths were observed (146 participants) (Chirico 2013; Elalfy 2015a; Sanjeeva 2015) (Analysis 3.1).

#### Secondary outcomes

##### 1. Reduced end-organ damage due to iron deposition

One study evaluated the incidence of thyroid disease after two years of treatment (18 participants) (Chirico 2013) (Analysis 3.2). No significant difference was seen between both groups, but the population ( $n = 18$ ) was very small.

One study reported AST, ALT, urea and creatinine levels and neutrophil count at nine months (38 participants) (Sanjeeva 2015) (Analysis 3.3; Analysis 3.4; Analysis 3.5; Analysis 3.6 Analysis 3.7). P values for change from baseline were given, so we were able to calculate the SD for change from baseline. No significant differences between both groups were observed.

Although Kakkar reported the performance of monthly renal function tests and measurements of liver enzymes, no results were presented (Kakkar 2014).

##### 2. Measures of iron overload

##### a. Serum ferritin

Two studies measured serum ferritin concentration at end of study (Sanjeeva 2015; Elalfy 2015a). Mean change from baseline was calculated from P values (baseline to end-value) for the Sanjeeva study (Sanjeeva 2015). The thesis document additionally reported serum ferritin in different subgroups which were categorized according to their baseline serum ferritin. The second study reported median and interquartile ranges, so we calculated mean and SD at end of study (Elalfy 2015a). No significant difference between both treatment groups was observed for all participants and for subgroups split according to baseline ferritin values (83 participants) (Analysis 3.8).

Two other studies measured serum ferritin every three months, but data could not be extracted (Chirico 2013; Kakkar 2014). In the Chirico study, data on serum ferritin could not be extracted due to insufficient information on the data (Chirico 2013): it was unclear if mean or median, range or interquartile range were given. The authors described, that they did not find statistical differences between serum ferritin changes in all treatment groups after therapy. In the Kakkar study, the authors describe that "serum ferritin reduced significantly in group I [DFP] and II [DFX] [...]" (Kakkar 2014).

##### b. Liver iron concentration (LIC)

One study measured LIC by MRI R2\* at end of study (Elalfy 2015a). We calculated the SD for change from baseline from P values. No significant difference was seen between both treatment groups (45 participants) (Analysis 3.9).

A further study measured liver MRI T2\* but no data could be extracted (Kakkar 2014). Mean values for liver MRI T2\* were reported, but it remains unclear if these values represent baseline or end of study data.

##### c. Myocardial iron concentration

One study measured cardiac T2\* at end of study (Elalfy 2015a). We calculated the SD for change from baseline from P values. No significant difference was seen between both treatment groups (45 participants) (Analysis 3.10).

Data from the Kakkar study measuring cardiac T2\* could not be extracted (Kakkar 2014). The authors describe, that cardiac MRI T2\* at the end of the study were slightly better in [deferiprone] group as compared to [deferiprone and deferasirox] group, although this was not statistical significant ( $P = 0.07$ ).

##### 3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)

No data on iron excretion were available from any study.

##### 4. Adverse events

Three studies provided information on AEs (Elalfy 2015a; Kakkar 2014; Sanjeeva 2015).

In the Sanjeeva study, AEs were very common in the deferiprone (15 out of 22, 68.2%) and deferasirox group (seven out of 19, 36.8%), but overall no significant difference was observed (41 participants) (Sanjeeva 2015) (Analysis 3.11). Significantly more

participants experienced arthralgia in the deferiprone group compared to the deferasirox group, RR 0.13 (95% CI 0.02 to 0.93) (41 participants) (Analysis 3.12), resulting in three participants discontinuing deferiprone treatment. Due to the high number of different types of AEs reported and compared, likelihood for a false-positive result is increased. Nausea and vomiting appeared frequently in both groups: deferasirox 31.5% (six out of 19), deferiprone 27.2% (six out of 22), respectively, with no significant differences between both groups (41 participants) (Analysis 3.12). One participant in the deferiprone group had abdominal pain (Analysis 3.12, 41 participants). None of the participants experienced rashes or diarrhoea (41 participants) (Analysis 3.12). One participant in the deferiprone group experienced neutropenia, however, agranulocytosis was not observed in any of the groups (38 participants) (Analysis 3.12). The number of participants with ALT or AST levels of 2x above ULN was equal in both treatment groups (38 participants) (Analysis 3.12). One participant in the deferasirox group had 50% increase in serum creatinine levels from baseline (Analysis 3.12, 38 participants). Renal failure was not observed in any of the groups (38 participants) (Analysis 3.12).

Elalfy only states that "no serious adverse reaction to iron chelators nor to vitamin C administration have been reported" (Elalfy 2015a). No data on adverse events could be extracted from the Kakkar study (Kakkar 2014).

### 5. Participant satisfaction and adherence

No data on participant satisfaction and adherence could be extracted from any study.

One study measured adherence by either pill or vial count, but no results were reported (Elalfy 2015a).

No significant difference was observed in the number of participants discontinuing the study overall (Chirico 2013; Elalfy 2015a; Sanjeeva 2015) (Analysis 3.13, 179 participants) or discontinuing the study due to AEs (41 participants) (Analysis 3.14).

### 6. Cost of intervention per year

No data on cost of intervention were available from any study.

### 7. Other additional outcomes

Comparing deferasirox to deferiprone in the identified studies, other, in this review not a priori defined outcomes were measured. A significant higher transferrin saturation was seen in the deferiprone group at end of one study (45 participants), MD -7.40 (95% CI -13.28 to -1.52) (Elalfy 2015a) (Analysis 3.15). No significant differences were observed regarding haemoglobin or transfusion index in this study (45 participants) (Analysis 3.16, Analysis 3.17). Additionally, ALP levels were reported at nine months in one study (Sanjeeva 2015). Due to P values for change from baseline given, we were able to calculate the SD for change from baseline. No significant difference was observed (38 participants) (Analysis 3.18). Moreover, the thesis document reporting the Sanjeeva study also reported phosphorous and calcium levels, which we did not include in our review (Sanjeeva 2015). In the Elalfy study, also iron, total iron binding capacity and vitamin C at end of study are reported (Elalfy 2015a).

### 4. Transfusion-dependent thalassaemia: deferasirox compared to deferasirox in combination with deferiprone

One study with 40 participants reported in one abstract included the comparison of deferasirox versus deferasirox and deferiprone administered sequentially (Kakkar 2014).

Cardiac and liver MRI, serum ferritin, CBC, liver enzymes and renal function tests were assessed during the study. Results for liver MRI, serum ferritin and adverse events were only reported narratively and no data could be extracted:

"Liver MRI T2\* was not significantly different before and after the study. Serum ferritin reduced significantly in group I [DFP] and II [DFX] but not in group III [DFX+DFP]. Group receiving combination therapy did not show any untoward side effects as compared to single drug regimen."

No results regarding cardiac MRI, CBC, liver enzymes and renal function tests were reported.

### 5. Transfusion-dependent thalassaemia: deferasirox in combination with deferiprone compared to deferiprone alone

One study with 40 participants reported in one abstract included the comparison of deferiprone versus deferasirox and deferiprone administered sequentially (Kakkar 2014).

Cardiac and liver MRI, serum ferritin, CBC, liver enzymes and renal function tests were assessed during the study. Results for cardiac and liver MRI, serum ferritin and adverse events were only reported narratively and no data could be extracted:

"Cardiac MRI T2\* at the end of the study was slightly better in group I [DFP] as compared to group III [DFP + DFX] although was not statistical significant (p=0.07). [...] Liver MRI T2\* was not significantly different before and after the study. Serum ferritin reduced significantly in group I [DFP] and II [DFX] but not in group III [DFP+DFX]. Group receiving combination therapy did not show any untoward side effects as compared to single drug regimen."

No results regarding CBC, liver enzymes and renal function tests were reported.

### 6. Transfusion-dependent thalassaemia: deferasirox in combination with deferoxamine compared to deferoxamine alone

One study compared deferasirox in combination with deferoxamine to deferoxamine alone (Molavi 2014).

#### Primary outcomes

#### 1. Overall mortality measured at any point in time

No loss-to-follow-up was reported in the study (94 participants) (Molavi 2014) (Analysis 6.1). Therefore, we assumed no deaths occurred in any of the groups.

#### Secondary outcomes

#### 1. Reduced end-organ damage due to iron deposition

Molavi measured neutrophils, ALT, AST at baseline and at 12 months (Molavi 2014). Due to missing P values for change from baseline, no SDs for change from baseline could be calculated. No significant differences were observed in neutrophils, ALT, and AST levels (94

participants) between the two groups at 12 months ([Analysis 6.2](#); [Analysis 6.3](#); [Analysis 6.4](#)).

No other data on end-organ damage were available from this study.

## 2. Measures of iron overload

### a. Serum ferritin

The Molavi study measured serum ferritin at 12 months ([Molavi 2014](#)). Due to missing P values (baseline to end of study), SD for change from baseline couldn't be calculated. No significant difference was observed between both groups at end of study (94 participants) ([Analysis 6.5](#)).

### 3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)

No data on iron excretion were available from the study.

### 4. Adverse events

No AEs were reported.

### 5. Participant satisfaction and adherence

No data on this outcome were available from the Molavi study; however, no participant discontinued the study (94 participants) ([Analysis 6.6](#)).

### 6. Cost of intervention per year

No data on cost of intervention was available from the study.

### 7. Other additional outcomes

Haemoglobin at 12 months was slightly higher in participants treated with deferoxamine alone (94 participants) ([Analysis 6.7](#)). ALP was significantly higher in participants treated with both deferasirox and deferoxamine (94 participants) ([Molavi 2014](#)) ([Analysis 6.8](#)).

### 7. Transfusion-dependent thalassaemia: deferasirox in combination with deferiprone compared to deferiprone + deferoxamine

One study compared deferasirox and deferiprone to deferiprone and deferoxamine ([Elalfy 2015b](#)).

#### Primary outcomes

##### 1. Overall mortality measured at any point in time

No deaths were observed during the study (96 participants) ([Elalfy 2015b](#)) ([Analysis 7.1](#)).

#### Secondary outcomes

##### 1. Reduced end-organ damage due to iron deposition

The authors reported that "change in mean LVEF after one year was not different between the two treatment groups (data not shown)." ([Elalfy 2015b](#)). No quantitative data were available.

##### 2. Measures of iron overload

###### a. Serum ferritin

One study measured serum ferritin at 12 months and reported mean and SD values ([Elalfy 2015b](#)). Although not directly stated, we considered the given P value to describe change from baseline so we were able to calculate the mean change and SD. Serum ferritin decreased in both groups, but no significant difference was observed (96 participants) ([Analysis 7.2](#)).

###### b. Liver iron concentration (LIC)

LIC was measured by MRI R2\* in the included study and mean and SD values at end of study were reported ([Elalfy 2015b](#)). Although not directly stated, we considered the given P value to describe change from baseline, so we calculated the mean change and SD. No significant difference was seen between both groups (96 participants) ([Analysis 7.3](#)).

###### c. Myocardial iron concentration

Myocardial iron concentration was measured by T2\* in the included study and mean and SD values at end of study were reported ([Elalfy 2015b](#)). Although not directly stated, we considered the given P value to describe change from baseline, so we were able to calculate the mean change and SD. No significant difference was seen between the groups (96 participants) ([Analysis 7.4](#)).

### 3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)

No data on iron excretion were available from the included study ([Elalfy 2015b](#)).

### 4. Adverse events

The number of participants with a SAE was equal in both groups (96 participants) ([Analysis 7.5](#)). An acute cholecystitis was assessed as a drug-related SAE in a participant receiving deferasirox and deferiprone (96 participants) ([Analysis 7.6](#)). A SAE, classified as unrelated to the drugs and which did not lead to death, was reported in one participant who developed appendicitis while receiving deferiprone and deferoxamine (96 participants) ([Analysis 7.7](#)).

Mild-moderate neutropenia was observed in both groups, which resolved with decreasing deferiprone dose (96 participants) ([Analysis 7.8](#)). No cases of agranulocytosis were observed (96 participants) ([Analysis 7.8](#)). Overall, drug-related AEs "were mostly of mild to moderate severity" and common in both groups (96 participants) ([Analysis 7.9](#)). In the Elalfy study, agranulocytosis, neutropenia, arthralgia, gastrointestinal problems, ALT (at least a three-fold increase), serum creatinine (an increase of at least 33%) above baseline on two consecutive occasions and skin rash were assessed as drug-related with similar frequencies in both groups (96 participants) ([Elalfy 2015b](#)) ([Analysis 7.10](#)).

Non-drug-related AEs were reported by 17 of 48 (35.41%) participants in the deferasirox and deferiprone group versus 18 of 48 (37.5%) in the deferiprone and deferoxamine group (96 participants) ([Analysis 7.11](#)). Only the three most common non-drug-related AEs were reported (infections, gastrointestinal disorders, skin and subcutaneous tissue disorders) and no significant differences were observed (96 participants) ([Analysis 7.12](#)). Mild elevation of hepatic transaminases at the start of therapy were observed in both groups, which returned to normal within the first two months (96 participants) ([Analysis 7.13](#)). Initial



gastrointestinal manifestations also occurred in both groups and "were in form of nausea and mild abdominal pain" (96 participants) (Analysis 7.14).

## 5. Participant satisfaction and adherence

Quality of life was measured by SF-36 in one study (Elalfy 2015b). Data were not given, therefore mean and SD at end of study were obtained through estimation from a figure, and SD for change from baseline was calculated from given P values. No significant differences were observed between both groups (96 participants) (Analysis 7.15).

The definition of adherence in the Elalfy study was the actual dose divided by the total prescribed dose (Elalfy 2015b). We calculated missing SD from given P value. Adherence was significantly higher in the deferasirox and deferiprone group, MD 0.15 (95% CI 0.06 to 0.24) (96 participants) (Analysis 7.16).

Overall, no participant discontinued the study (96 participants) (Analysis 7.17) and there were no SAEs necessitating discontinuation or interruption of therapy in any of the groups (96 participants) (Analysis 7.18).

## 6. Cost of intervention per year

No data on cost of intervention were available from any study.

## 7. Other additional outcomes

No other additional outcomes were reported.

## 8. Non-transfusion-dependent thalassaemia: deferasirox compared to placebo

One study evaluated people with non-transfusion-dependent thalassaemia and compared deferasirox 5 mg/kg/day and deferasirox 10 mg/kg/day starting doses to matching placebos (Taher 2012).

### Primary outcomes

#### 1. Overall mortality measured at any point in time

No deaths occurred during the study in any treatment group during one year of treatment (148 participants) (Taher 2012) (Analysis 8.1).

### Secondary outcomes

#### 1. Reduced end-organ damage due to iron deposition

No data on end-organ damage were available from the study.

#### 2. Measures of iron overload

##### a. Serum ferritin

Different types of data on change in serum ferritin were reported in the journal publication and on [clinicaltrials.gov](http://clinicaltrials.gov). The journal publication reports least squares mean (LSM), median and 95% CI; the mean and SD are reported on [clinicaltrials.gov](http://clinicaltrials.gov). In the journal publication, a LSM of -121 ng/mL (95% CI -203 to -38; median -99 ng/mL) and a LSM of -222 ng/mL (95% CI -304 to -140; median -190 ng/mL) are given in the 5 and 10 mg/kg/day subgroups, respectively. In the placebo group a LSM of 115 ng/mL (median 78 ng/mL) is reported, but due to missing SD or 95% CI we were not able to include these data in our meta-analysis.

The change in serum ferritin reported on [clinicaltrials.gov](http://clinicaltrials.gov) was significant in both the 5 and 10 mg/kg/day deferasirox subgroups compared to placebo, with a MD of -259.10 (95% CI -377.35 to -140.85) and -377.79 (95% CI -522.21 to -233.37) in the 5 and 10 mg/kg/day subgroups respectively (154 participants) (Analysis 8.2). The overall result was also significant, MD -306.74 (95% CI -398.23 to -215.24). Only participants with both baseline and post-baseline values were included in the analyses of the study.

##### b. Liver iron concentration (LIC)

In the Taher study, the primary efficacy end point was change in LIC from baseline to 52 weeks (159 participants) (Taher 2012). The authors used LSM and SEM when reporting data, so we calculated SD to include the results in our meta-analysis. Regarding both starting dose subgroups, decrease in LIC was significant in both groups. For the 5 mg/kg/day group, MD -2.33 (95% CI -4.00 to -0.66); for the 10 mg/kg/day group the decrease was larger, MD -4.18 (95% CI -5.83 to -2.53) (Taher 2012) (Analysis 8.3). Regarding the different types of thalassaemia, results, reported as mean (SD), were only significant in favour of deferasirox in the  $\beta$ -thalassaemia subgroups, with a larger decrease in the 10 mg/kg/day group. Results for  $\alpha$ -thalassaemia and HbE/ $\beta$ -thalassaemia participants were not significant, but included participant populations were smaller than for the  $\beta$ -thalassaemia subgroup. Comparing LIC regarding age of the participants, LIC decrease in the subgroup of participants under 18 years of age with a deferasirox starting dose of 5 mg/kg/day was the only of the four subgroups without significant LIC decrease, but only 10 out of the 159 participants were included (Analysis 8.4).

In the 5 mg/kg/day group, neither the decrease of  $\geq 3$  mg Fe/g dry weight in LIC, nor the reduction in Fe/g dry weight  $\geq 30\%$  were significant compared to placebo. However, in the 10 mg/kg/day group, significantly more participants had a LIC decrease of  $\geq 3$  mg Fe/g dry weight, RR 5.26 (95% CI 1.76 to 15.71) (83 participants) (Analysis 8.5) and a reduction in Fe/g dry weight  $\geq 30\%$ , RR 13.75 (95% CI 1.97 to 95.97) (83 participants) (Analysis 8.6). When combined, both of these results were significant across dose groups (Analysis 8.5; Analysis 8.6). Significantly more participants in both dose groups combined moved to a lower iron burden range (166 participants), RR 3.35 (95% CI 1.62 to 6.91); for the 5 mg/kg/day group, RR 3.39 (95% CI 1.10 to 10.45) and for the 10 mg/kg/day group, RR 3.31 (95% CI 1.28 to 8.55) (Analysis 8.7). No significant difference was observed in the number of participants in the 5 and 10 mg/kg/day subgroups who had LIC  $< 5$  mg Fe/g dry weight (166 participants) (Analysis 8.8); however, when these data were combined the result was significant, RR 5.35 (95% CI 1.30 to 21.99) (Analysis 8.8).

##### c. Myocardial iron concentration

No data on myocardial iron concentration were available from the study.

#### 3. Measures of iron excretion (urine and faeces) over 24 hours (mg/kg/day)

No data on iron excretion were available from the study.

#### 4. Adverse events

An extensive data on SAEs and other AEs are available on [clinicaltrials.gov](http://clinicaltrials.gov). We were not able to include these data in our

meta-analysis, because the data were not reported separately for the core trial.

Six investigator-assessed drug-related SAEs were reported in four participants receiving deferasirox (abdominal, pyrexia, hepatotoxicity, cellulitis, pruritus, rash), no drug-related SAEs were reported with placebo (166 participants), these results were not significant ([Analysis 8.9](#); [Analysis 8.10](#)).

No significant difference was found in the number of participants experiencing at least one AE (166 participants) ([Analysis 8.11](#)) and in the number of participants with mild, moderate or severe AEs (166 participants) ([Analysis 8.12](#); [Analysis 8.13](#); [Analysis 8.14](#)). Neurosensory deafness was reported in a participant receiving placebo 10 mg/kg/day and proteinuria was reported in one participant receiving deferasirox 5 mg/kg/day (166 participants) ([Analysis 8.15](#)). No numbers are given, but the authors report that "the overall number of AEs and SAEs reported before and after dose increases was comparable within each treatment group." Comparisons of the number of participants with notable abnormal post-baseline laboratory results extracted from clinicaltrials.gov (platelet count, neutrophil count, ALT, AST, serum creatinine, creatinine clearance, urinary protein/creatinine ratio, low/high blood pressure, low/high pulse rate), showed no significant differences between both groups (166 participants) ([Analysis 8.15](#)).

Investigator-assessed drug-related AEs "were reported in 40 (24.1%) patients", but no values for each treatment group separately were given. Most common (at least three participants in total) investigator-assessed drug-related AEs were reported (nausea, skin rash, diarrhoea, headache, upper abdominal pain, abdominal pain), but no difference was seen between treatment groups (166 participants) ([Analysis 8.16](#)).

### 5. Participant satisfaction and adherence

No data on participant satisfaction were available from the study.

Adherence was defined as number of participants taking the planned study dose in Taher study ([Taher 2012](#)). Adherence was high, showing no difference between treatment groups (166 participants) ([Analysis 8.17](#)).

Overall, no significant difference was observed in participants discontinuing the study (166 participants) ([Analysis 8.18](#)).

No significant difference was observed in the number of participants who discontinued overall due to AEs (166 participants) ([Analysis 8.19](#)): three participants discontinued in the deferasirox 5 mg/kg/day cohort (fractured pelvis, anaemia, increased urine protein level), three participants in the deferasirox 10 mg/kg/day subgroup (pregnancy (n = 2), rash and pruritus) and two participants in the placebo group (optic neuritis and severe anaemia).

No significant differences were observed in the number of participants with dose increase (166 participants) ([Analysis 8.20](#)), dose interruption (166 participants) ([Analysis 8.21](#)), dose reduction (166 participants) ([Analysis 8.22](#)) and dose reduction due to AE (166 participants) ([Analysis 8.23](#)).

A total of 46.4% of participants had a dose doubling after 24 weeks.

### 6. Cost of intervention per year

No data on cost of intervention were available from the study.

### 7. Other additional outcomes

Taher also reported no significant difference in change in haemoglobin (144 participants) ([Analysis 8.24](#)). However, the study reported a significant difference in transferrin saturation in the 5 mg/kg/day subgroup only, MD -7.16 (95% CI -12.15 to -1.37) (70 participants) ([Analysis 8.25](#)) ([Taher 2012](#)). When dose groups were combined, the difference was also significant, MD -7.10 (95% CI -11.71 to -2.50) (141 participants) ([Analysis 8.25](#)).

## DISCUSSION

### Summary of main results

In the two pharmacokinetic, dose-finding studies iron eliminating efficacy could be shown. In conclusion, in our opinion efficacy measures in these early studies were of limited value. However, since they fulfilled the review's inclusion criteria and were relevant in particular for safety issues, we included them. They showed a dose-response effect as expected, but conclusions regarding efficacy when taken continuously were not really appropriate. In conclusion, pharmacodynamic efficacy and acceptable safety could be confirmed justifying further clinical testing in phase II and phase III studies based on an estimated equivalence ratio of deferasirox to deferoxamine of approximately 1 mg: 2 mg.

A phase III study showed that depending on the actual dose of deferasirox, sufficient efficacy could be achieved to lower both serum ferritin level and liver iron concentration (LIC) (measured by biopsy or superconducting quantum interference device (SQUID)) in people with iron-overloaded thalassaemia ([Cappellini 2005b](#)). In comparison to deferoxamine, at a ratio of more than 2:1, deferoxamine showed a higher efficacy compared to deferasirox; however, similar efficacy of deferasirox could be achieved at a mean ratio of 1.8:1 of deferoxamine to deferasirox. Also, of five smaller studies which didn't consider the actual dose in particular, two showed significantly reduced serum ferritin in participants who received deferoxamine compared with deferasirox. Pooling of all six studies showed a significant reduction in serum ferritin favouring deferoxamine, mean difference (MD) 454.42 (95% confidence interval (CI) 337.13 to 571.71). One study showed a significantly greater change in LIC measured by magnetic resonance imaging (MRI) in favour of deferoxamine, but no significant difference was seen when pooled with a smaller study.

Adverse effects, particularly rare adverse effects, are difficult to investigate in randomised clinical studies with a limited number of participants and incomplete or inconsistent reporting. Accordingly, with the exception of "increase in creatinine" (which may also be a false-positive result due to the large number of different types of adverse events reported and compared) no significant differences in frequencies were observed between deferasirox and deferoxamine. However, from the data it seems that gastrointestinal problems are more common with deferasirox. Due to the low number of included participants who were investigated for adverse events, estimation of rare adverse events (1 to 10 of 10,000 participants) is not possible. Also, data on patient-relevant outcomes such as mortality or end-organ damage are either sparse (low number of events for mortality) or too limited to adequately evaluate the efficacy of deferasirox. Due to study

duration of maximum two years, long-term effects of deferasirox can not be judged.

Satisfaction with, and convenience of, deferasirox among those who had previously received deferoxamine treatment was judged significantly better resulting in higher willingness to continue treatment; time lost from normal activities was also reported to be less with deferasirox. The proportion of people who discontinued treatment for any reason or who required dose interruptions or adjustments was similar for both drugs.

Comparing deferasirox to deferiprone, only two small studies reported markers of iron overload. Given the limited patient population, no difference was seen between either treatment. In one study, significantly more participants experienced arthralgia in the deferiprone group, but the validity of the data are limited because the patient population was very small.

Four studies were identified including deferasirox as monotherapy compared to combination therapy or as part of a combination therapy. There was only one study for every comparison and a patient population of 100 or less per study, so the data are very limited. No significant differences were observed in any outcome, except for adherence comparing deferasirox and deferiprone to deferiprone and deferoxamine, which favoured the combination of oral iron chelators, MD 0.15 (95% CI 0.06 to 0.24).

Treatment with deferasirox appears to reduce serum ferritin and LIC significantly in people with non-transfusion-dependent thalassaemia as reported in one study including 166 participants. From the available safety data regarding overall number of participants with AEs, similar frequencies were observed, but more detailed and complete information on safety is needed. Results should be confirmed in further studies of longer duration, where patient-relevant outcomes, such as mortality or satisfaction, are also considered. A total of 46.4% of participants had a dose doubling after 24 weeks due to LIC being more than 7 mg Fe/g dry weight and a LIC reduction less than 15% from baseline, which reflects the importance of dose adjustments.

### Overall completeness and applicability of evidence

Given our comprehensive search strategy and contact with Novartis, we are confident that we have identified all relevant randomised studies of deferasirox. However, evidence on deferasirox for treatment of iron overload in people with thalassaemia is still limited due to the limited number of randomised participants included in studies comparing deferasirox to other iron chelators ( $n = 1594$ ) and the methodological limitations of most of the studies.

Also, pooling of data from different studies was only feasible for a few outcomes, so that for most outcomes data from only one or very few studies were available. Results from ongoing studies and studies which have not been published in full so far will hopefully add information regarding some of these outcomes in the near future.

The applicability of our results is hampered by the use of surrogate endpoints and the short duration of studies. Long-term studies comparing deferasirox to placebo would be ethically unjustifiable, given that the benefit and therefore also the necessity of iron chelation therapy in people with thalassaemia requiring regular transfusion, has been shown. Since the value of iron chelation

therapy with deferoxamine in people with thalassaemia is well-established (Fisher 2013a), change in surrogate parameters such as serum ferritin or LIC would be acceptable to deduce changes in patient-relevant endpoints such as mortality or end-organ damage for studies comparing deferasirox to placebo. However, to adequately compare the efficacy of two iron chelating drugs such as deferasirox and deferoxamine, information on patient-relevant endpoints such as mortality or end-organ damage should be available. In particular, there is a lack of data from randomised studies regarding the removal of cardiac iron and the prevention of cardiac complications.

Although long-term studies investigating these patient-important endpoints would be important to adequately weigh benefits and AEs of deferasirox compared to standard treatment with deferoxamine, it must be acknowledged that such studies take a long time to conduct and are very cost-intensive. Therefore, it is not surprising that the producers of deferasirox have no particular interest in undertaking these types of studies after treatment has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). However, such studies are necessary for a comprehensive evaluation of the effects of deferasirox as compared to deferoxamine.

Furthermore, it has to be acknowledged that six included studies were supported by the manufacturer of deferasirox.

Finally, the oral mode of application of deferasirox offers an important advantage of deferasirox over deferoxamine, which is of high relevance to those with the disease (Taher 2010). Comparing the two oral iron chelators (deferasirox and deferiprone), deferasirox allows for an easier application - once-daily compared to three-times daily. Therefore, physicians prefer to prescribe deferasirox. Nevertheless, data on adherence from randomised controlled studies are still limited. One such study comparing deferasirox to deferoxamine showed no difference in adherence (Pennell 2014), while a study comparing deferasirox and deferiprone to deferiprone and deferoxamine showed a significant higher adherence favouring the combination of oral iron chelators (Elalfy 2015b). Whether this advantage will translate into better long-term adherence and improved patient-relevant outcomes is still to be shown (Trachtenberg 2011). Recently, the FDA and the EMA have approved a new formulation of deferasirox (Chalmers 2016; EMA 2016; Novartis 2015). These tablets can be swallowed with some water in a single step without dispersing in water, which could further increase adherence. Results of studies investigating this new formulation are not yet available, but may influence future updates of this review, in particular regarding adherence and safety compared to other iron chelators.

### Quality of the evidence

The evidence on deferasirox for treating iron overload in thalassaemia is still limited.

The quality of included studies comparing deferasirox to deferoxamine in people with transfusion-dependent thalassaemia was moderate to low, mainly due to a lack of blinding and selective reporting, the use of a surrogate marker instead of patient-important outcomes and imprecision. For the comparison of deferasirox to placebo in people with non-transfusion-dependent thalassaemia, the quality of the evidence was moderate to very low based on only one small study. For the other comparisons, quality

of evidence was low to very low, mainly due to the inclusion of even fewer participants.

### Potential biases in the review process

A very comprehensive search strategy was applied to identify all potential studies and their reports. However, information on several relevant outcome data prespecified in our protocol were not reported. Several of these outcome measures are, however, important to make an informed and balanced decision on which chelator to choose. Some of these outcome measures were most likely not ascertained during the study, however, others could have well been collected but not reported. Unfortunately, even after contacting the primary investigators, to date we have not been able to obtain any additional data.

We followed the rigorous methodology for systematic reviews outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011), e.g. extracting data independently in duplicate to minimize errors and reduce bias in the process of doing this systematic review.

### Agreements and disagreements with other studies or reviews

Vanorden and Hagemann published the first review on deferasirox based on a systematic literature search in 2006 (Vanorden 2006). Besides data from the phase III study (Cappellini 2005b), this review includes evidence from phase I and phase II as well as pharmacokinetic studies in both humans and non-humans. The authors made no attempt to pool the data; so findings are presented narratively (including observational data). The authors concluded that their findings suggest that deferasirox is as safe and effective as deferoxamine.

Lindsey and co-authors summarized the available data from five phase I/II and the one phase III study in their systematic review published in 2007 (Lindsey 2007). All six studies are critically discussed, but no pooling of data was performed and data are synthesized qualitatively. Based on the only study looking at efficacy as a primary endpoint (Cappellini 2006), the authors come to the conclusion that the two agents have similar efficacy, although overall the non-inferiority of deferasirox could not be shown by the primary phase III study investigators. Tolerability is assessed as good, even though deferasirox is associated with a higher incidence of adverse effects. The authors conclude that long-term efficacy and safety remain to be established.

In 2009, McLeod and co-authors published a comprehensive health technology assessment on deferasirox for secondary iron overload in individuals with chronic anaemia, such as thalassaemia and sickle cell disease (McLeod 2009). They identified 14 randomised studies looking at various iron chelation regimens with a high degree of heterogeneity between studies in terms of study design and outcome reporting. Only three of these compared deferasirox to deferoxamine, but data were not included in a meta-analysis. Furthermore, eight economic evaluations were included in their report. The authors conclude that it appears that there is little difference between agents in terms of reducing serum ferritin. The economic evaluations appear to demonstrate the cost-effectiveness of deferasirox compared to deferoxamine. However, the authors state that both their clinical and economic analyses

were restricted by the available evidence and should only be considered exploratory.

Cochrane Reviews on the effects of deferasirox in people with sickle cell disease (Meerpohl 2014a) and myelodysplastic syndrome (Meerpohl 2014) have been published; both conclude that data on deferasirox in these groups of people are still limited and therefore evidence is insufficient to recommend first-line use of deferasirox in sickle cell disease or myelodysplastic syndrome. Several narrative reviews on deferasirox have also been published of late. These have usually concluded that efficacy is given and the profile of adverse events manageable and therefore acceptable (Cappellini 2008; Cappellini 2009; Porter 2009).

A clinical practice guideline by the Italian Society of Hematology for the management of iron overload in thalassaemia major and related disorders supports our findings and conclusions by recommending deferoxamine for children who start iron chelation therapy before six years of age and in whom the goal of chelation therapy is the prophylactic maintenance of iron balance; while oral chelators (such as deferasirox) should be considered investigational and be used primarily within clinical trials or registries or for patients with poor adherence to, or experiencing AEs from deferoxamine (Angelucci 2008). Due to the limited evidence, these recommendations were given a level D according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system reflecting consensus of the experts (SIGN 2008). This recommendation is in line with the approval by the EMA as first-line only in people with thalassaemia major from six years of age (EMA 2016). In contrast, the FDA have already approved deferasirox in individuals with thalassaemia major aged two years of age and older and in non-transfusion-dependent thalassaemia individuals aged 10 years and older with a LIC of at least 5 mg Fe/g dry weight and serum ferritin over 300 µg/L (FDA 2013).

A systematic review published by Maggio in 2011 reviewed randomised controlled studies for all three iron chelators used in people with thalassaemia major (Maggio 2011). The authors included two studies considering deferasirox (Cappellini 2005b; Nisbet-Brown 2001). They did not pool data from the different dosing subgroups, but analysed the comparisons separately and found significantly lower increases in serum ferritin favouring deferoxamine compared to deferasirox 5 mg/day and 10 mg/day, significantly higher decreases in the deferoxamine group compared to deferasirox 20 mg/day and no significant difference in decrease in the deferasirox 30 mg group versus deferoxamine.

Some additional data, including longer-term effects on deferasirox, were available from observational studies. However, these studies were not systematically searched for nor critically evaluated within this review. Also, due to a higher risk of bias and potential confounding, these types of data are not as well-suited for comparison of two interventions as are data from high quality randomised studies.

It is important to note, however, that other more severe AEs have been reported, such as: cytopenias; Fanconi syndrome and renal failure (Grange 2010; Rafat 2009; Yew 2010); liver failure; and gastrointestinal bleeding, which resulted in a boxed warning by the FDA (FDA Boxed Warning 2010). These potential severe AEs must be taken into consideration when prescribing or using deferasirox.

Also, some studies have shown that higher doses of deferasirox than those evaluated in the early included studies are often needed to achieve adequate reduction of iron overload or prevent further iron accumulation in heavily-transfused individuals (Chirnomas 2009; Taher 2009).

## AUTHORS' CONCLUSIONS

### Implications for practice

Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload. Based on the available data, deferasirox does not seem to be superior to deferoxamine at the usually recommended ratio of 1 mg of deferasirox to 2 mg of deferoxamine. However, similar efficacy seems to be achievable depending on the dose and ratio of deferasirox compared to deferoxamine. Whether this will result in similar efficacy and will translate to similar benefits in the long term, as has been shown for deferoxamine, needs to be confirmed. Data from randomised controlled trials on rare toxicities and long-term safety are still limited. However, after a detailed discussion of the potential benefits and risks, deferasirox could be offered as the first-line option to individuals who show a strong preference for deferasirox, and may be a reasonable treatment option for people showing an intolerance or poor adherence to deferoxamine.

### Implications for research

Although the efficacy of deferasirox to reduce iron overload has been shown, data for a comprehensive comparison with the standard treatment of deferoxamine are still insufficient. Therefore, patients should ideally be included in further, investigator-initiated clinical trials independent from the producer Novartis assessing patient-relevant outcomes and long-term effects of deferasirox. However, given its broad availability, it is unlikely that these studies will ever be conducted. In addition, assessment of rarer AEs, as well as assessment of long-term adherence, in particular with the new formulation, are important to pursue. Finally, it should be ensured that relevant outcomes are measured in a consistent way across studies to allow combination of data in a meta-analysis.

Since this review only included evidence from randomised studies and additional evidence is available from non-randomised, uncontrolled studies, a systematic review also considering this observational evidence would most likely shed some additional light on this topic. Taking into account that there is a third chelator, deferiprone, available and approved in some countries for treatment of iron overload in people with thalassaemia, a network analysis comparing these three interventions would seem useful in the future, if more data are available.

## ACKNOWLEDGEMENTS

We thank the peer reviewers for their valuable comments which helped us to improve protocol and review. We would also like to thank the editorial team namely Tracey Remington and Nikki Jahnke for their great support in preparing the protocol and this review. Christina Reese and Rachel Couban helped with the literature search and retrieval of full articles. Claire McLeod gave valuable input at the protocol stage.

We would like to thank Yaolong Chen for the data extraction and risk of bias assessment of one study published in Chinese language.

We would like to thank Ali Taher for clarification and additional information on his study.

We thank Nigel Fleeman for his contribution as co-author of the previous version.

We thank Andrea Stuermer from Novartis for confirming that our list of included studies is complete and providing some further additional information.

We would like to thank R. Galanello for contribution to the previous version of the review. However, unfortunately, he died in 2013.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

## REFERENCES

### References to studies included in this review

#### Cappellini 2005b {published data only}

Angelucci E, Turlin B, Canatan D, Mangiagli A, De Sanctis V, Meddeb B, et al. Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. *Blood* 2005;**106**(11 Pt 1). [Abstract no: 2696]

Aydinok Y, Agaoglu L, Bejaoui M, Canatan D, Drelichman G, Economou M, et al. Growth and development of paediatric patients with beta-thalassaemia treated with deferasirox for up to 5 years. *Haematologica* 2010;**95**:429.

Aydinok Y, Arikian C, Karakas Z, Sasmaz I, Canatan D, Agaoglu L, Kilinc Y, Canatar A, Ocak O, Alnigenis E. A comparison of novel serum markers for the assessment of liver fibrosis in patients with beta thalassemia major treated with deferasirox. *Haematologica* 2010;**95**:718.

Brissot P, Turlin B, Forni GL, Alimena G, Quarta G, Selleslag D, et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia. *Blood* 2005;**106**(11). [Abstract no: 823]

Cappellini M, Bejaoui M, Perrotta S, Agaoglu L, Kattamis A, Giardina P, et al. Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta-thalassemia and transfusional hemosiderosis. *Blood* 2004;**104**(11 Pt 1). [Abstract no: 3619]

Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. *Blood* 2011;**118**(4):884-93.

Cappellini MD, Bejaoui M, Agaoglu L, Lai ME, Mangiagli A, Strauss G, et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. *Blood* 2005;**106**(11). [Abstract no: 2704]

Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. *Clinical Therapeutics* 2007;**29**(5):909-17.

\* Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood* 2006;**107**(9):3455-62.

Cappellini MD, Giardina P, Porter J, Coates T, Della Porta MG, Siegal J, et al. Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. *Blood* 2006;**108**(11). [Abstract no: 1768]

Christoforidis A, Tsatra I, Karasmanis K, Zevgaridou E, Koussi A, Tsitourides I, et al. Evaluation of myocardial deposition

assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine. *Haematologica* 2006;**91**(S1):209.

Cohen A, Masera G, Zoumbos N, Uysal Z, Boulet D, Watman N, et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade(R)), ICL670). *Blood* 2005;**106**(11 Pt 1). [Abstract no: 822]

Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. *Blood* 2008;**111**(2):583-7.

Deugnier Y, Turlin B, Dong V, Giannone V, Zhang Y, Griffel L, et al. Deferasirox improves liver pathology in beta-Thalassemia patients with transfusional iron overload. *Blood* 2010;**116**(21):1734-5.

Deugnier Y, Turlin B, Ropert M, Bejaoui M, Athanassiou-Metaxa M, Cario H, et al. Semi-quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion-dependent anemia. *Blood* 2005;**106**(11 Pt 1):761A.

Deugnier Y, Turlin B, Ropert M, Cappellini MD, Porter JB, Giannone V, et al. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. *Gastroenterology* 2011;**141**(4):1202-11.

Deugnier Y, Turlin B, Ropert-Bouchet M, Rabault B, Brissot P. Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion-dependent anemia. *Journal of Hepatology* 2008;**48**(Suppl 2):S79-80.

Fischer R, Harmatz P, Nielsen P. Does liver biopsy overestimate liver iron concentration?. *Blood* 2006; Vol. 108, issue 5:1775-6; author reply 1776. [PUBMED: 16926297]

Galanello R. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload. *Annals of the New York Academy of Sciences* 2005;**1054**:183-5.

Grosse R, Janssen G, Engelhardt R, Groeger M, Leismann O, Nielsen P, et al. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry. *Blood* 2006;**108**(11). [Abstract no: 1779]

Karnon J, Akehurst RL, Jewitt K, Ossa D. Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom. *Haematologica* 2007;**92** Suppl 1:222.

Kattamis A, Paley C, Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients-treated with deferasirox(Exjade (R), ICL670). *Pediatric Blood & Cancer* 2007;**48**(6):609.

Kattamis C, Kilinc Y, Fattoum S, Ferster A, Gallisai D, Maggio A, et al. Deferasirox (Exjade (R), ICL670) demonstrates iron chelating

efficacy related to transfusional iron intake in pediatric patients. *Blood* 2005;**106**(11 Pt 1):756A. [Abstract no: 2692]

Kattamis C, Meddeb B, Ressayre-Djaffer C, Alberti D, Parsing Using Smart Source. Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme. *Haematologica* 2006;**91**(Suppl 1):415.

Kleinert DA, Jones E, Sison CP, Marks P, Giardina PJ. Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5-40mg/kg/day and deferoxamine 20-60 mg/kg/day in beta-thalassemia patients with transfusional hemosiderosis. *Blood* 2005;**106**(11 Pt 2):44B. [Abstract no: 3853]

Martin MG, Arcasoy MO. Deferasirox versus deferoxamine. *Blood* 2006;**108**(2):774-5; author reply 775-6. [PUBMED: 16822908]

Piga A, Fischer R, Harmatz P, St Pierre TG, Longo F, Fung E, et al. Comparison of LIC obtained from biopsy, BLS and R-2-MRI in iron overloaded patients with beta-thalassemia, treated with deferasirox (Exjade (R), ICL670). *Blood* 2005;**106**(11 Pt 1):755A.

Walter P, Macklin E, Porter J, Evans P, Coates T, Olivieri NF, et al. Control of oxidant-stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta-thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial. *Blood* 2005;**106**(11). [Abstract no: 3598]

Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, et al. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. *Haematologica* 2008;**93**(6):817-25.

Walter PB, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, et al. Increased leucocyte apoptosis in transfused beta-thalassaemia patients. *British journal of haematology* 2013;**160**(3):399-403. [PUBMED: 23216540]

Walter PB, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, et al. Leukocyte apoptosis and mitochondrial dysfunction in beta-thalassemia patients treated with deferasirox or deferoxamine. *Blood* 2007;**110**(11 Pt 1):815A. [Abstract no: 2773]

#### Chirico 2013 {published data only}

\* Chirico V, Antonio L, Vincenzo S, Luca N, Valeria F, Basilia P, et al. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. *European Journal of Endocrinology* 2013;**169**(6):785-93.

Chirico V, Rigoli L, Piraino B, La Rosa M, Salpietro C, Arrigo T. Endocrinopathies in beta-thalassemia major: Evidences from ten years of follow-up and evaluation of combined iron chelation therapy. *Hormone Research in Paediatrics* 2013;**80**:318.

#### Elalfy 2015a {published data only}

Elalfy M, Adly AA, Ismail E, Elalfy O. Efficacy and safety of vitamin C as an adjuvant to iron chelation therapy in young

patients with b-thalassemia major: a randomized prospective trial [abstract]. *Haematologica* 2015;**100** Suppl 1:131.

Elalfy MS, Saber M, Adly A, Ismail E, Tarif M, Ibrahim F, et al. Role of vitamin C As an adjuvant therapy with different iron chelators in young beta-thalassemia major patients: Safety and efficacy in relation to tissue Iron overload. *Blood* 2014;**124**(21):4046.

\* Elalfy MS, Saber MM, Adly AA, Ismail EA, Tarif M, Ibrahim F, et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young beta-thalassemia major patients: efficacy and safety in relation to tissue iron overload. *European Journal of Haematology* 2016;**96**(3):318-26. [DOI: [10.1111/ejh.12594](https://doi.org/10.1111/ejh.12594)]

#### Elalfy 2015b {published data only}

Elalfy M, Walli Y, Adly A, Henawy Y. 18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B-thalassemia major. *Haematologica* 2014;**99**:443-4. [Abstract no: ABSSUB-5856]

\* Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. *European Journal of Haematology* 2015;**95**(5):411-20.

Elalfy MS, Wali Y, Tony S, Samir A, Adly A. Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with  $\beta$ -thalassemia major. *Blood* 2013;**122**(21):559.

#### Galanello 1999 {published data only}

\* Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. *Journal of Clinical Pharmacology* 2003;**43**(6):565-72.

Piga A, Galanello R, Dessi C, Sedaro M, Loehrer F, Schaud R, et al. A novel oral iron chelator (ICL670A): results of a phase I single-dose safety study. *Blood* 1999;**10**(Suppl 1 Pt 2):35b.

#### Habibian 2014 {published data only}

Habibian N. Comparison of therapeutic effect of osveral & desferal in patients with thalassemia (bahonar hospital in karaj 2012-13). *Iranian Journal of Pediatrics* 2014;**24**(Suppl 2):S27.

#### Hassan 2016 {published data only}

Hassan MA, Tolba OA. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine. *Electronic Physician* 2016;**8**(5):2425-31. [CENTRAL: 1164827; CRS: 5500135000001568; PUBMED: 27382454]

#### Kakkar 2014 {published data only}

Kakkar S, Sobti PC, Jhinger, PK. Safety and efficacy of combination of deferiprone and deferasirox in patients with thalassemia major. *Haematologica* 2014;**99** Suppl 1:735. [Abstract no: PB1923]

**Molavi 2013** {published data only}

Molavi MA, Doozandeh H, Nazemi A, Evazi R, Mansoori F. Comparison of therapeutic response and complications of oral Osveral and injection Desferal chelating agent in patient with thalassemia major. *Asian Journal of Medical and Pharmaceutical Researches* 2013;**3**(3):93-7.

**Molavi 2014** {published data only}

Molavi MA, Poor ST, Malesksabet M. Combined Desferrioxamine (Desferal) and Deferasirox in children. *Advances in Biological Research* 2014;**8**(4):171-5.

**Nisbet-Brown 2001** {published data only}

Giardina P, Olivieri NF, Nisbet-Brown E, Grady RW, Sizer KC, Sechaud R, et al. ICL670, a tridentate orally-active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron-overloaded patients with thalassemia. 7th Congress of the European Hematology Association; 2002 June 6-9; Florence, Italy. 2002. [Abstract no: 0236]

\* Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. *Lancet* 2003;**361**(9369):1597-602.

Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Sizer K, Sechaud R, et al. ICL670A, a tridentate orally-active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron-overloaded patients with thalassemia. *Blood* 2001;**98**(11 Pt 1):747a.

**Peng 2013** {published data only}

Peng P, Long LL, Huang ZK, Zhang L, Li XH, Feng X, et al. Comparison of deferasirox and deferoxamine treatment in iron-overloaded patients: Liver iron concentration determined by quantitative MRI-R2\*. *Chinese Journal of Radiology* 2013;**47**(1):55-9.

**Pennell 2014** {published and unpublished data}

Aydinok Y, Porter JB, Piga A, Elalfy M, El-Beshlawy A, Kilinc Y, et al. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. *European Journal of Haematology* 2014;**95**(3):244-53.

Pennell D, Porter J, Piga A, El-Alfy M, El-Beshlawy A, Kilinc Y, et al. Prevalence of cardiac iron overload in patients with transfusion-dependent anemias: data from the randomized, active-controlled deferasirox CORDELIA trial. *Haematologica* 2012;**97** Suppl 1:384. [CENTRAL: 977599; CRS: 550010000011087; Abstract no: 0928]

Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul K, et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta-thalassemia major: 2-Year data from the Cordelia extension. *Blood* 2013;**122**(21):1018.

\* Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, et al. A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia

major (CORDELIA). *Blood* 2014;**123**(10):1447-54. [CENTRAL: 977602; CRS: 550012500000573; PUBMED: 24385534]

Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Beloul K, et al. A multicenter, randomized, open-label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with  $\beta$ -thalassemia major and iron overload (CORDELIA). *Blood* 2012;**121**(21). [CENTRAL: 977601; CRS: 550012500000570; Abstract no: 2124]

Pennell DJ, Porter JB, Piga A, Lai YR, El-Beshlawy A, Elalfy M, et al. Sustained improvements in myocardial T2\* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. *American Journal of Hematology* 2015;**90**(2):91-6.

**Piga 2002** {published data only}

Cappellini M, Galanello R, Piga A, Forni GL, Zanaboni L, Muroli P, et al. Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Meeting of the European Hematology Association; 2002 Jun 6-9; Florence, Italy Florence, Italy, 6-9 June, 2002. 2002:184.

Cappellini MD, Galanello R, Piga A, Forni GL, Opitz H, Ford JM, et al. Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association; 2003 Jun 12-15; Lyon, France. Lyon, 2003.

Piga A, Galanello R, Cappellini M, Forni GL, Opitz H, Ford JM, et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. *Blood* 2002;**100**(11 Pt 1):5a.

Piga A, Galanello R, Cappellini MD, Forni GL, Lupo G, Ford JM, et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. *Blood* 2003;**102**(11). [Abstract no: 412]

\* Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. *Haematologica* 2006;**91**(7):873-80.

**Sanjeeva 2015** {published data only}

Matti M. Study on comparison of efficacy and adverse effects of deferasirox vs deferiprone in treatment of iron overload in thalassemia [doctoral thesis]. Bangalore (India): Rajiv Gandhi University of Health Sciences, 2013.

\* Sanjeeva GN, Nijaguna N, Matti M, Chebbi PG. Efficacy and safety of deferasirox when compared to deferiprone as oral iron chelating agent: A randomized control trial. *Journal of Evolution of Medical and Dental Sciences* 2015;**4**(24):4178-85. [DOI: 10.14260/jemds/2015/601]



**Taher 2012** {published and unpublished data}

Porter J, Cappellini M, Kattamis A, Viprakasit V, Lawniczek T, Ros J, et al. Relationships between plasma non-transferrin-bound iron and markers of iron overload, anaemia and ineffective erythropoiesis in non-transfusion-dependent thalassaemia syndromes. *Haematologica* 2011;**96** Suppl:228-9.

Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, et al. Changes in alternative iron overload parameters following 1 year of deferasirox therapy in patients with non-transfusion-dependent thalassemia: A longitudinal analysis from the thalassa study. *Haematologica* 2014;**99** Suppl:441-2.

Taher A, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Estimation of liver iron concentration by serum ferritin measurement in non-transfusion-dependent thalassemia patients: Analysis from the 1-year thalassa study. *Haematologica* 2012;**97** Suppl:383.

Taher A, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox: Results from the 1-year thalassa study. *Haematologica* 2012;**97** Suppl:381-2.

Taher A, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Serum ferritin for predicting clinically relevant lic thresholds to guide management of patients with nontransfusion-dependent thalassemia treated with deferasirox: Thalassa study extension analysis. *Haematologica* 2013;**98** Suppl:486.

Taher A, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. The safety profile of deferasirox remains consistent as non-transfusion-dependent thalassemia patients approach the target liver iron concentration of <3 mg fe/g dw for interrupting chelation. *Haematologica* 2013;**98** Suppl 1:165-6.

Taher A, Porter JB, Kattamis A, Viprakasit V, Lawniczek T, Pereno R, et al. Randomized phase two study evaluating the efficacy and safety of deferasirox in non-transfusion-dependent thalassemia patients with iron overload [abstract]. *Blood* 2009;**114**(Issue 22). [Abstract no: 5111]

Taher A, Viprakasit V, Porter J, Kattamis A, Lawniczek T, Pereno R, et al. Factors associated with iron accumulation in non-transfusion-dependent thalassaemia syndromes: Baseline data from multicenter international deferasirox study (Thalassa). *Haematologica* 2010;**95** Suppl:707.

\* Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. *Blood* 2012;**120**(5):970-7. [CRS: 550012500000556; PUBMED: 22589472]

Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Online supplemental appendix to "Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled

study". *Blood* 2012;**120**(5):970-7. [CENTRAL: 842274; CRS: 550012500000551; PUBMED: 22589472]

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasirox. *European Journal of Haematology* 2014;**92**(6):521-6. [CENTRAL: 977521; CRS: 550012500000555; PUBMED: 24460655]

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox continues to reduce iron overload in non-transfusion-dependent thalassemia: a one-year, open-label extension to a one-year, randomized, double-blind, placebo-controlled study (THALASSA). *Blood* 2012;**120**(21). [CENTRAL: 977519; CRS: 550012500000550; Abstract no: 3258]

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. *American Journal of Hematology* 2013;**88**(6):503-6. [CENTRAL: 964527; CRS: 550012500000552; PUBMED: 23553596]

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. *Annals of Hematology* 2013;**92**(11):1485-93. [CENTRAL: 876359; CRS: 550012500000553; PUBMED: 23775581]

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Deferasirox significantly reduces liver iron concentration in non-transfusion-dependent thalassemia patients with iron overload: results from the 1-year randomized, double-blind, placebo-controlled phase II THALASSA study. *Blood* 2011;**118**(21):412-3. [CENTRAL: 977518; CRS: 550012500000549]

Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. *British Journal of Haematology* 2015;**168**(2):284-90.

Taher AT, Temraz S, Cappellini MD. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. *Expert Review of Hematology* 2013;**6**(5):495-509. [CENTRAL: 977520; CRS: 550012500000554; PUBMED: 24083402]

**References to studies excluded from this review**
**Economou 2010** {published data only}

Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. *Acta Haematologica* 2010;**123**(3):148-52.

**EPIC 2008** {published data only}

Cappellini MD, El-Beshlawy A, Porter JB, Kattamis A, Taylor K, Rose C, et al. Concomitant medications and gastrointestinal events in thalassemia and MDS patients receiving deferasirox for transfusional iron overload: data from the EPIC study. *Blood* 2012;**120**(21):5182.

\* Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. *Haematologica* 2010;**95**(4):557-66. [PUBMED: 19951979]

Cilloni D, Messa E, Biale L, Bonferroni M, Salvi F, Lunghi M, et al. High rate of erythroid response during iron chelation therapy in a cohort of 105 patients affected by hematologic malignancies with transfusional iron overload: an Italian multicenter retrospective study. *Blood* 2011;**118**(21):280-1.

El-Beshlawy A, Elalfy M, Chan LL, Lai Y, Lin KH, Aydinok Y, et al. Deferasirox treatment for up to 3 years in iron-overloaded pediatric patients reduces serum ferritin with a manageable safety profile. *Blood* 2012;**120**(21):1028.

Lai YR, Liu RR, Li CF, Huang SL, Li Q, Habr D, et al. Efficacy of deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial. *Transfusion Medicine* 2013;**23**(6):389-96.

Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2 in patients with beta-thalassemia major. *Haematologica* 2012;**97**(6):842-8.

Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Continued improvement in myocardial T2(star) over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. *Haematologica* 2011;**96**(1):48-54.

Porter J, Bowden DK, Economou M, Troncy J, Ganser A, Habr D, et al. Health-related quality of life, treatment satisfaction, adherence and persistence in beta-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the EPIC clinical trial. *Anemia* 2012 Aug 12 [Epub]. [DOI: [10.1155/2012/297641](https://doi.org/10.1155/2012/297641); Article ID: 297641]

Porter JB, Elalfy M, Viprakasit V, Giraudier S, Chan LL, Lai Y, et al. Serum ferritin, labile plasma iron and transferrin saturation: comparison between underlying anemias with transfusional iron overload before and after treatment with deferasirox. *Blood* 2012;**120**(21):2126.

Viprakasit V, Ibrahim H, Ha SY, Ho PJ, Li CK, Chan LL, et al. Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. *International Journal of Hematology* 2011;**93**(3):319-28.

**Erdogan 2013** {published data only}

Erdogan E, Canatan D, Ormeci AR, Vural H, Aylak F. The effects of chelators on zinc levels in patients with thalassemia major. *Journal of Trace Elements in Medicine and Biology* 2013;**27**(2):109-11.

**ESCALATOR 2005** {published data only}

Daar S, Pathare A, Nick H, Kriemler-Krahn U, Hmissi A, Habr D, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. *European Journal of Haematology* 2009;**82**(6):454-7. [PUBMED: 19191863]

Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2\* in heavily iron-overloaded patients with beta-thalassemia major. *Annals of Hematology* 2010;**89**(4):405-9. [PUBMED: 19798501]

Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassaemia: Results from the ESCALATOR Trial. *Acta Haematologica* 2010;**123**(4):220-5. [PUBMED: 20424435]

\* Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. *European Journal of Haematology* 2009;**82**(6):458-65. [PUBMED: 19187278]

Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, et al. Importance of optimal dosing > 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with beta-thalassaemia. *European Journal of Haematology* 2011;**87**(4):355-65.

**Fernandes 2013** {published data only}

Fernandes JL, Sampaio EF, Fertrin K, Coelho OR, Loggetto S, Piga A, et al. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. *American Journal of Medicine* 2013;**126**(9):834-7.

**Gao 2011** {published data only}

Gao HY, Li Q, Chen JJ, Chen GF, Li CG. Curative effects and safety of deferasirox in treatment of iron overload in children with beta-thalassemia major. *Zhongguo Dang Dai Er Ke Za Zhi*[Chinese Journal of Contemporary Pediatrics] 13;**7**:531-4.

**Garadah 2011** {published data only}

Garadah TS, Mahdi N, Kassab S, Abu-Taleb A, Shoroqi I, Alawadi AH. The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major. *European Journal of Haematology* 2011;**87**(3):267-73.

**Genc 2015** {published data only}

Genc GE, Ozturk Z, Gumuslu S, Kupesiz A. Mineral levels in thalassaemia major patients using different iron chelators. *Biological Trace Element Research* 2016;**170**(1):9-16.

**Gomber 2016** {published data only}

Gomber S, Jain P, Sharma S, Narang M. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. *Indian Pediatrics* 2016;**53**(3):207-10. [CRS: 5500135000001569; PUBMED: 27029681]

**Grady 2012** {published data only}

Grady RW, Galanello R, Randolph RE, Kleinert DA, Dessi C, Giardina PJ. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. *Haematologica* 2013;**98**(1):129-35.

**Hagag 2013** {published data only}

Hagag AA, Elfrargy MS, Gazar RA, El-Lateef AE. Therapeutic value of combined therapy with deferasirox and silymarin on iron overload in children with Beta thalassemia. *Mediterranean Journal of Hematology & Infectious Diseases* 2013;**5**(1):e2013065.

**Hesham 2014** {published data only}

Hesham MA, Elsafy UR, Beshar MR, Fathy MM, Gerges GS. Neutrophil gelatinase-associated lipocalin (NGAL) level in beta thalassemia patients. *Haematologica* 2014;**99** Suppl:740.

**Inati 2011** {published data only}

Inati A, Khoriaty E, Sbeiti N, Koussa S, Abi Nasr T, Musallam K, Taher A. A prospective randomized trial comparing phlebotomy and deferasirox for the treatment of iron overload in paediatric thalassemia major patients cured by stem cell transplantation: 6-month follow-up. *Haematologica* 2011;**96** Suppl 2:178. [Abstract no: 0428]

Inati A, Sbeiti N, Khoriaty E, Cappellini MD, Koussa S, Nasr TA, et al. 1-year results from a prospective randomised trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. *Blood* 2011;**118**(21):413-4. [CENTRAL: 977600; CRS: 5500125000000568]

Inati A, Sbeiti N, Taher AT, Koussa S, Pierre TG. Relationship between total iron removed by phlebotomy and iron removed from the liver in pediatric thalassemia major patients following curative stem cell transplant. *Blood*. 2011; Vol. 118, issue 21. [Abstract no: 5300]

Inati AC, Khoriaty E, Sbeiti N, St Pierre TG, Koussa S, Musallam KM, et al. Iron overload indices in thalassemia major children cured by stem cell transplantation at enrollment in a prospective randomized trial comparing phlebotomy and deferasirox. *Blood* 2010;**116**(21):864.

**Kallistheni 2012** {published data only}

Kallistheni F, Berdoukas V, Chouliaras G, Pappa C, Cabantchik ZI, Tzoumari I. Evaluating toxic free iron and options for keeping it at bay in iron overloaded patients. *Blood* 2012;**120**(21):2021.

**Karakukcu 2012** {published data only}

Karakukcu C, Karakukcu M, Unal E, Patiroglu T, Ozdemir MA, Torun YA, et al. Coenzyme Q10 levels in  $\beta$ -thalassemia and its association with ferritin levels and chelation therapy. *Hemoglobin* 2012;**36**(3):219-29.

**Keikhaei 2011** {published data only}

Keikhaei B. Combined and alternative iron chelator drugs in treatment of thalassemia major. *Pakistan Journal of Medical Sciences* 2011;**27**(3):630-3.

**Lu 2015** {published data only}

Lu MY, Wang N, Wu WH, Lai CW, Kuo PH, Chiang PH, et al. Simultaneous determination of plasma deferasirox and deferasirox-iron complex using an HPLC-UV system and pharmacokinetics of deferasirox in patients with beta-thalassemia major: once-daily versus twice-daily administration. *Clinical Therapeutics* 2015;**37**(8):1751-60.

**Medrano Engay 2013** {published data only}

Medrano Engay B, Irun MP, Sarria L, Andrade M, Murillo I, Montes A, et al. Analysis of efficacy and safety of two iron chelators in patients with iron overload (QueLaFer study). *Leukemia Research* 2013;**37**:S105.

Medrano-Engay B, Irun P, Sarria L, Andrade M, Murillo I, Montes A, et al. Evaluation of quality of life and analysis of efficacy and safety of two iron chelators in patients with iron overload. *Haematologica* 2013;**98**:704.

**Ozturk 2015** {published data only}

Ozturk Z, Genc GE, Kupesiz A, Kurtoglu E, Gumuslu S. Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress. *Free Radical Research* 2015;**49**(3):309-16.

**Pakakasama 2011** {published data only}

Pakakasama S, Sirireung A, Thinkhamrop B, Sirachainan N, Hongeng S. Efficacy of deferasirox on iron chelation in thalassemia patients after hematopoietic stem cell transplantation. *Blood* 2011;**118**(21):1355.

**Pepe 2010** {published data only}

Pepe A, Rossi G, Meloni A, Dell'Amico MC, Spasiano A, Capra M, et al. A T2\* MRI prospective survey on heart and liver iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy. *Blood* 2010;**116**(21):1731-2.

**Pepe 2011** {published data only}

Pepe A, Meloni A, Rossi G, D'Ascola DG, Capra M, Filosa A, et al. A MRI prospective survey on cardiac and hepatic iron and cardiac function in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferasirox. *Blood* 2011;**118**(21):499-500.

**Pileri 2014** {published data only}

Pileri F, Vegetti A, De Pietri L, Abbati G, Ventura P, Gamberini MR, et al. Randomized, open label, phase IIa controlled trials evaluating the safety of the association of deferasirox with standard antiviral therapy (Peg-interferon and Ribavirin) in patients with chronic hepatitis C. *Blood* 2014;**124**(21):4075.

**Song 2014** {published data only}

Song TS, Hsieh YW, Peng CT, Chen TL, Lee HZ, Chung JG, et al. Combined versus monotherapy or concurrent therapy for treatment of thalassaemia. *In Vivo* 2014;**28**(4):645-9.

**Torcharus 2011** {published data only}

Torcharus K, Pankaew T. Health-related quality of life in Thai thalassaemic children treated with iron chelation. *Southeast Asian Journal of Tropical Medicine & Public Health* 2011;**42**(4):951-9.

**Walter 2012** {published data only}

Walter PB, Harmatz P, Higa A, Ng V, Weyhmler MG, Evans P, et al. Innate immune cell expression of pattern recognition receptors from beta-thalassemia patients during intensive combination chelation therapy. *Blood* 2012;**120**(21):1025.

**References to studies awaiting assessment**
**Ansari 2015** {published data only}

Ansari S, Miri Ali Abadi G, Azarkeivan A. Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2\* MRI in thalassemia major [abstract]. *Haematologica* 2015;**100** Suppl 1:595, Abstract no: E1484. [CENTRAL: 1098922; CRS: 5500135000001406]

**EUCTR2010-023217-61-GB** {unpublished data only}

**Hagag 2015** {published data only}

Hagag AA, Hamam MA, Taha OA, Hazaa SM. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. *Infectious Disorders Drug Targets* 2015;**15**(2):98-105.

**IRCT201110087677N1** {unpublished data only}

**Kakkar 2015** {published data only}

Kakkar S, Sobti PPC, Kalra A. Efficacy and safety of deferasirox in single vs divided dosage in Thalassaemic children. *Haematologica* 2015;**100** Suppl 1 785:PB2010.

**NCT02198508** {unpublished data only}

**References to ongoing studies**
**Cutino 2009** {unpublished data only}

Sequential DFX-DFP versus DFX or DFP multicentre randomised study. Ongoing study Date of first enrolment: 27/01/2010.

**DEEP-2 2012** {unpublished data only}

Efficacy and safety study to compare deferiprone versus deferasirox in paediatric patients. Ongoing study Date of first enrolment: 29/11/2012.

**NCT02125877** {unpublished data only}

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet). Ongoing study July 2014.

**NCT02435212** {unpublished data only}

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2 - < 18 years old) With Iron Overload. Ongoing study September 2015.

**Additional references**
**Angastiniotis 1998**

Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. *Annals of the New York Academy of Sciences* 1998;**850**:251-69.

**Angelucci 2008**

Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. *Haematologica* 2008;**93**(5):741-52. [PUBMED: 18413891]

**Borgna-Pignatti 2004**

Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. *Haematologica* 2004;**89**(10):1187-93.

**Borgna-Pignatti 2005**

Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. *Annals of the New York Academy of Sciences* 2005;**1054**:40-7.

**Brittenham 1994**

Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. *New England Journal of Medicine* 1994;**331**(9):567-73.

**Cappellini 2005a**

Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. *Seminars in Hematology* 2005;**42**(2 Suppl 1):S19-21.

**Cappellini 2006**

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood* 2006;**107**(9):3455-62.

**Cappellini 2007**

Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine

for iron overload in patients with beta-thalassemia. *Clinical Therapeutics* 2007;**29**(5):909-17.

#### Cappellini 2008

Cappellini MD. Long-term efficacy and safety of deferasirox. *Blood Reviews* 2008;**22** Suppl 2:S35-41. [PUBMED: 19059055]

#### Cappellini 2009

Cappellini MD, Pattoneri P. Oral iron chelators. *Annual Review of Medicine* 2009;**60**:25-38. [PUBMED: 19630568]

#### Carpenter 2011

Carpenter, John-Paul, et al. On T2\* magnetic resonance and cardiac iron. *Circulation* 2011;**123**:1519-1528.

#### Ceci 2002

Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. *British Journal of Haematology* 2002;**118**(1):330-6.

#### Chalmers 2016

Chalmers AW, Shammo JM. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. *Ther Clin Risk Manag.* 2016;**12**:201-8.

#### Chirnomas 2009

Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. *Blood* 2009;**114**(19):4009-13. [PUBMED: 19724055]

#### Cooley 1925

Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. *Transactions of the American Pediatric Society* 1925;**37**:29-30.

#### Curtin 2002a

Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. *Statistics in Medicine* 2002;**21**(15):2131-44.

#### Curtin 2002b

Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. *Statistics in Medicine* 2002;**21**(15):2145-59.

#### Curtin 2002c

Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. *Statistics in Medicine* 2002;**21**(15):2161-73.

#### Davis 2004

Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. *Blood* 2004;**104**(1):263-9. [PUBMED: 15001468]

#### Delea 2008

Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. *American Journal of Hematology* 2008;**83**(4):263-70.

#### Elbourne 2002

Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. *International Journal of Epidemiology* 2002;**31**(1):140-9.

#### EMA 2016

European Medicines Agency (EMA). Exjade: EPAR. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000670/WC500033925.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000670/WC500033925.pdf) (accessed 2 January 2017).

#### EMEA 2007

European Medicines Agency, London, UK. Exjade: European Public Assessment Report: Summary of Product Characteristics. [www.emea.europa.eu/humandocs/Humans/EPAR/exjade/exjade.htm](http://www.emea.europa.eu/humandocs/Humans/EPAR/exjade/exjade.htm) (accessed 14 February 2008).

#### Farmaki 2006

Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. *British Journal of Haematology* 2006;**134**(4):438-44.

#### FDA 2005

Food, Drug Administration (FDA). USA. Exjade. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2010/021882s010lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021882s010lbl.pdf) (accessed 02 September 2011).

#### FDA 2013

Food, Drug Administration (FDA). USA. Exjade (deferasirox) Prescribing Information. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/021882s019lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021882s019lbl.pdf) (accessed 02 January 2017).

#### FDA Boxed Warning 2010

US Food, Drug Administraton. Exjade (Deferasirox): Boxed Warning. <http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm200850.htm> (accessed 02 September 2011).

#### Fisher 2013a

Fisher SA, Brunskill S, Doree C, Gooding S, Chowdhury O, Roberts DJ. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. *Cochrane Database of Systematic Reviews* 2013, Issue 8. [DOI: [10.1002/14651858.CD004450.pub2](https://doi.org/10.1002/14651858.CD004450.pub2)]

#### Fisher 2013b

Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Oral deferiprone for iron chelation in people with thalassaemia. *Cochrane Database of Systematic Reviews* 2013, Issue 8. [DOI: [10.1002/14651858.CD004839.pub3](https://doi.org/10.1002/14651858.CD004839.pub3)]

**Freedman 1990**

Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. *American Journal of Diseases of Children* 1990;**144**(5):565-9.

**Gabutti 1996**

Gabutti V, Piga A. Results of long-term iron-chelating therapy. *Acta Haematologica* 1996;**95**(1):26-36.

**Galanello 2006**

Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. *Haematologica* 2006;**91**(9):1241-3.

**GRADE**

Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;**336**(7650):924-6.

**GRADEpro GDT 2015 [Computer program]**

GRADE Working Group, McMaster University. GRADEpro GDTool. Hamilton (ON): GRADE Working Group, McMaster University, (accessed prior to 22 August 2016).

**Grange 2010**

Grange S, Bertrand DM, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. *Nephrology, dialysis, transplantation* 2010;**25**(7):2376-8. [PUBMED: 20466673]

**Higgins 2002**

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**(11):1539-58.

**Higgins 2003**

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60.

**Higgins 2011**

Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

**Higgins 2011a**

Higgins JPT, Altman DG, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

**Higgins 2011b**

Higgins JPT, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration,

2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011.

**Hoffbrand 1989**

Hoffbrand AV, Bartlett AN, Veys PA, O'Connor NT, Kontoghiorghe GJ. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. *Lancet* 1989;**2**(8660):457.

**Kattamis 2003**

Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassaemic patients: effect on urinary iron excretion. *Haematologica* 2003;**88**(12):1423-25.

**Kolnagou 2008**

Kolnagou A, Economides C, Eracleous E, Kontoghiorghe GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. *Hemoglobin* 2008;**32**(1-2):41-7.

**Kontoghiorghe 1987a**

Kontoghiorghe GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. *BMJ (Clinical Research Edition)* 1987;**295**(6612):1509-12.

**Kontoghiorghe 1987b**

Kontoghiorghe GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. *Lancet* 1987;**1**(8545):1294-95.

**Koren 1991**

Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. *International Journal of Hematology* 1991;**54**(5):371-5.

**Kushner 2001**

Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. *Hematology / the Education Program of the American Society of Hematology* 2001;**1**:47-61. [DOI: [10.1182/asheducation-2001.1.47](https://doi.org/10.1182/asheducation-2001.1.47)]

**Lefebvre 2011**

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies.. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.

**Lindsey 2007**

Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. *Clinical Therapeutics* 2007;**29**(10):2154-66. [PUBMED: 18042472]

**Maggio 2002**

Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus deferoxamine in patients

with thalassemia major: a randomized clinical trial. *Blood Cells, Molecules and Diseases* 2002;**28**(2):196-208.

#### Maggio 2011

Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. *Blood Cells, Molecules & Diseases* 2011;**47**(3):166-75.

#### McLeod 2009

McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. *Health Technology Assessment (Winchester, England)* 2009;**13**(1):iii-iv, ix-xi, 1-121. [PUBMED: 19068191]

#### Meerpohl 2014

Meerpohl Joerg J, Schell Lisa K, Rücker G, Fleeman N, Motschall E, Niemeyer Charlotte M, et al. Deferasirox for managing iron overload in people with myelodysplastic syndrome. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014, issue 10. [DOI: [10.1002/14651858.CD007461.pub3](https://doi.org/10.1002/14651858.CD007461.pub3); CD007461]

#### Meerpohl 2014a

Meerpohl Joerg J, Schell Lisa K, Rücker G, Motschall E, Fleeman N, Niemeyer Charlotte M, et al. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2014, issue 5. [DOI: [10.1002/14651858.CD007477.pub3](https://doi.org/10.1002/14651858.CD007477.pub3); CD007477]

#### Modell 2000

Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. *Lancet* 2000;**355**(9220):2051-2.

#### Modell 2008

Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. *Bulletin of the World Health Organization* 2008;**86**(6):480-7.

#### Nisbet-Brown 2003

Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. *Lancet* 2003;**361**(9369):1597-602.

#### Novartis 2015

Novartis. Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload. <https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-jadenu™-simplify-treatment-administration>.

#### Olivieri 1994

Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. *New England Journal of Medicine* 1994;**331**(9):574-8.

#### Olivieri 1997

Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. *Blood* 1997;**89**(3):739-61.

#### Olivieri 1998

Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. *New England Journal of Medicine* 1998;**339**(7):417-23.

#### Olivieri 1999

Olivieri NF. The beta-thalassaemias. *New England Journal of Medicine* 1999;**341**(2):99-109.

#### Origa 2005

Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. *Haematologica* 2005;**90**(10):1309-14.

#### Parmar 1998

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;**17**(24):2815-34.

#### Peng 2008

Peng CT, Tsai CH, Wu KH. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. *Hemoglobin* 2008;**32**(1-2):49-62.

#### Peters 2013

Peters M, Heijboer H, Smiers F, Giordano PC. Diagnosis and management of thalassaemia. *BMJ* 2012;**25**(344):e228.

#### Porter 2009

Porter JB. Deferasirox: an update. *Hemoglobin* 2009;**33** Suppl 1:S70-5. [PUBMED: 20001635]

#### Rafat 2009

Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M. Fanconi syndrome due to deferasirox. *American Journal of Kidney Diseases* 2009;**54**(5):931-4. [PUBMED: 19493602]

#### Review Manager 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

#### Richer 2005

Richer J, Chudley AE. The hemoglobinopathies and malaria. *Clinical Genetics* 2005;**68**(4):332-6.

#### Rund 2005

Rund D, Rachmilewitz E. Beta-thalassemia. *New England Journal of Medicine* 2005;**353**(11):1135-46.

**SIGN 2008**

Scottish Intercollegiate Guidelines Network. A guideline developer's handbook. Guideline No. 50. <http://www.sign.ac.uk/guidelines/fulltext/50/index.html> (accessed 02 September 2011).

**Taher 2006**

Taher A, Isma'eel H, Cappellini MD. Thalassaemia intermedia: revisited. *Blood Cells, Molecules & Diseases* 2006;**37**(1):12-20.

**Taher 2009**

Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. *British Journal of Haematology* 2009;**147**(5):752-9.

**Taher 2010**

Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassaemia: Results from the ESCALATOR Trial. *Acta Haematologica* 2010;**123**(4):220-5. [PUBMED: 20424435]

**Tanner 2007**

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. *Circulation* 2007;**115**(14):1876-84.

**Trachtenberg 2011**

Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassaemia. *American Journal of Hematology* 2011;**86**(5):433-6.

**Vanorden 2006**

Vanorden HE, Hagemann TM. Deferasirox--an oral agent for chronic iron overload. *Annals of Pharmacotherapy* 2006;**40**(6):1110-7.

**Wan 2014**

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Medical Research Methodology* 2014;**19**(14):135.

**Wanless 2002**

Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al. Lack of progressive hepatic fibrosis during long-term

therapy with deferiprone in subjects with transfusion-dependent beta-thalassaemia. *Blood* 2002;**100**(5):1566-9.

**Weatherall 1998**

Weatherall DJ. Thalassaemia in the next millennium. Keynote address. *Annals of the New York Academy of Sciences* 1998; Vol. 850:1-9.

**Weatherall 2000**

Weatherall DJ, Clegg JB. *The Thalassaemia Syndromes*. 4th Edition. Oxford: Blackwell Sciences Ltd., 2000.

**Williamson 2002**

Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. *Statistics in Medicine* 2002;**21**(22):3337-51.

**Witte 2004**

Witte S, Victor N. Some problems with the investigation of noninferiority in meta-analysis. *Methods of Information in Medicine* 2004;**43**(5):470-4.

**Wu 2006**

Wu SF, Peng CT, Wu KH, Tsai CH. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassaemia major patients. *Hemoglobin* 2006;**30**(2):215-8.

**Yew 2010**

Yew CT, Talaulikar GS, Falk MC, Clayton P, D'Rozario J, Brown M. Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. *Nephrology (Carlton, Vic.)* 2010;**15**(3):377. [PUBMED: 20470310]

**Zurlo 1989**

Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. *Lancet* 1989;**2**(8653):27-30.

**References to other published versions of this review**
**Meerpohl 2008**

Meerpohl JJ, Antes G, Rücker G, McLeod C, Fleeman N, Niemeyer CM, Bassler D. Deferasirox for managing iron overload in people with thalassaemia. *Cochrane Database of Systematic Reviews* 2008, Issue 4. [DOI: [10.1002/14651858.CD007476](https://doi.org/10.1002/14651858.CD007476)]

**Meerpohl 2012**

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D. Deferasirox for managing iron overload in people with thalassaemia. *Cochrane Database of Systematic Reviews* 2012, Issue 2. [DOI: [10.1002/14651858.CD007476.pub2](https://doi.org/10.1002/14651858.CD007476.pub2)]

\* Indicates the major publication for the study

**CHARACTERISTICS OF STUDIES**
**Characteristics of included studies [ordered by study ID]**



## Cappellini 2005b

Methods	Open-label, multinational, multicentre, randomised, phase III, non-inferiority study.
Participants	<p>586 <math>\beta</math>-thalassaemia individuals</p> <p>Age (mean (SD)): DFX: 17 (9.47) years; DFO: 17.3 (9.96) years</p> <p>Gender (male/female): DFX: 140/156 DFO: 142/148</p> <p>Setting and country: 65 centres (mentioned in full text publication) in 12 countries: Argentina, Belgium, Brazil, Canada, France, Germany, Greece, Italy, Tunisia, Turkey, UK, USA</p> <p><b>Inclusion criteria</b></p> <ul style="list-style-type: none"> <li>• <math>\geq 2</math> years</li> <li>• <math>\beta</math>-thalassaemia and chronic iron overload from blood transfusions</li> <li>• LIC <math>\geq 2</math> mg/g dry weight</li> <li>• <math>\geq 8</math> blood transfusions/year</li> <li>• Female participants: required to use double-barrier contraception</li> </ul> <p><b>Exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• ALT <math>&gt; 250</math> U/L during year prior to enrolment</li> <li>• Chronic hepatitis B infection</li> <li>• Active hepatitis C infection</li> <li>• History of a positive HIV test</li> <li>• Serum creatinine above the ULN</li> <li>• Urinary protein/creatinine ratio <math>&gt; 0.5</math> mg/mg</li> <li>• Nephrotic syndrome</li> <li>• Uncontrolled systemic hypertension</li> <li>• Prolonged corrected QT interval</li> <li>• Systemic infection within the 10 days prior to entry</li> <li>• GI conditions preventing absorption of oral medication</li> <li>• Concomitant conditions preventing therapy with deferasirox or DFO</li> <li>• History of ocular toxicity related to iron chelation therapy</li> <li>• A poor response to DFO</li> <li>• Noncompliance with prescribed therapy</li> </ul> <p>Follow-up: 1 year</p>
Interventions	<p>2 groups</p> <ul style="list-style-type: none"> <li>• <b>DFX</b> (n = 296): once-daily at the assigned dose as a suspension in water half an hour prior to breakfast 7 days a week</li> </ul> <p>Protocol assigned dose, mg/kg, Average daily dose, mg/kg/day (mean (SD)):</p> <ul style="list-style-type: none"> <li>- LIC <math>\leq 3</math> mg Fe/g dry weight: 5; 6.2 (1.6)</li> <li>- LIC <math>&gt; 3</math> mg Fe/g dry weight - 7 mg Fe/g dry weight: 10; 10.2 (1.2)</li> <li>- LIC <math>&gt; 7</math> mg Fe/g dry weight - 14 mg Fe/g dry weight: 20; 19.4 (1.7)</li> <li>- LIC <math>&gt; 14</math> mg Fe/g dry weight: 30; 28.2 (3.5)</li> </ul> <ul style="list-style-type: none"> <li>• <b>DFO</b> (n = 290): Slow subcutaneous infusion using electronic infusion pumps over 8 - 12 hours, 5 days a week</li> </ul> <p>Protocol assigned dose, mg/kg, Average daily dose, mg/kg/day (mean (SD)):</p> <ul style="list-style-type: none"> <li>- LIC <math>\leq 3</math> mg Fe/g dry weight: 20 - 30; 33.9 (9.9)</li> </ul>

**Cappellini 2005b** (Continued)

- LIC > 3 mg Fe/g dry weight - 7 mg Fe/g dry weight: 25 - 35; 36.7 (9.2)
- LIC > 7 mg Fe/g dry weight - 14 mg Fe/g dry weight: 35 - 50; 42.4 (6.6)
- LIC > 14 mg Fe/g dry weight:  $\geq$  50; 51.6 (5.8)
- Exceptions were permitted to the number of days of administration (ranged 3 - 7 days)
- DFO doses reported are normalized to administration for 5 days a week

**Outcomes**

- Primary response criterion: maintenance or reduction of LIC:

Success criteria:

LIC at baseline (mg Fe/g dry weight): success, LIC value after 1 year (mg Fe/g dry weight); failure, LIC value after 1 year (mg Fe/g dry weight)

2 to less than 7: 1 to less than 7, less than 1 or at least 7

7 to less than 10: 1 to less than 7, less than 1 or at least 7

10 or more: decrease in LIC of at least 3, decrease in LIC below 3

- CBC/differential
- Electrolytes
- Liver function tests
- Trace element analysis
- Urinary protein/creatinine
- Serum ferritin
- Fe
- Transferrin
- ECGs
- Ophthalmologic and auditory examinations
- Individuals < 16 years of age: assessment of growth rate (growth velocity) and sexual development
- LIC (liver biopsy or SQUID)
- Iron excretion-intake ratio

Furthermore, mortality, discontinuations, willingness to continue treatment, time lost from normal activities due to treatment, satisfaction with treatment, dose adjustments and dose interruptions, convenience and AEs were reported.

**Notes**

Funding and conflict of interests

Study was supported in part by research funding from Novartis Pharma to some of the authors. Two authors have declared a financial interest in a company whose product was studied in the present work. Several of the authors are employed by Novartis Pharma.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given with regard to sequence generation.  "Randomisation was stratified by age groups: 2 to younger than 12 years, 12 to younger than 18 years, and 18 years or older. After randomization, patients were assigned by the investigator to a dose dependent on their baseline LIC according to the algorithm noted in Table 2."
Allocation concealment (selection bias)	Unclear risk	No details given with regard to concealment of allocation.

**Cappellini 2005b** (Continued)

"Randomisation was stratified by age groups: 2 to younger than 12 years, 12 to younger than 18 years, and 18 years or older. After randomisation, patients were assigned by the investigator to a dose dependent on their baseline LIC according to the algorithm noted in Table 2."

Blinding (performance bias and detection bias) All outcomes	High risk	This was an open-label study.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	<p>No flowchart according to CONSORT available.</p> <p>586 individuals were randomised of which 29 discontinued and 4 died. The primary efficacy population consists of 553 individuals. However, it is stated that 541 participants completed one year of therapy. It remains unclear, what happened to the remaining 12 participants.</p> <p>"Most patients completed 1 year of therapy on this study: 541 (92.3%) of 586 underwent both baseline and 1-year LIC assessments. Discontinuations were relatively similar in the groups receiving deferasirox (n = 17) and deferoxamine (n = 12)."</p> <p>"The primary efficacy population in this study consisted of 553 patients with LIC evaluations at baseline and after 52 weeks and those who discontinued due to safety reasons (AE, abnormal laboratory value or test procedure result, or iron overload-related death)."</p>
Selective reporting (reporting bias)	Unclear risk	See also "Outcomes" in "Characteristics of included studies" table <a href="#">Cappellini 2005b</a> above. Not all time points nor all parameters (secondary: e.g. trace elements) reported. However, EOS primary results are reported and secondary as outlined in methods section. However, it remains unclear whether any others were measured.
Other bias	Low risk	No other risk of bias detected.

**Chirico 2013**

Methods	Prospective study with randomised groups in the last 2 years of study period.
Participants	<p>72 <math>\beta</math>-thalassaemia participants: 21 non-transfusion-dependent thalassaemia participants, 51 transfusion-dependent thalassaemia participants</p> <p>Randomised in the last 2 years of study: n = 37</p> <p>Age (mean (SD)): DFO : 30.2 (7.3) years; DFP: 28.8 (8.9) years; DFX: 31.4 (7.4) years</p> <p>Gender: not mentioned</p> <p>Setting: Thalassaemia Unit, Department of Pediatrics, University of Messina</p> <p>Country: Italy</p> <p>Inclusion criteria: not mentioned</p> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> <li>• <math>\beta</math>T minor</li> <li>• Acute illness</li> <li>• Severe renal and liver disease</li> <li>• Heart failure or cardiomyopathy</li> </ul>

**Chirico 2013** (Continued)

- Endocrine complications (e.g. diabetes mellitus, thyroid dysfunction or assuming hormonal therapy)

Follow-up: whole study: 8 years; randomised phase: 2 years

Interventions	<p>All participants received DFO monotherapy for 4 years or until the appearance of thyreopathy. Afterwards, individuals with thyreopathy received DFO (20 - 40 mg/kg, 8 - 12 hours, 2 - 6 days/week) and DFP (daily oral administration 75 - 100 mg/kg/day in 3 divided doses). Individuals without thyreopathy continued with DFO. After the end of 2 years, participants with a new diagnosis of thyreopathy started combined chelation therapy, whereas those without thyroid dysfunction were randomised in 3 arms for further 2 years.</p> <ul style="list-style-type: none"> <li>• <b>DFX</b> (Exjade) (n = 12)</li> <li>• <b>DFP</b> (n = 12)</li> <li>• <b>DFO</b> (n = 13)</li> </ul> <p>Only results of participants randomised to the 3 monotherapy groups in the last phase of the study were included in this systematic review.</p> <p>All transfusion-dependent thalassaemia participants followed a standard treatment protocol and were regularly transfused with packed red cells every 3 weeks, with the aim of maintaining pre-transfusion haemoglobin levels above 9 g/dL.</p>
Outcomes	<ul style="list-style-type: none"> <li>• Thyroid disease</li> <li>• Serum ferritin</li> </ul> <p>Furthermore, FT<sub>3</sub>, FT<sub>4</sub>, TSH, TGA, TPO, thyroid dysfunction (overt hypothyroidism: low FT<sub>4</sub> and/or FT<sub>3</sub>, increased TSH levels; subclinical hypothyroidism: normal FT<sub>4</sub>, FT<sub>3</sub> and increased TSH concentration (&gt; 5 TSH uIU/mL)); central hypothyroidism (inappropriately low serum TSH concentration in the presence of subnormal serum T<sub>4</sub> and T<sub>3</sub> concentrations), thyroid volumes, lipid profile, blood pressure and metabolic parameters (in particular insulin resistance) were measured.</p>
Notes	<p>The authors declare that they have no conflict of interest.</p> <p>The authors state that this research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.</p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"This latter group was randomised into three arms, based on the type of iron chelation [...]"  Not mentioned how random sequence was generated.
Allocation concealment (selection bias)	Unclear risk	Not details given with regard to allocation concealment.
Blinding (performance bias and detection bias) All outcomes	High risk	"The patients, physicians, laboratory staff and the epidemiologist who analysed the data were not aware of the intervention of each group"  No placebo treatment is mentioned, so blinding of participants and physicians is unlikely due to different administration routes and frequencies of application.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Results of all randomised participants at end of study are reported.
Selective reporting (reporting bias)	High risk	No results reported for TSH, FT <sub>3</sub> , FT <sub>4</sub> , but likely included in definition for thyroid dysfunction.

**Chirico 2013** (Continued)

No results reported for TGA, TPO, thyroid volumes, insulin resistance, lipid profile, blood pressure at the end of the randomised phase.

Other bias	Unclear risk	Baseline data for randomised patients not reported apart from serum ferritin, age, splenectomy rate and haemoglobin before transfusion.
------------	--------------	---

**Elalfy 2015a**

Methods	Randomised, prospective study.
Participants	<p>180 people with <math>\beta</math>-thalassaemia major</p> <p>Age: <math>\leq 18</math> years</p> <p>Gender: not mentioned</p> <p>Setting: regular attendants of the Hematology Clinic, Pediatric Hospital, Ain Shams University</p> <p>Country: Egypt</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> <li>Moderately iron-overloaded people with <math>\beta</math>-thalassaemia major without clinical symptoms of cardiac dysfunction</li> <li>Vitamin C deficiency</li> <li>Serum ferritin <math>&gt; 1000 - 2500</math> ng/mL</li> <li>Cardiac T2* <math>&gt; 10</math> ms calculated as geometric mean</li> <li>Ejection fraction <math>&gt; 56\%</math></li> </ul> <p>Exclusion criteria</p> <ul style="list-style-type: none"> <li>Insulin-dependent diabetes</li> <li>LVEF <math>\leq 56\%</math></li> <li>Active hepatitis (serum transaminases <math>&gt; 5</math> times above ULN)</li> <li>Renal impairment (serum creatinine <math>&gt; 2</math> times ULN),</li> <li>Sepsis or active infection</li> <li>Participation in a previous investigational drug study within the 30 days preceding screening</li> <li>Patients with a known allergy to DFX, DFP, and DFO</li> </ul> <p>Follow up: 1 year</p>
Interventions	<p>3 groups:</p> <ul style="list-style-type: none"> <li><b>DFX</b> (n = 60): 25 mg/kg/day</li> <li><b>DFO</b> (n = 60): subcutaneous 40 mg/kg/day (5 days a week)</li> <li><b>DFP</b> (n = 60): 75 mg/kg/day</li> </ul> <p>- Each chelation group were further randomly divided into two subgroups according to vitamin C supplementation (n = 30 in each group): Oral vitamin C in the morning 100 mg daily</p> <p>- Previous chelation therapy was withdrawn for 2 weeks before randomisation</p> <p>- Patients consumed a low-iron diet (11 - 15 mg of iron/day) and standard vitamin C diet during the study</p>
Outcomes	<ul style="list-style-type: none"> <li>Serum ferritin</li> <li>LIC</li> <li>Cardiac MRI</li> </ul>

**Elalfy 2015a** (Continued)

- AEs

Furthermore: transfusion index, haemoglobin, iron, total iron binding capacity, transferrin saturation, vitamin C, compliance.

## Notes

The authors declare that they have no conflict of interests.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Drug administration was according to a predetermined schedule generated from random numbers in a 1:1:1 manner based on a computer-generated randomisation sequence maintained within the investigational drug pharmacy[...]"
Allocation concealment (selection bias)	Low risk	"[...] with allocation concealment by opaque sequentially numbered sealed envelope".
Blinding (performance bias and detection bias) All outcomes	High risk	No details given with regard to blinding. No placebo treatment is mentioned. Due to different administration routes, blinding is not likely.
Incomplete outcome data (attrition bias) All outcomes	Low risk	"Five patients in DFO subgroup did not continue till the end of study because of poor compliance [...]"  No ITT analysis performed, but proportion of missing outcome data was regarded as too low to have a large impact on effect size.
Selective reporting (reporting bias)	High risk	"The same improvement was found when each chelation subgroup receiving vitamin C supplementation was compared separately with the subgroup without vitamin C (data not shown)".  Only summarized data for patients with vitamin C supplementation versus patients without vitamin C supplementation and data for all chelation groups with vitamin C supplementation were reported.  The outcome "occurrence of AE" is mentioned, but only serious AE related to iron chelators are reported.  Serum ferritin is reported as median and IQR, but no reason for this reporting style is mentioned.
Other bias	Unclear risk	Baseline data are not given for all treatment groups

**Elalfy 2015b**

Methods	Interventional prospective randomised open-labelled study with blinded data management and data analyses.
Participants	96 people with $\beta$ -thalassaemia major were randomised.  Age (mean (SD)): DFX + DFP : 14.05 (2.21), DFP + DFO: 15.25 (2.31)  Gender (male/female): 62/34  Setting: Thalassaemia Centers of Ain Shams University, Egypt and Sultan Qaboos University Hospital, Oman

**Elalfy 2015b** (Continued)

Countries: Egypt and Oman

Inclusion criteria

- $\beta$ -transfusion-dependent thalassaemia
- Aged 10 - 18 years
- Serum ferritin > 2500  $\mu\text{g/L}$  on maximum tolerated dose of a single iron chelator with uptrend of serum ferritin over the last 12 months prior to the study
- Participants with LIC more than 7 mg/g by MRI R2\* and mean cardiac T2\* less than 20 and more than 6 ms calculated as geometric mean without clinical symptoms of cardiac dysfunction (shortness of breath at rest of exertion, orthopnoea, exercise intolerance, lower extremity edema, arrhythmias). Adequacy of prior chelation was defined as taking > 75% of the calculated dose/month on maximum tolerated dose with upward ferritin trend. For DFX, this should be 40 mg/kg/day, for DFP 100 mg/kg/day and for DFO at least 40 - 50 mg/kg.

Exclusion criteria

- History of agranulocytosis
- Clinically significant GI or renal disease
- Clinical cardiac disease, or with LEVF < 50% on baseline echocardiography
- Evidence of active hepatitis
- Serum transaminase > 3 times above ULN
- Renal impairment (serum creatinine > ULN)
- Participation in a previous investigational drug study within the 30 d preceding screening
- Individuals with a known allergy to DFX, DFP and DFO

Follow-up: 1 year

Interventions	<p>2 groups:</p> <ul style="list-style-type: none"> <li>• <b>DFX + DFP</b> (n = 48): DFP 75 mg/kg/day, divided into 2 doses taken orally at 8 a.m. and 3 p.m. combined with DFX 30 mg/kg/day taken orally at 10 p.m. for 7 days a week</li> <li>• <b>DFP + DFO</b> (n = 48): DFP 75 mg/kg/day divided into 2 doses taken orally at 8 a.m. and 3 p.m., for 7 days (with 6 - 8 hour interval between the 2 doses) combined with DFO 40 mg/kg/day by subcutaneous infusion over 10 hours starting at 10 p.m. for 6 days a week</li> </ul> <p>- Chelation therapy was withdrawn for 2 weeks before randomisation</p> <p>- The patients consumed a low-iron diet (11 - 15 mg of iron per day) during the study</p> <p>- The transfusion regimen aimed to maintain the patients pre-transfusion haemoglobin <math>\geq</math> 8.0 g/dL by receiving approximately 15 mL/kg packed red blood cells every 3 - 4 week</p>
Outcomes	<ul style="list-style-type: none"> <li>• Serum ferritin</li> <li>• LIC</li> <li>• Cardiac MRI</li> <li>• SAE</li> <li>• AE</li> <li>• Adherence</li> <li>• Satisfaction</li> <li>• QoL</li> <li>• Self-reported adherence</li> <li>• Proportion of participants who never thought about stopping iron-chelating therapy</li> </ul>
Notes	<p>The authors state that they have nothing to declare</p>

**Risk of bias**

**Elalfy 2015b** (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"The randomisation sequence was based on a computer randomised list in permuted blocks of 10 with a 1:1 ratio, generated at both University of Ain Shams and Sultan Qaboos".
Allocation concealment (selection bias)	Low risk	"To ensure no allocation bias, treatment group was assigned by telephone contact from the coordinating centre in Ain Shams".
Blinding (performance bias and detection bias) All outcomes	High risk	"[...] open-labelled study with blinded data management and data analyses" High risk of bias in particular of performance bias.
Incomplete outcome data (attrition bias) All outcomes	Low risk	" [...] all the included patients continued till the end of study with no patients were lost follow-up".
Selective reporting (reporting bias)	High risk	<p>Patient-reported satisfaction, percentage of patient's with self reported adherence, proportion of patients who never thought about stopping iron-chelating therapy and 18-months-follow-up results were reported incompletely so that they cannot be entered in a meta-analysis.</p> <p>Serum creatinine, liver function, audiometric and ophthalmological assessment were conducted as described in a conference abstract, but no or only incomplete results are published.</p> <p>Although not pre-defined as an outcome, the authors describe that "change in mean LVEF after 1 yr was not different between the two treatment groups (data not shown)."</p> <p>On clinicaltrials.gov, only change in serum ferritin and the number of patients developing adverse reactions are predefined as outcomes.</p>
Other bias	Low risk	No other bias detected.

**Galanello 1999**

Methods	2-period, randomised, double-blind, placebo-controlled, sequential parallel-group design.
Participants	<p>25 people with transfusion-dependent <math>\beta</math>-thalassaemia were randomised</p> <p>Age (mean (SD)): 21.6 (3.3) years</p> <p>Gender (male/female): 25/0</p> <p>Setting and country: 2 centers in Italy</p> <p>Country: Italy</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• White males</li> <li>• Age <math>\geq</math> 18 years</li> <li>• Transfusion-dependent <math>\beta</math>-thalassaemia</li> <li>• Participants had serum ferritin values between <math>\geq</math> 1500 ng/mL and <math>\leq</math> 5000 ng/mL, as well as post-transfusion haemoglobin levels of at least <math>13 \pm 0.5</math> g/dL</li> <li>• All patients had previously been treated with a mean daily dose of 20 to 50 mg/kg/day DFO for at least 4 weeks before screening.</li> </ul>



**Galanello 1999** (Continued)

Exclusion criteria:

- History of systemic reactions to treatment with DFO
- History of systemic disease
- Any medical condition that might have significantly altered the absorption, distribution, metabolism, or excretion of the study drug

Follow-up: safety: Up to 10 days post dose

Interventions	"Following a 16-day run-in period, 24 patients were allocated to one of three study groups, with each group consisting of 8 patients. Each group was administered two single oral doses of ICL670 at an interval of at least 7 weeks, first a lower dose and later a higher dose. Group 1 received 2.5 and 20 mg/kg, group 2 received 5 and 40 mg/kg, and group 3 received 10 and 80 mg/kg ICL670, in all cases given as an oral suspension of 100 mL prepared from dispersible tablets. Before proceeding to a higher dose, the safety and tolerability of the preceding dose had to be assessed as satisfactory. In each treatment period, 2 of 8 patients received placebo in such a way that a given patient did not receive placebo more than once. Patients went back to their usual deferoxamine therapy and transfusion scheme in the interval between study periods."
Outcomes	<ul style="list-style-type: none"> <li>• Urinary iron excretion</li> <li>• Serum iron</li> <li>• Transferrin</li> <li>• Safety assessment: physical examination, vital signs, ECG, audiometry, clinical laboratory evaluations, and AE monitoring.</li> <li>• Safety laboratory evaluations: hematology (including transferrin and serum iron), biochemistry (including routine renal and liver function parameters, zinc, copper, and vitamin C), special kidney function parameters (<math>\alpha</math>-glutathione-S-transferase, N-acetyl-<math>\beta</math>-Dglucosaminidase, <math>\beta</math>2-microglobulin, and retinol-binding protein), urinalysis</li> </ul>
Notes	Novartis involved in trial. No details given and no information available with regard to potential conflicts of interest.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given with regard to sequence generation. From information given in paper, unclear, whether randomisation took place both in group assignment and in allocating patients to placebo. Author confirmed that randomisation was used to allocate placebo.  "Randomization was used to assign both drug (all treatment groups) and placebo. Hope to have clarified."
Allocation concealment (selection bias)	Unclear risk	No details given with regards to concealment of allocation.
Blinding (performance bias and detection bias) All outcomes	Low risk	"The study employed a two-period, randomised, double-blind, placebo-controlled, sequential parallel group design."  However, no definition of double-blind. Unclear whether, e.g. outcome assessors and data analysts were blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Not applicable. Data from all participants are presented.

**Galanello 1999** (Continued)

Selective reporting (reporting bias)	Unclear risk	Only general information with regard to safety issues. No clear-cut comparison of placebo vs verum groups. Unclear, whether other parameters were evaluated than those reported.
Other bias	Low risk	No other risk of bias detected.

**Habibian 2014**

Methods	Randomised clinical study
Participants	30 people with thalassaemia major Age: not mentioned Gender: not mentioned Setting: Bahonar hospital of Karaj Country: Iran Inclusion criteria: not mentioned Exclusion criteria: not mentioned Follow-up: 1 year
Interventions	2 groups: <ul style="list-style-type: none"> <li>• <b>DFX</b></li> <li>• <b>DFO</b></li> </ul>
Outcomes	Serum ferritin
Notes	The study was only reported in a conference abstract

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"In this randomized clinical trial [...]" Not mentioned how random sequence generation was generated.
Allocation concealment (selection bias)	Unclear risk	No details given with regard to concealment of allocation.
Blinding (performance bias and detection bias) All outcomes	High risk	No details given with regard to blinding.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not reported how many patients reached end of study.
Selective reporting (reporting bias)	High risk	No results were reported.

**Habibian 2014** (Continued)

Other bias	Unclear risk	No baseline characteristics were reported.
------------	--------------	--

**Hassan 2016**

Methods	Prospective randomised study
Participants	<p>60 <math>\beta</math>-thalassemia major participants</p> <p>Age (mean (SD)): DFX group: 8.9 (2.2), DFO group: 9.7 (1.9)</p> <p>Gender: 19 male, 41 female</p> <p>Setting: Out-patient paediatric hematology clinic of Al-Hussein University Hospital, Al-Azhar University, Cairo</p> <p>Country: Egypt</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• <math>\geq 6</math> years</li> <li>• Serum ferritin <math>&gt; 1500 \mu\text{g/L}</math></li> <li>• Irregular subcutaneous DFO chelation therapy</li> </ul> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> <li>• Serum creatinine above the upper age-related normal range</li> <li>• Significant proteinuria (urinary protein/creatinine ratio <math>&gt; 1.0</math> in a non-first-void urine sample at baseline)</li> <li>• Elevated ALT more than 3-fold of the ULN</li> <li>• GI diseases,</li> <li>• Clinically relevant auditory or ocular toxicity (or both) related to iron chelation therapy</li> <li>• Cardiac disease</li> <li>• Serious AEs with DFO or DFX</li> <li>• Absolute neutrophilic count <math>&lt; 1500/\text{mm}^3</math></li> <li>• Platelet count <math>&lt; 100,000/\text{mm}^3</math></li> </ul> <p>Follow-up: 1 year</p>
Interventions	<p>Two groups:</p> <ul style="list-style-type: none"> <li>• <b>DFX</b> (n = 30): Orally single daily dose of 20 - 40 mg/kg/day on an empty stomach after dissolution in water, apple juice, or orange juice; Starting dose of DFX was individualized based on the frequency of blood transfusions</li> <li>• <b>DFO</b> (n = 30): 20 - 50 mg/kg/day via subcutaneous infusion over 8 - 10 hours, 5 days per week</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Serum ferritin <math>&lt; 1500 \mu\text{g/L}</math></li> <li>• Safety</li> </ul> <p>Furthermore, serum ferritin, ALT, AST, blood urea, serum creatinine, neutrophilic and platelet counts and some AEs were reported</p>
Notes	The authors state that there is no conflict of interest to be declared.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

**Hassan 2016** (Continued)

Random sequence generation (selection bias)	Unclear risk	"[...] the patients were randomized in a 1:1 ratio based on permuted blocks [...]"  Not mentioned how random sequence generation was generated.
Allocation concealment (selection bias)	Unclear risk	No details given with regard to concealment of allocation.
Blinding (performance bias and detection bias) All outcomes	High risk	No details given with regard to blinding.  Due to different administration routes, blinding is not likely.
Incomplete outcome data (attrition bias) All outcomes	Low risk	"[...] no discontinuation of drugs or drop-out of follow-up occurred."
Selective reporting (reporting bias)	Low risk	No protocol available. All predefined outcomes in the method section were reported.
Other bias	Low risk	No other bias detected.

**Kakkar 2014**

Methods	Randomised controlled study.
Participants	40 thalassaemia major participants  Age: 5 - 18 years  Gender: not mentioned  Setting: unclear  Country: unclear  Inclusion criteria: not mentioned  Exclusion criteria: not mentioned  Follow-up: not mentioned
Interventions	Three groups: <ul style="list-style-type: none"> <li>• <b>DFP</b> (n = 10): 75 - 100 mg/kg/day</li> <li>• <b>DFX</b> (n = 10): 30 - 40 mg/kg/day</li> <li>• <b>Both drugs</b> administered sequentially every alternate week (n = 20)</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Cardiac MRI T2*</li> <li>• Liver MRI T2*</li> <li>• Serum ferritin</li> <li>• CBC</li> <li>• Liver enzymes</li> <li>• Renal function tests</li> </ul>
Notes	The study was only reported in a conference abstract.

**Kakkar 2014** (Continued)

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"[...] were randomised to three groups [...]" Not mentioned how random sequence generation was generated.
Allocation concealment (selection bias)	Unclear risk	No details given with regard to concealment of allocation.
Blinding (performance bias and detection bias) All outcomes	High risk	No placebo treatment mentioned. High risk of bias in particular of performance bias and outcome assessment.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not reported how many patients reached end of study.
Selective reporting (reporting bias)	High risk	Regarding cardiac MRI T2*, only baseline data and P value for DFP vs DFP+DFX at the end of the study was reported. For liver MRI T2* it is unclear whether values given are baseline or end of study data. Missing data for serum ferritin, CBC, liver enzymes and renal function tests. Only untoward side-effects reported and only for group receiving combination therapy.
Other bias	Unclear risk	No baseline data reported.

**Molavi 2013**

Methods	Randomised controlled open-label study.
Participants	138 patients with $\beta$ -thalassemia major (n = 122) and thalassaemia intermedia (n = 16) Age (mean (SD)): 13.59 (6.81) (range: 4 - 27 years) Gender (male/female): 62/76 Setting: Bandar Abbas Pediatric Hematology Clinic Country: Iran Inclusion criteria <ul style="list-style-type: none"> <li>• major/intermedia thalassaemia</li> <li>• &gt; 2 years</li> <li>• Serum ferritin &gt; 1000 ng/mL</li> <li>• Normal creatinine</li> <li>• Acceptable CBC</li> <li>• Negative PCR in terms of HCV, negative HBV and HIV</li> <li>• Absence of heart disease and cardiac drugs</li> <li>• EF &gt; 55%</li> <li>• Absence of proteinuria</li> </ul> Exclusion criteria <ul style="list-style-type: none"> <li>• Serum creatinine increased by more than 33% compared to baseline</li> <li>• Vision and hearing problems</li> </ul>

**Molavi 2013** (Continued)

- Hyperemesis
- Lack of response to anti-nausea medication and fluids therapy
- Severe and rapidly progressive skin rash
- Increase in liver enzymes more than 5 times normal
- Platelets < 150 000
- Neutrophils < 1500

Follow-up: 8 months

Interventions	2 groups: <ul style="list-style-type: none"> <li>• <b>DFX</b> (n = 69): 20 mg/kg/day oral, once a day on an empty stomach at least half an hour before a meal</li> <li>• <b>DFO</b> (n = 69): 40 - 50 mg/kg subcutaneous for 6 nights a week</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• CBC</li> <li>• ALT, AST</li> <li>• Ferritin</li> <li>• Creatinine</li> <li>• Urinalysis</li> </ul> <p>Furthermore, patients were visited weekly on the base of drug tolerance and side effects.</p>
Notes	No funding or conflict of interest mentioned.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Patients were assigned randomly in two groups" No details given with regard to sequence generation.
Allocation concealment (selection bias)	Unclear risk	No details given with regard to concealment of allocation.
Blinding (performance bias and detection bias) All outcomes	High risk	No placebo treatment mentioned. Due to different administration routes, blinding is not likely.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Although number of patients who reached end of study was not clearly stated, we concluded from given means, SDs and P values, that 69 participants were included in the results.
Selective reporting (reporting bias)	High risk	ALT, AST, creatinine evaluated at EOS, but only baseline values given  Only ferritin level, haemoglobin level and drug side effects predefined as outcomes on clinicaltrials.gov  Exclusion criteria were stated as, among others, "vision and hearing problems", "severe skin rash": implies that AEs were known for DFX/DFO and these data were collected; however they were not reported;  Only AEs reported: leukopenia, thrombocytopenia, although patients were visited weekly for drug tolerance and side effects.
Other bias	Low risk	No other bias detected.

**Molavi 2014**

Methods	Randomised clinical study.
Participants	<p>100 children with thalassaemia major were selected, 94 participants entered study</p> <p>Age (mean (SD)):12.23 (4.09) years (range: 2 - 15 years)</p> <p>Gender (male/female): 44/48</p> <p>Setting: Thalassaemia medical centre of Bandar Abbas</p> <p>Country: Iran</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Age: 2 - 15 years</li> <li>• Serum ferritin &gt; 2000 ng/mL despite the treatment with DFO (50 mg/kg 3 times a week)</li> </ul> <p>Exclusion criteria: not mentioned</p> <p>Follow-up: 12 months</p>
Interventions	<p>Two groups:</p> <ul style="list-style-type: none"> <li>• <b>DFO</b> (n = 48): 50 mg/kg transfused 3 times a week</li> <li>• <b>DFO and DFX</b> (n = 46): DFX 20-40 mg/kg (in case there was no desirable response, the dosage was altered to 20 mg/kg, and when no consequences were observed, it was increased to 40 mg/kg)</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Serum ferritin</li> <li>• Neutrophil, ALT, AST, ALP</li> <li>• Creatinine</li> <li>• Hemoglobin</li> </ul>
Notes	Conflict of interest not mentioned.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	<p>"Randomly and in the order of visiting the centre, they were divided in two 50-member groups"</p> <p>No details given on how random sequence was generated.</p>
Allocation concealment (selection bias)	Unclear risk	No details mentioned with regard to concealment of allocation.
Blinding (performance bias and detection bias) All outcomes	High risk	No placebo treatment in the Desferal monotherapy group is mentioned, so blinding is not likely in particular of performance bias.
Incomplete outcome data (attrition bias) All outcomes	Low risk	It remains unclear whether six patients were excluded due to exclusion criteria before or after randomisation; small number doesn't seem to affect results.
Selective reporting (reporting bias)	High risk	Level of creatinine was measured, but results were not reported.
Other bias	Low risk	No other bias detected.

**Nisbet-Brown 2001**

Methods	Randomised, double-blind, placebo-controlled dose-escalation study.
Participants	<p>24 participants with transfusion-dependent <math>\beta</math>-thalassaemia (23 analysed, 3 replacements for participants who were withdrawn for serious AEs during the study)</p> <p>Age (median (range)): placebo: 32 (22 - 38) years; 10 mg/kg DFX: 28 (20 - 39) years; 20 mg/kg DFX: 24 (18 - 38); 40 mg DFX: 27 (19 - 34)</p> <p>Gender (male/female): 11/12</p> <p>Setting: Children's Hospital, Boston; Weill Medical College, New York; Toronto General Hospital, Toronto</p> <p>Country: USA (2 centres) and Canada (1 centre)</p> <p>Participant characteristics:</p> <ul style="list-style-type: none"> <li>• Transfusion-dependent <math>\beta</math>-thalassaemia</li> <li>• <math>\geq 16</math> years</li> <li>• Serum ferritin values: 1000 - 8000 ng/mL</li> <li>• Liver biopsies done in the previous 3 months with <math>\geq 3.5</math> mg Fe/g dry weight</li> <li>• All participants required treatment with DFO at 20 mg/kg/day (mean daily dose) for at least 4 weeks before screening and a post transfusion haemoglobin concentration of at least 130 g/L</li> </ul> <p>Follow-up: 12 days</p>
Interventions	<p>Four groups:</p> <ul style="list-style-type: none"> <li>• <b>DFX</b> (n = 5): 10 mg/kg</li> <li>• <b>DFX</b> (n = 6): 20 mg/kg</li> <li>• <b>DFX</b> (n = 7): 40 mg/kg</li> <li>• <b>Placebo</b> (n = 5)</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Dietary, urine and faecal iron measured by atomic absorption spectrometry</li> <li>• Net faecal iron excretion calculated by individual iron content in faeces minus individual iron content in the diet (the net iron excretion for each participant in mg Fe kg<sup>-1</sup> day<sup>-1</sup> was derived from the sum of the daily measurements of net faecal iron excretion and urinary iron excretion)</li> <li>• UIBC calculated from serum iron concentration and total iron binding capacity</li> </ul>
Notes	<p>Conflict of interest and funding:</p> <p>Novartis was involved in design and monitoring of the study. Study was financially supported by Novartis Pharmaceuticals Corporation.</p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	<p>Details of sequence generation process not stated.</p> <p>"The randomisation sequence was generated by Novartis Pharmaceuticals and delivered to the research pharmacy in duplicate sealed envelopes."</p>
Allocation concealment (selection bias)	Unclear risk	Sealed envelopes were used. However, unclear whether opaque and numbered.



**Nisbet-Brown 2001** (Continued)

		"The randomisation sequence was generated by Novartis Pharmaceuticals and delivered to the research pharmacy in duplicate sealed envelopes."
Blinding (performance bias and detection bias) All outcomes	Low risk	<p>This was a placebo-controlled study, in which investigators and those responsible for administering study drug were blinded with regard to treatment allocation. However, it remains unclear whether outcome assessors and data analysts were blinded as well.</p> <p>"The investigators and those responsible for administering study drug were unaware of treatment allocation."</p> <p>"Placebo and ICL670 were prepared as dispersible tablets with standard excipients. Tablets were suspended in water, and patients ingested the drug or placebo on an empty stomach."</p>
Incomplete outcome data (attrition bias) All outcomes	Low risk	"Therefore, all patients who began either placebo or drug were included in the data analysis, whether they completed the 12-day course or withdrew prematurely."
Selective reporting (reporting bias)	Unclear risk	<p>"We did clinical, laboratory, and other safety assessments regularly throughout the study."</p> <p>However, only a limited amount of data are presented in the publication.</p>
Other bias	Low risk	No other bias detected.

**Peng 2013**

Methods	Randomised controlled study.
Participants	<p>26 individuals were recruited, who were diagnosed as <math>\beta</math>-severe thalassaemia by gene screening, 2 met exclusion criteria</p> <p>24 participants were randomised</p> <p>Gender: 13 male, 11 female</p> <p>Age (mean (SD) (range)): (14 (3) (11 - 26)) years</p> <p>Setting: First Affiliated Hospital, Guangxi Medical University, Nanning</p> <p>Country: China</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Age <math>\geq</math> 10 years</li> <li>• History of 50 unit red blood cell transfusion (1 unit = 200 mL red blood cell) at least</li> <li>• Receiving red blood cell transfusion (<math>\geq</math> 10 unit per year)</li> </ul> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> <li>• <math>T_2^* \geq</math> 6.3 ms at first MRI screening or LIC <math>\leq</math> 2 mg/g (1 mg/g = 17.9 mmol/kg)</li> <li>• Dysfunction of liver and kidney</li> <li>• Contraindication of MR screening or disagreement doing the screening</li> </ul> <p>Follow up: 12 months</p>
Interventions	Two groups:

**Peng 2013** (Continued)

- **DFX** (n = 12): 40 mg/kg daily before breakfast
  - **DFO** (n = 12): 50 mg/kg, diluted by 10% solution, subcutaneous injection 8 - 12 hours continuously per day, at least 5 days every week
- Parameters of the body of patient, LIC, serum ferritin, serum creatinine, liver function and toxicity of the drugs are regarded as standards to adjust the dose or discontinue the therapy
- Meanwhile, the patients still receive the former transfusion program (red blood cell transfusion  $\geq$  10 units per year) to maintain the haemoglobin > 90 g/L
- 5-day washout period without chelation therapy before treatment

Outcomes	<ul style="list-style-type: none"> <li>• Serum ferritin</li> <li>• Liver R<sub>2</sub>*</li> <li>• Severity of iron deposition in liver</li> </ul>
Notes	Study funding sources: National Natural Science Foundation of China, the Natural Science Foundation of Guangxi, China

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"[...] 24 iron-overloaded patients were randomly divided into 2 groups [...]" No details given with regard to sequence generation.
Allocation concealment (selection bias)	Unclear risk	No details given with regard to concealment of allocation.
Blinding (performance bias and detection bias) All outcomes	High risk	No details given with regard to blinding. Due to different administration routes, blinding is not likely.
Incomplete outcome data (attrition bias) All outcomes	Low risk	There were no missing outcome data.
Selective reporting (reporting bias)	High risk	Side effects were not reported.
Other bias	Low risk	No other bias detected.

**Pennell 2014**

Methods	Prospective, multinational, randomised, open-label, parallel-group, phase 2 study; Non-inferiority study.
Participants	197 participants were randomised 160 participants completed one year of treatment Age (mean (SD)): 19.8 (6.4) years (range: 10 - 40 years) Gender (male/female): 115/82 Setting and countries: 22 centres across 11 countries

**Pennell 2014** (Continued)

Inclusion criteria:

- People with  $\beta$ -thalassaemia major, Diamond-Blackfan anaemia, low/intermediate 1 myelodysplastic syndromes, or sideroblastic anaemia
- Aged  $\geq 10$  years
- Myocardial T2\* 6 to 20 ms without clinical symptoms of cardiac dysfunction (shortness of breath at rest or exertion, orthopnoea, exercise intolerance, lower-extremity edema, arrhythmias)
- LVEF  $\geq 56\%$ ,
- R2 magnetic resonance imaging LIC  $\geq 3$  mg Fe/g dry weight
- Lifetime history of  $\geq 50$  U red blood cell transfusions
- Receiving  $\geq 10$  U/y of red blood cell transfusion
- Only people with  $\beta$ -thalassaemia major fulfilled the inclusion criteria and were enrolled in the study

Exclusion criteria:

- Serum creatinine above the ULN
- Significant proteinuria (urinary protein/creatinine ratio  $\geq 1.0$  mg/mg in a non-first-void urine sample at baseline)
- ALT  $> 5$  times the ULN only if their LIC was  $< 10$  mg Fe/g dry weight
- Considerable impaired GI function or GI disease
- History of clinically relevant ocular and/or auditory toxicity related to iron chelation therapy
- History of HIV seropositivity or malignancy within the past 5 years

Follow-up: 12 months

Interventions	<p>Two groups:</p> <ul style="list-style-type: none"> <li>• <b>DFX</b> (n = 96): Once-daily starting dose was 20 mg/kg per day for 2 weeks, followed by 30 mg/kg per day for 1 week, and then continued with 40 mg/kg per day</li> <li>• <b>DFO</b> (n = 91): 50 to 60 mg/kg per day via subcutaneous infusion over 8 to 12 hours, 5 to 7 days a week; dose adjustment recommendations were provided based on continuous assessment of efficacy and safety markers</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Ratio of geometric mean myocardial T2* with DFX divided by the ratio of geometric mean for DFO</li> <li>• LVEF</li> <li>• LIC</li> <li>• Serum ferritin</li> </ul> <p>Furthermore, safety, compliance, dose interruptions/reductions and laboratory parameters (serum creatinine, blood creatinine, ALT) were measured.</p>
Notes	<p>Study was sponsored by Novartis Pharma AG. Novartis Pharma AG was involved in design of the study, conducted the statistical analysis and paid a medical writer who assisted with writing the article. Some of the authors received research grant funding, honoraria or lecture fees from Novartis Pharmaceuticals and/or other pharmaceutical companies.</p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"[...]patients were randomised in a 1:1 ratio [...]"  "Randomization was based on permuted blocks; stratification by centre was not conducted."
Allocation concealment (selection bias)	Unclear risk	No details given with regard to concealment of allocation.

**Pennell 2014** (Continued)

Blinding (performance bias and detection bias) All outcomes	High risk	"Core laboratories were blinded to treatment allocation."  "In order to eliminate potential unrecognised biases, the core clinical trial team was blinded to the treatment assignment prior to the database lock for the primary analysis."  "Open-label trial"  No placebo treatment mentioned. Due to different administration routes, blinding is not likely in particular of performance bias.
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT was done regarding myocardial T2*, but the number of included patients (n=180) was lower than the number of randomised patients (n=197)  Apart from that, per-protocol analysis was done for the other outcomes.
Selective reporting (reporting bias)	High risk	Only most common AE ( $\geq 5\%$ ) and drug related AE $\geq 2$ participants were reported
Other bias	Low risk	No other bias detected.

**Piga 2002**

Methods	Open label, randomised, multicenter, phase II study.
Participants	<p>71 people with thalassaemia and transfusional iron overload: 69 people with <math>\beta</math>-thalassemia major, 2 people with <math>\beta</math>-thalassemia intermedia</p> <p>Age mean (range): DFX 10 mg/kg/day: 23.7 years (17 - 33 years); DFX 20 mg/kg/day: 25.6 years (19 - 50 years); DFO: 22.7 (18 - 29 years)</p> <p>Gender (male/female): 26/45</p> <p>Setting and country: 4 centres in Italy</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Should have been regularly transfused</li> <li>• Should have received a mean daily dose of DFO <math>\geq 30</math> mg/kg for 5 days/week for at least 4 weeks prior to entering the screening period</li> <li>• Serum ferritin between 2000 - 8000 ng/mL on at least two evaluations in the last 12 months or</li> <li>• LIC of 5 - 15 mg Fe/g dry weight measured in the last 12 months by SQUID</li> <li>• Average post-transfusion haemoglobin level between 10.5 - 13.5 g/dL during last 12 months</li> </ul> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> <li>• AST or ALT <math>&gt; 250</math> U/L</li> <li>• Creatinine clearance <math>&lt; 80</math> mL/minute</li> <li>• People with hypertension</li> <li>• People with any degree of A-V block, clinically relevant QT prolongation</li> <li>• Treatment with digoxin or any other drug that could induce prolongation of A-V conduction</li> <li>• People with diagnosis of cataract or a previous history of clinically relevant ocular toxicity related to iron chelation</li> </ul> <p>Follow-up: 48 weeks</p>
Interventions	3 groups:

**Piga 2002** (Continued)

- **DFX** (n = 24): 10 mg/kg once-daily using 250 mg tablets which were divisible into four parts. The correct number of tablets was dispersed in a glass of non-carbonated mineral water, stirred and ingested 30 minutes before breakfast
  - **DFX** (n = 24): 20 mg/kg once daily using 250 mg tablets which were divisible into four parts. The correct number of tablets was dispersed in a glass of non-carbonated mineral water, stirred and ingested 30 minutes before breakfast
  - **DFO** (n = 23): 40 mg/kg on 5 consecutive days per week. Doses were prepared as a 10% solution using commercially available vials of 500 or 2000 mg dry powder. Subcutaneous infusion was performed using a pump over 8 - 12 hours.
- During the 14-day run-in period, eligible patients had their usual DFO therapy adjusted to 40 mg/kg given on 5 consecutive days each week
- The study protocol allowed for dose adjustment within the range of 5 - 40 mg/kg/day in the DFX groups and 20 - 50 mg/kg in the DFO group
- Depending on response, assessed primarily using the change in LIC at 3 consecutive determinations, dose increases or decreases were made by  $\pm 5$  or  $\pm 10$  mg/kg in the DFX groups and by  $\pm 10$  mg/kg in the DFO group
- Dose reductions were performed if the decrease in LIC was extrapolated to fall below 2 mg Fe/g dry weight within the next 12 weeks and dose increases were prescribed if an increasing trend in LIC was noted
- Dose adjustments were decided on a case-by-case basis in joint consultation between the Study Monitoring Committee and the sponsor
- On day -5, participants were admitted to the study site to receive a blood transfusion to achieve a target haemoglobin level of  $\geq 13$ g/dL prior to commencing study treatment followed by a DFO washout period of 5 days

**Outcomes**

- Mortality
- LIC (SQUID)
- Serum ferritin
- Serum iron
- Serum transferrin
- Transferrin saturation
- Blood indices
- Liver and renal function
- Serum electrolytes
- Copper and zinc
- Second void urine samples with measurement of N-acetyl-beta-glucosaminidase and beta2-microglobulin
- Ophthalmological examination including slit lamp examination of the lens and retinal fundoscopy
- Audiometry, ECG and liver ultrasonography

**Notes**

Study was supported by Novartis Pharma AG. Some of the authors are employed by Novartis Pharma or received lecture fees from the manufacturer.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomization was performed using a validated system that generates an automated random assignment of numbers to treatment groups."  We expect that using this system resulted in an adequate sequence generation.

**Piga 2002** (Continued)

Allocation concealment (selection bias)	Unclear risk	"Randomization was performed using a validated system that generates an automated random assignment of numbers to treatment groups."  No information is given with regard to allocation concealment.
Blinding (performance bias and detection bias) All outcomes	High risk	It is classified as an open-label study. There is no mentioning of blinding.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants are included in safety analysis (primary objective). Few patients only are not included in efficacy analysis (secondary objective).
Selective reporting (reporting bias)	Unclear risk	"Laboratory tests, including evaluation of blood indices, liver and renal function, serum electrolytes, copper and zinc, were performed at baseline and at 2-weekly intervals throughout the study. All laboratory parameters were measured at a central laboratory (EXACTA Clinical Trials Services, Verona, Italy). Second void urine samples were collected for measurement of N-acetyl-b-glucosaminidase and an aliquot of urine was alkalinized for measurement of b-2 microglobulin. An ophthalmology examination, including a slit lamp examination of the lens and retinal funduscopy, was performed every 2 weeks. Audiometry, ECG and liver ultrasonography were carried out every 3 months. Adverse events were recorded at each study visit and the severity of each adverse event was graded as mild, moderate or severe. A serious adverse event was defined as a medically significant event that was either fatal or life threatening, required surgical intervention, prolonged hospitalization or resulted in persistent disability. All adverse events and serious adverse events were assessed by the investigator for a possible relationship to the study drug. Adverse events were ranked according to incidence in the deferasirox 20 mg/kg/day treatment group."  "All biomagnetic liver susceptometry evaluations were performed at the Ospedale Regina Margherita, University of Turin, Italy. LIC was determined at screening and then every 12 weeks during treatment and at the end of the study..... During the study, markers of iron metabolism (serum ferritin, serum iron, serum transferrin and transferrin saturation) were analyzed by a central laboratory (EXACTA Clinical Trials Services, Verona, Italy). The transferrin saturation was calculated from the serum iron and the transferrin concentrations. Urinary iron excretion was determined in 24-hour urine collections in ten patients taking deferasirox (five in each dose group) who also underwent blood sampling for pharmacokinetic analyses. Urinary iron excretion was measured using atomic absorption spectrometry."  Only selected parameters at selected time points are reported.
Other bias	Low risk	No other bias detected.

**Sanjeeva 2015**

Methods	Prospective randomised comparative study.
Participants	41 participants were randomised  38 participants reached end of study  Age (mean (SD)): DFX (n = 19): 5.23 (2.76) years; DFP (n = 19): 7.26 (2.42) years  Gender (male/female): 22/16

**Sanjeeva 2015** (Continued)

Setting: Thalassemia day care centre of Indira Gandhi Institute of child health, Bengaluru

Country: India

Inclusion criteria

- Thalassemia diagnosis and regular blood transfusion
- Serum ferritin > 1000 ng/mL
- No chelation therapy

Exclusion criteria

- Already on chelation therapy
- Chronic liver or renal disease

Follow-up: 12 months

Interventions	2 groups: <ul style="list-style-type: none"> <li>• <b>DFX</b> (n = 19): dose of 20 mg/kg/day, once a day</li> <li>• <b>DFP</b> (n = 22): 75 mg/kg/day in 3 divided doses</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Serum ferritin</li> <li>• WBC</li> <li>• Platelet count</li> <li>• Blood urea</li> <li>• Serum creatinine</li> <li>• Serum enzymes (AST, ALT)</li> <li>• Side effects</li> </ul>
Notes	No funding or conflict of interest mentioned

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"These children were randomly divided into two groups as group 1 and group 2 by computer generated randomisation."
Allocation concealment (selection bias)	Unclear risk	No details mentioned with regard to concealment of allocation.
Blinding (performance bias and detection bias) All outcomes	High risk	No details given with regard to blinding.  Due to different application frequencies, blinding is not likely, in particular regarding performance bias.
Incomplete outcome data (attrition bias) All outcomes	High risk	3 dropouts due to AEs in deferiprone group, per protocol analysis.
Selective reporting (reporting bias)	High risk	Measurements other than serum ferritin and AEs only given for 9 months (and only in the thesis document), but not for end of study (unsure whether not measured or not reported), although the author report measurements every 3 months.  In the thesis document, funduscopy, growth harm and hearing were part of the evaluation sheet at 12-month follow-up, but no results were reported.

**Sanjeeva 2015** (Continued)

Other bias	Low risk	No other bias detected.
------------	----------	-------------------------

**Taher 2012**

Methods	Multinational, prospective, randomised, double-blind, placebo-controlled phase 2 study.
Participants	<p>166 participants were randomised.</p> <p>95 non-transfusion-dependent <math>\beta</math>-thalassaemia, 22 <math>\alpha</math>-thalassaemia, 49 HbE/<math>\beta</math>-thalassaemia</p> <p>148 participants completed 1 year of the study.</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> <li>• <math>\geq 10</math> years of age with</li> <li>• Non-transfusion-dependent <math>\beta</math>-thalassaemia</li> <li>• Iron overload (R2-MRI-measured LIC <math>\geq 5</math> mg Fe/g dry weight)</li> <li>• Serum ferritin <math>&gt; 300</math> ng/mL at screening based on 2 consecutive values <math>\geq 14</math> days apart were eligible</li> <li>• Participants were required to have not received transfusions within 6 months or chelation therapy within 1 month before study entry</li> </ul> <p>Exclusion criteria</p> <ul style="list-style-type: none"> <li>• People with previous exposure to DFX</li> <li>• Anticipated regular transfusions; unplanned transfusions during the study were allowed</li> <li>• HbS variants of thalassaemia syndromes</li> <li>• Active hepatitis B (positive hepatitis B surface antigen with negative hepatitis B surface Ab) or hepatitis C (positive hepatitis C virus Ab and detectable hepatitis C virus RNA with alanine aminotransferase [ALT] above the normal range)</li> <li>• Cirrhosis</li> <li>• Levels of ALT <math>&gt; 5</math> x ULN</li> <li>• Serum creatinine <math>&gt; \text{ULN}</math> or creatinine clearance <math>\leq 60</math> mL/min on 2 measurements</li> <li>• Significant proteinuria (urine protein/urine creatinine ratio <math>&gt; 1.0</math> mg/mg) on 2 measurements</li> </ul> <p>Follow-up: 1 year</p>
Interventions	<p>4 groups:</p> <ul style="list-style-type: none"> <li>• <b>DFX</b> (n = 55): 5 mg/kg/day</li> <li>• <b>DFX</b> (n = 55): 10 mg/kg/day</li> <li>• <b>Placebo</b> (n = 28): 5 mg/kg/day</li> <li>• <b>Placebo</b> (n = 28): 10 mg/kg/day</li> </ul> <p>- Doses were doubled at 24 weeks for patients with LIC <math>&gt; 7</math> mg Fe/g dry weight and LIC reduction <math>&lt; 15\%</math> from baseline</p> <p>- Dose adjustment recommendations were also provided based on continuous safety assessments</p> <p>- If serum ferritin was <math>&lt; 100</math> ng/mL or LIC was <math>&lt; 3</math> mg Fe/g dry weight at any visit, treatment was to be suspended until LIC increased to <math>\geq 5</math> mg Fe/g dry weight and serum ferritin to <math>&gt; 300</math> ng/m</p>
Outcomes	<ul style="list-style-type: none"> <li>• LIC</li> <li>• Number and proportion of patients with a LIC decrease of <math>\geq 3</math> mg Fe/g dry weight, those with <math>\geq 30\%</math> reduction in LIC, and those with LIC <math>\leq 7</math>, <math>\leq 5</math>, and <math>\leq 3</math> mg Fe/g dry weight</li> <li>• Serum ferritin</li> <li>• Correlation of serum ferritin and LIC</li> </ul>



**Taher 2012** (Continued)

- AEs
- Serious AEs
- Adherence

Notes Study was sponsored by Novartis Pharma AG. Novartis was involved in design and statistical analysis

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"[...] patients were block randomised [...]".  No details given on how random sequence was generated.
Allocation concealment (selection bias)	Low risk	"[...] patients were block randomised using an interactive voice response system. After confirming that the patient fulfilled the inclusion/exclusion criteria, the investigator contacted the interactive voice response system to obtain a randomisation number linking the patient to a treatment arm."
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"Because blinding of dose was not possible, blinding was only applied to the treatment received. All persons were blinded to the treatment from the time of randomisation until database lock."
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Attrition was 12.7%, 10.9% and 8.9% for the DFX 5 mg, DFX 10 mg and the placebo group, respectively  In the journal publication, the authors state that "efficacy was assessed for the full analysis set (all randomised patients).[...] If there was no LIC measurement available at week 52, the last available post-baseline LIC measurement was carried forward."  Number of participants analysed on clinicaltrials.gov doesn't include all randomised patients for continuous outcomes.
Selective reporting (reporting bias)	High risk	Extensive data set available on ClinicalTrials.gov (along with prespecified protocol), but AEs and SAEs were not reported separately for the core phase  In the journal publication AEs and drug-related AEs were not reported completely
Other bias	Low risk	No other bias detected.

AE: adverse event  
 ALP: alkaline phosphatase  
 ALT: alanine aminotransferase  
 AST: aspartate aminotransferase  
 A-V: atrio-ventricular  
 CBC: complete blood count  
 CONSORT: consolidated standards of reporting trials  
 DFO: deferoxamine  
 DFP: deferiprone  
 DFX: deferasirox  
 ECG: electrocardiogram  
 EF: ejection fraction  
 EOS: eosinophil count  
 Fe: iron  
 FT<sub>3</sub>: serum-free triiodothyronine  
 FT<sub>4</sub>: serum-free thyroxine  
 GI: gastrointestinal

HBV: hepatitis B virus  
 ITT: intention-to-treat  
 LVEF: left ventricular ejection fraction  
 LIC: liver iron concentration  
 MRI: magnetic resonance imaging  
 QoL: quality of life  
 PCR: polymerase chain reaction  
 RBCs: red blood cells  
 RNA: ribonucleic acid  
 SD: standard deviation  
 SQUID: superconducting quantum interference device  
 TGA: antithyroglobulin  
 TSH: thyroid-stimulating hormone  
 TPO: antithyroid peroxidase  
 UIBC: unsaturated iron binding capacity  
 ULN: upper limit of normal  
 WBC: white blood count

### Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
<a href="#">Economou 2010</a>	Not randomised. Two-arm observational study.
<a href="#">EPIC 2008</a>	Not randomised, no comparison group. Single-arm observational study.
<a href="#">Erdogan 2013</a>	Not randomised. Two-arm observational study.
<a href="#">ESCALATOR 2005</a>	Not randomised, no comparison group. Single-arm observational study.
<a href="#">Fernandes 2013</a>	Randomised, evaluating amlodipine added to standard iron chelation therapy.
<a href="#">Gao 2011</a>	Not randomised. Study comparing different doses of DFX and DFX to deferiprone and DFO.
<a href="#">Garadah 2011</a>	Not randomised. Single-arm interventional study.
<a href="#">Genc 2015</a>	Not randomised. Three-arm observational study.
<a href="#">Gomber 2016</a>	Not randomised. No adequate random sequence generation.
<a href="#">Grady 2012</a>	Non-randomised. Single-arm interventional study.
<a href="#">Hagag 2013</a>	Randomised. Evaluating silymarin versus placebo added to DFX.
<a href="#">Hesham 2014</a>	Not randomised. Case-control study.
<a href="#">Inati 2011</a>	Randomised controlled study on people with thalassaemia having undergone curative hematopoietic stem cell transplantation.
<a href="#">Kallistheni 2012</a>	Not randomised. Two-arm interventional study.
<a href="#">Karakukcu 2012</a>	Not randomised. Three-arm observational study.
<a href="#">Keikhaei 2011</a>	Not randomised. Two single-arm interventional studies.
<a href="#">Lu 2015</a>	Randomised. Pharmacokinetic study with a very small population (n = 8).
<a href="#">Medrano Engay 2013</a>	Randomised. No individuals with thalassaemia included.

Study	Reason for exclusion
<a href="#">Ozturk 2015</a>	Not randomised. Three-arm observational study.
<a href="#">Pakakasama 2011</a>	Randomised controlled study on people with thalassaemia having undergone curative hematopoietic stem cell transplantation.
<a href="#">Pepe 2010</a>	Study not randomised. Three-arm observational study.
<a href="#">Pepe 2011</a>	Study not randomised. Two-arm observational study.
<a href="#">Pileri 2014</a>	Randomised. No individuals with thalassaemia included.
<a href="#">Song 2014</a>	Randomised. Pharmacokinetic study with a very small population (n = 8).
<a href="#">Torcharus 2011</a>	Not randomised. Three-arm observational study.
<a href="#">Walter 2012</a>	Not randomised. Single-arm interventional study.

DFO: deferoxamine

DFX: deferasirox

### Characteristics of studies awaiting assessment *[ordered by study ID]*

#### [Ansari 2015](#)

Methods	Unclear, if study was randomised.
Participants	108 people with thalassaemia major Age: > 10 years Inclusion criteria <ul style="list-style-type: none"> <li>• Iron overload in cardiac T2* MRI assay</li> </ul>
Interventions	3 groups: <ul style="list-style-type: none"> <li>• DFX</li> <li>• DFO</li> <li>• DFO + DFP</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Myocardial iron (T2* MRI)</li> <li>• Liver T2*</li> <li>• AEs</li> </ul>
Notes	Author was contacted.

#### [EUCTR2010-023217-61-GB](#)

Methods	A phase IV, open-label, partial cross-over partial parallel, randomised, multi-centre study.
Participants	Target sample size: 64 Inclusion criteria

**EUCTR2010-023217-61-GB** (Continued)

- $\geq 18$  years
- Ability to provide informed consent
- Ability to meet all study requirements
- Adequate renal function (e.g. creatinine clearance = 60 mL/min)
- Willingness to stop other iron chelation therapy
- No known allergies to the drug
- Not pregnant or breastfeeding and willing to use effective contraception

For non-naïve cohort

- Transfusional iron overload as defined by a minimum of 20 lifetime transfusion episodes
- Transfusional iron loading with ferritin levels  $> 500$  mcg/L and/or LIC  $> 3$  mg of iron/g dry weight (as previously demonstrated by liver biopsy or MRI prior to the study)
- Established on deferasirox therapy for at least 1 year
- GI side effects believed to be related to their therapy as suggested by at least one of the following:
  - The temporal relationship of GI side effects occurrence with the administration of deferasirox.

Exclusion criteria

- People with GI symptoms assumed or known not to be caused by DFX
- People who are treated for any condition with aspirin daily, those under chronic steroid therapy and those on anticoagulant therapy that could all lead to potential GI symptoms/bleeding
- Presence of GI disease that may significantly alter the absorption of deferasirox (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, GI or rectal bleeding)
- History of GI surgery (except appendicitis and cholecystectomy) e.g. stomach/bowel surgery or awaiting elective surgery in the next 2 months
- Undergoing acute medical intervention or hospitalisation
- Psychiatric illness (schizophrenia, major depression) which may interfere with study requirements
- Any other medical condition that, in the opinion of the site investigator would interfere with completing the study (visual problems or cognitive impairment)
- Platelet count less than 100,000
- Currently on treatment for hepatitis C
- Patients with severe iron loading in the heart (T2\* less than 10 ms)
- Patients with severe total body iron load (LIC over 30 mg/g dry weight)
- Patients who have historical evidence of severe iron loading in the heart
- Women of child-bearing potential who are planning a pregnancy, pregnant, lactating and unwilling to use effective means of contraception
- Inadequate renal function (e.g. creatinine clearance  $< 60$  mL/min)
- Patients unwilling to stop using other iron chelation therapy for the study duration
- Known allergy to the drug
- Patients on aluminium containing antacid preparations
- Patients who are on vitamin C at doses higher than 200 mg/day
- Patients receiving or having received any investigational drug within 30 days prior to study enrolment
- Patients unable to understand oral or written English

Interventions	Once daily oral DFX (dispersible tablet), when administered before or after food in people with transfusional haemosiderosis
Outcomes	<p>Primary outcome</p> <ul style="list-style-type: none"> <li>• Between-treatment arm-difference of the mean individual change of GIQLI (follow-up minus baseline) in the non-naïve cohort (patients on established deferasirox therapy)</li> </ul> <p>Secondary outcomes</p>

**EUCTR2010-023217-61-GB** (Continued)

- Difference between mean follow-up (1 month and 2 months) vs baseline changes of GIQLI per arm in naive cohort
- Difference of the mean GSRS score changes in both arms of the established cohort and the naive cohort
- Difference of the mean SF-36 score changes in both arms of the established cohort and the naive cohort
- Arm difference of geometric mean steady state Cmin at visit 3 and visit 4 in the cross-over group
- Arm difference of geometric mean AUC and Cmax at visit 3 and visit 4 in cross-over group
- Arm difference of geometric mean steady-state Cmin at Visit 3 for all patients (after 1 month of treatment)
- Effect of food on systemic exposure of deferasirox as assessed by pharmacokinetics approach. Pooled pharmacokinetic data from all arms will be analysed with a population pharmacokinetic model and appropriate covariates will be examined for clinical and statistical relevance

Notes

Date of first enrolment: 27/01/2012

Date of the global end of the study: 16/07/2012

Sponsor: University College London

Recruitment status: Not Recruiting

In the EU Clinical Trials Register, a premature end of the study is reported. As of now, no data have been published.

Author was contacted

**Hagag 2015**

Methods

Unclear, if study was randomised.

Participants

120 people with  $\beta$ -thalassaemia major were included.

Age (mean (SD)): 5.43 (1.37) (range 4 - 7) years

Gender: 68 males, 52 females

Setting: Hematology Unit, Pediatric Department, Tanta University Hospital

Country: Egypt

Inclusion criteria

"Children with beta thalassaemia major with serum ferritin levels of more than 1000 ng/mL who had not received iron chelation before this study and maintained on regular use of chelation during this study."

Exclusion criteria

"Children with thalassaemia with serum ferritin level less than 1000 ng/mL. Children with thalassaemia with hepatitis A, B or C."

Follow-up: 6 months

Interventions

Group A: "30 patients were treated with 8 hours intravenous infusion of Desferrioxamine, 40 mg/kg/day, 6 days per week for 6 months."

Group B: "30 patients were treated with subcutaneous infusion of Desferrioxamine, 40 mg/kg/day, 6 days per week 8 hours per day at night using Desferal pump for 6 months."

**Hagag 2015** (Continued)

Group C: " 30 patients were treated with oral Deferiprone 75 mg/kg/day in three divided doses daily for 6 months."

Group D: " 30 patients were treated with oral Deferasirox 30 mg/kg/day in single daily dose on empty stomach for 6 months."

Outcomes	<ul style="list-style-type: none"> <li>• Serum ferritin</li> <li>• Serum TIBC</li> <li>• White blood cells</li> <li>• Neutrophils</li> <li>• Platelets count</li> <li>• Liver enzymes</li> <li>• Creatinine</li> <li>• Blood urea</li> <li>• Kidney function</li> </ul>
Notes	Author was contacted.

**IRCT201110087677N1**

Methods	Comparative study of incidence of lens opacity between Osferal and Deferoxamine in thalassaemia major.
Participants	<p>50 people with thalassaemia major</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>- children with thalassaemia major</li> <li>- being candidate for chelator therapy because of iron overload</li> </ul> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> <li>- diabetes mellitus and rheumatologic diseases</li> <li>- any lens disease or chelator therapy before the study</li> </ul> <p>Follow-up: 12 months</p>
Interventions	<p>"Then the patients will be divided into two 25 membered groups, and each group will receive one of the chelators randomly."</p> <p>"Intervention: In this group, 25 patients are put on a new Iranian drug Osferal, and then it's side effect that is "lens opacity", will be compared with that of the control group."</p> <p>"Control: Based on the present policy, 25 patients who receive Deferoxamine and have a known percent of "lens opacity", are considered as the control group."</p>
Outcomes	Lens opacity
Notes	<p>Expected recruitment start date: 2010-12-22</p> <p>Expected recruitment end date: 2011-12-22</p> <p>Author was contacted</p>

### Kakkar 2015

Methods	Prospective randomised study.
Participants	<p>Size of study population: not mentioned</p> <p>Setting: Thalassemia ward of Department of Pediatrics, Dayanand Medical College and Hospital, Ludhiana</p> <p>Country: India</p> <p>Inclusion and exclusion criteria: not mentioned</p> <p>Follow-up: not mentioned</p>
Interventions	<p>2 groups:</p> <ul style="list-style-type: none"> <li>• DFX: 40 - 50 mg/kg/day in once daily doses</li> <li>• DFX: 40 - 50 mg/kg/day in 2 divided doses</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Serum ferritin</li> <li>• Cardiac MRI T2*</li> <li>• Liver MRI T2*</li> <li>• LVEF</li> <li>• Safety profile in terms of gastrointestinal side effects, rash and change in serum creatinine values, SGPT and GFR</li> </ul>
Notes	<p>The study was only reported in a conference abstract.</p> <p>Author was contacted.</p>

### NCT02198508

Methods	Randomised, open-label, single-centre, cross-over study.
Participants	<p>Target sample size: 13</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> <li>• 18 years of age or older</li> <li>• Serum ferritin greater than 2000 ng/mL</li> <li>• Serum creatinine within normal range for a measuring laboratory</li> <li>• Platelet count exceeding 140000/mm<sup>3</sup></li> <li>• Body weight at least 40 kg</li> <li>• None had a history of clinical significant of gastrointestinal, hepatic, renal, endocrine, oncologic, infectious, pulmonary or cardiovascular disease</li> </ul> <p>Exclusion criteria</p> <ul style="list-style-type: none"> <li>• HIV positive, history of immunologic hypersensitivity to any medication</li> <li>• Women pregnant or breastfeeding</li> <li>• Drug or alcohol abuse</li> <li>• Patients showed abnormal or irregular bowel function (defined as more than three bowel movements a day or less than one bowel movement every other day)</li> <li>• Receiving warfarin, digoxin, or anti-arrhythmic or anti-seizure medication</li> </ul>
Interventions	<p>Experimental: combination treatment: DFX and DFP</p> <p>Active comparator: DFX</p>

### Deferasirox for managing iron overload in people with thalassaemia (Review)

**NCT02198508** (Continued)

	Active comparator: DFP
Outcomes	Primary outcome: <ul style="list-style-type: none"> <li>Iron excretion from urine and faeces by flame atomic absorption spectroscopy [time frame: 25 days]</li> </ul> Secondary outcome: <ul style="list-style-type: none"> <li>Drug concentration in plasma by pharmacokinetics analysis [time frame: 25 days]</li> </ul>
Notes	Primary completion date: July 2008 Recruitment status: completed Author was contacted

AE: adverse event

AUC: area under the curve

Cmax: maximum or peak concentration (of a drug observed after its administration)

Cmin: minimum concentration (of a drug observed after its administration)

DFO: deferoxamine

DFP: deferiprone

DFX: deferasirox

EU: European Union

GFR: glomerular filtration rate

GIQLI: Gastrointestinal Quality of Life Index

GI: gastrointestinal

GSRS: Gastrointestinal Symptom Rating Scale

LIC: liver iron concentration

LVEF: left ventricular ejection fraction

MRI: magnetic resonance imaging

SD: standard deviation

SGPT: serum glutamic-pyruvic transaminase

TIBC: total iron binding capacity

**Characteristics of ongoing studies** [ordered by study ID]

**Cutino 2009**

Trial name or title	Sequential DFX-DFP versus DFX or DFP multicentre randomised study
Methods	Randomised, parallel-group, open study.
Participants	Planned number of participants to be included in the member state: 363 Inclusion criteria: <ul style="list-style-type: none"> <li>Male and female</li> <li>Age &gt; 12 and &lt; 50 years old</li> <li>Diagnosis of <math>\beta</math>-thalassaemia major</li> <li>Serum ferritin concentration &gt; 1000 <math>\mu\text{g/L}</math></li> </ul> Exclusion criteria: <ul style="list-style-type: none"> <li>Diagnosis other than <math>\beta</math>-thalassaemia major</li> <li>Participants with renal failure (creatinine clearance &lt; 60 mL/min)</li> <li>ALT/AST &gt; 300 U/L</li> <li>Severe cardiomyopathy</li> <li>Individuals with previous significant ocular toxicity related to iron chelating drugs</li> </ul>



**Cutino 2009** (Continued)

- Individuals with previous significant idiosyncratic reaction or severe toxicity to previous therapy with DFP or DFX
- Platelets < 100.000/mmc
- Leukocytes < 300/mm
- Severe liver insufficiency (Child-Pugh Score C)

Interventions	Experimental: sequential DFX-DFP  Comparator 1: DFX  Comparator 2: DFP
Outcomes	Primary outcome measure: <ul style="list-style-type: none"> <li>• Chelating efficacy assessment of sequential therapy DFX-DFP versus DFX or DFP alone</li> </ul> Secondary outcome measures: <ul style="list-style-type: none"> <li>• To assess in the sequential deferasirox-deferiprone treated group a reduction at least in 50% of cases of creatininemia significant increase (&gt; 33%) compared to the deferasirox alone group</li> <li>• To assess in the sequential DFX-DFP group a reduction at least in 70% of cases of neutropenia compared to the DFP alone group</li> <li>• To assess, using MRI, in a subgroup, the possible organ-specific (heart, liver, pancreas) iron overload variation during therapy</li> </ul>
Starting date	Date of first enrolment: 27/01/2010
Contact information	N/A  Sponsor: FONDAZIONE FRANCO E PIERA CUTINO
Notes	Initial estimate of the duration of the study: 5 years

**DEEP-2 2012**

Trial name or title	Efficacy and safety study to compare deferiprone versus deferasirox in paediatric patients
Methods	Multicentre, randomised, open label, non-inferiority active-controlled study
Participants	Estimated enrolment: 344  Inclusion criteria; <ul style="list-style-type: none"> <li>• People of both genders aged from 1 month up to less than 18 years at the time of enrolment</li> <li>• People affected by any hereditary haemoglobinopathy requiring chronic transfusion therapy and chelation, including but not limited to thalassaemia syndromes and sickle cell disease</li> <li>• People on current treatment with DFO or DFX or DFP in a chronic transfusion program receiving at least 150 mL/kg/year of packed red blood cells (corresponding approximately to 12 transfusions)</li> <li>• For participants naive to chelation treatment: participants that have received at least 150 mL/kg of packed red blood cells (corresponding to approximately 12 transfusions) in a chronic transfusion program and with serum ferritin levels <math>\geq</math> 800 ng/mL</li> <li>• For participants aged from 1 month to less than 6 years: known intolerance or contraindication to DFO;</li> <li>• Written informed consent and participant's informed assent, relating to his/her comprehension abilities and level of maturity</li> </ul> Exclusion criteria:

**DEEP-2 2012** (Continued)

- Participants with known intolerance or contraindication to either DFP or DFX
- Participants receiving DFX at a dose > 40 mg/kg/day or DFP at a dose > 100 mg/kg/day at screening
- Platelet count < 100.000/mm<sup>3</sup> during the run-in phase
- Absolute neutrophils count < 1.500/mm<sup>3</sup> during the run-in phase
- Hb levels lower than 8 g/dL during the run-in phase
- Evidence of abnormal liver function
- Iron overload from causes other than transfusional haemosiderosis
- Severe heart dysfunction secondary to iron overload
- Serum creatinine level > ULN for age during the run-in phase
- History of significant medical or psychiatric disorder
- The patient has received another investigational drug within 30 days prior to this study
- Fever and other signs/symptoms of infection in the 10 days before baseline assessment
- Concomitant use of trivalent cation-dependent medicinal products such as aluminium-based antacids
- Positive test for β-HCG

Interventions	<p>Experimental: DFP oral solution</p> <p>Comparator: DFX</p>
Outcomes	<p>Primary outcome measure</p> <ul style="list-style-type: none"> <li>• Percentage of successfully chelated participants assessed by serum ferritin levels (all participants) and cardiac MRI T2* (participants above 10 years of age able to have an MRI scan without sedation)</li> </ul> <p>Secondary outcome measures</p> <ul style="list-style-type: none"> <li>• LIC as measured by MRI in participants able to undergo MRI scan without sedation</li> <li>• Safety and tolerability assessments</li> <li>• QoL</li> </ul>
Starting date	Date of first enrolment: 29/11/2012
Contact information	<p>Direzione Scientifica</p> <p>via Luigi Porta, 14</p> <p>27100 Pavia</p> <p>Italy</p> <p>Arianna Gambino, M.Sc.</p> <p>phone: +39.0382.25075</p> <p>email: deep.2@deep-project.net / agambino@cvbf.net</p>
Notes	<p>Estimated study completion date: December 2014</p> <p>Estimated primary completion date: December 2014 (Final data collection date for primary outcome measure)</p>

**NCT02125877**

Trial name or title	Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
---------------------	--

**NCT02125877** (Continued)

Methods	A randomised, open-label, multicentre, 2-arm, phase II study.
Participants	<p>Enrollment: 168</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Males and females aged <math>\geq 10</math> years</li> <li>• Individuals with transfusion-dependent thalassaemia and iron overload, requiring DFX dispersible tablets at doses of <math>\geq 30</math> mg/kg/day as per the investigator's decision OR those with very low, low or intermediate risk of myelodysplastic syndrome and iron overload, requiring DFX dispersible tablets at doses of <math>\geq 20</math> mg/kg/day as per the investigator's decision</li> <li>• History of transfusion of at least 20 PRBC units and anticipated to be transfused with at least 8 units of PRBCs annually during the study</li> <li>• Serum ferritin <math>&gt; 1000</math> ng/mL, measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria)</li> </ul> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> <li>• Creatinine clearance below the contraindication limit in the locally approved prescribing information. Creatinine clearance will be estimated from serum creatinine at screening Visit 1 and screening Visit 2 and the mean value will be used for eligibility criteria</li> <li>• Serum creatinine <math>&gt; 1.5 \times</math> ULN at screening measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria)</li> <li>• ALT (SGPT) <math>&gt; 5 \times</math>ULN, unless LIC confirmed as <math>&gt; 10</math> mg Fe/dry weight within 6 months prior to screening visit 1</li> <li>• Significant proteinuria as indicated by a urinary protein/creatinine ratio <math>&gt; 0.5</math> mg/mg in a non-first void urine sample at screening Visit 1 or screening Visit 2</li> <li>• People with significant impaired GI function or GI disease that may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases uncontrolled nausea, vomiting, diarrhoea, mal-absorption syndrome, or small bowel resection)</li> <li>• Liver disease with severity of Child-Pugh Class B or C</li> </ul>
Interventions	<p>Experimental: DFX film-coated tablet</p> <p>Active comparator: DFX dispersible tablet</p>
Outcomes	<p>Primary outcome</p> <ul style="list-style-type: none"> <li>• Overall safety [Time Frame: Screening visit thru post-treatment period - 30 weeks]</li> </ul> <p>Secondary outcome</p> <ul style="list-style-type: none"> <li>• Frequency of selected GI AEs (GI AEs) [time frame: on-treatment period (Day 1 - safety follow-up) - 28 weeks]</li> <li>• Pharmacokinetic parameters [Time frame: week 1, 3, 13 and 21]</li> <li>• Domain scores of treatment satisfaction and palatability over time [time frame: Week 2, 3, 13 and end of treatment (week 24 or within 7 days of last dose)]</li> <li>• Weekly average of daily scores of GI diary [Time frame: weekly (screening thru end of treatment visit) - 26 weeks]</li> <li>• Relative consumed film-coated tablet/dispersible tablet counts. Participant-reported medication consumption [Time frame: daily (day 1/visit 3 - last visit) 24 weeks]</li> </ul>
Starting date	July 2014
Contact information	Sponsor: Novartis Pharmaceuticals
Notes	Estimated study completion date: February 2016

**NCT02125877** (Continued)

Estimated primary completion date: February 2016 (Final data collection date for primary outcome measure)

**NCT02435212**

Trial name or title	Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2 - < 18 years old) With Iron Overload
Methods	Randomised, open-label, multicentre, 2-arm, phase II study. Randomisation will be stratified by age groups (2 to < 10 years, 10 to < 18 years). The study treatment duration will be 48 weeks
Participants	<p>Target sample size:120</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> <li>• Written informed consent/assent before any study-specific procedures. Consent will be obtained from parent(s) or legal guardians. Investigators will also obtain assent of participants according to local guidelines</li> <li>• Iron chelation therapy naive male and female children and adolescents aged <math>\geq 2</math> and &lt; 18 years</li> <li>• Any transfusion-dependent anaemia associated with iron overload requiring iron chelation therapy and with a history of transfusion of at least 20 PRBC units and a treatment goal to reduce iron burden</li> <li>• Serum ferritin &gt; 1000 ng/mL, measured at screening visit 1 and screening visit 2 (the mean value will be used for eligibility criteria)</li> </ul> <p>Exclusion criteria:</p> <ul style="list-style-type: none"> <li>• Creatinine clearance below the contraindication limit in the locally approved prescribing information. Creatinine clearance will be estimated from serum creatinine (using the Schwartz formula) at screening Visit 1 and screening visit 2 and the mean value will be used for eligibility criteria</li> <li>• Serum creatinine &gt; 1.5 x ULN at screening measured at screening visit 1 and screening visit 2 (the mean value will be used for eligibility criteria)</li> <li>• ALT &gt; 5 x ULN, unless LIC within 6 months is &gt; 10 mg Fe/dry weight</li> <li>• Prior iron chelation therapy</li> <li>• Liver disease with severity of Child-Pugh class B or C</li> <li>• Significant proteinuria as indicated by a urinary protein/creatinine ratio &gt; 0.5 mg/mg in a non-first void urine sample at screening visit 1 or screening visit 2</li> <li>• Patients with significant impaired GI function or GI disease that may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, mal-absorption syndrome, or small bowel resection)</li> </ul> <p>Other protocol-defined inclusion/exclusion may apply</p>
Interventions	<p>Experimental: DFX granule formulation</p> <p>Active comparator: DFX dispersible tablet formulation</p>
Outcomes	<p>Primary outcomes:</p> <ul style="list-style-type: none"> <li>• Change in serum ferritin [Time frame: baseline, 48 weeks]</li> <li>• Compliance (using stick/pack tablet count) [Time frame: 48 weeks]</li> </ul> <p>Secondary outcomes:</p> <ul style="list-style-type: none"> <li>• Domain scores of treatment satisfaction and palatability over time [time frame: 48 weeks]</li> <li>• Frequency of AEs as a measure of overall safety [Time frame: baseline, 48 weeks]</li> </ul>

**NCT02435212** (Continued)

- Pharmacokinetic parameters including clearance and volume of distribution in all participants (AUClast, AUCinf, AUCtau, Cmax, Tmax and R) [Time frame: Week 1, Week 5]
- Pre-dose DFX concentrations in all participants [time frame: at weeks 1, 3, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41 and 45]
- Rate of dosing instructions deviations ('Compliance', using a questionnaire) [Time Frame: 48 weeks]
- Severity of AEs as a measure of overall safety [Time frame: baseline, 48 weeks]

Starting date	September 2015
Contact information	Novartis Pharmaceuticals 1-888-669-6682
Notes	Estimated study completion date: August 2017  Estimated primary completion date: August 2017 (Final data collection for primary outcome measure)

Information given in table according to [www.clinicaltrials.gov](http://www.clinicaltrials.gov) or <http://apps.who.int/trialsearch/> or <http://www.irct.ir/>. Data were extracted in October 2015.

AEs: adverse events

ALT: alanine aminotransferase

AST: aspartate transaminase

AUCinf: area under the concentration-time curve extrapolated to time infinity

AUClast: area under the curve up to the last measurable concentration

AUCtau: area under the plasma concentration-time curve during the dosing interval

Cmax: maximum or peak concentration (of a drug observed after its administration)

CMR: cardiovascular magnetic resonance

DFO: deferoxamine

DFP: deferiprone

DFX: deferasirox

GI: gastrointestinal

HCG: human chorionic gonadotropin

LIC: liver iron concentration

LVEF: left ventricular ejection fraction

MRI: magnetic resonance imaging

PRBC: packed red blood cells

QoL: quality of life

SD: standard deviation

SGPT: serum glutamic-pyruvic transaminase

Tmax: amount of time that a drug is present at the maximum concentration in serum

ULN: upper limit of normal

## DATA AND ANALYSES

### Comparison 1. Transfusion-dependent thalassemia: deferasirox vs placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at any time point	2	47	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 AEs	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
2.1 Eye disorders - retinal infarct	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.2 GI disorders - abdominal pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 GI disorders - diarrhoea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.4 GI disorders - nausea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.5 Investigations - extended QT interval, hypocalcaemia, hypoparathyroidism	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.6 Skin and subcutaneous tissue disorders - rash	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Discontinuations due to serious AEs	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected

**Analysis 1.1. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 1 Mortality at any time point.**


Study or subgroup	Deferasirox n/N	Placebo n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
Galanello 1999	0/18	0/6			Not estimable
Nisbet-Brown 2001	0/18	0/5			Not estimable
<b>Total (95% CI)</b>	<b>36</b>	<b>11</b>			<b>Not estimable</b>
Total events: 0 (Deferasirox), 0 (Placebo)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					

**Analysis 1.2. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 2 AEs.**

Study or subgroup	Deferasirox n/N	Placebo n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
<b>1.2.1 Eye disorders - retinal infarct</b>					
Nisbet-Brown 2001	1/18	0/5			0.95[0.04,20.33]
<b>1.2.2 GI disorders - abdominal pain</b>					
Nisbet-Brown 2001	1/18	0/5			0.95[0.04,20.33]
<b>1.2.3 GI disorders - diarrhoea</b>					
Nisbet-Brown 2001	4/18	0/5			2.84[0.18,45.53]
<b>1.2.4 GI disorders - nausea</b>					
Nisbet-Brown 2001	4/18	0/5			2.84[0.18,45.53]



**Analysis 1.3. Comparison 1 Transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 3 Discontinuations due to serious AEs.**



**Comparison 2. Transfusion-dependent thalassemia: deferasirox vs deferoxamine**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<b>1 Mortality at any time point</b>	8	1170	Risk Ratio (M-H, Fixed, 95% CI)	0.48 [0.09, 2.63]
1.1 At 8 months	1	138	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 At 48 weeks (deferiasirox 10 mg/kg/day)	1	35	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.3 At 48 weeks (deferiasirox 20 mg/kg/day)	1	36	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.4 At 1 year	5	942	Risk Ratio (M-H, Fixed, 95% CI)	0.48 [0.09, 2.63]
1.5 At 2 years	1	19	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>2 LVEF (%): least squares mean change from baseline</b>	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
<b>3 LVEF (# participants affected)</b>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
3.1 Improvement from abnormal LVEF to normal range	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Decrease from normal LVEF to below LLN	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>4 Incidence of thyroid disease at end of study</b>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5 ALT (# participants affected): improvement from abnormal to normal range	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
6 ALT (U/L) at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
7 AST (U/L) at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
8 Serum creatinine (mg/dL) at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
9 Blood urea (mg/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
10 Serum ferritin (ng/mL): mean change from baseline and at end of study	6	1002	Mean Difference (IV, Fixed, 95% CI)	454.42 [337.13, 571.71]
10.1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30mg deferoxamine)	1	28	Mean Difference (IV, Fixed, 95% CI)	978.0 [544.71, 1411.29]
10.2 More than 3 to 7 mg Fe/g dw (10/35)	1	150	Mean Difference (IV, Fixed, 95% CI)	801.0 [572.53, 1029.47]
10.3 More than 7 mg Fe/g dw (20/41)	1	169	Mean Difference (IV, Fixed, 95% CI)	328.0 [124.94, 531.06]
10.4 More than 14 mg Fe/g dw (30/51)	1	216	Mean Difference (IV, Fixed, 95% CI)	77.0 [-303.18, 457.18]
10.5 Any iron overload	5	439	Mean Difference (IV, Fixed, 95% CI)	234.25 [-8.02, 476.52]
11 Sensitivity analysis: serum ferritin (ng/mL): mean change from baseline	2	701	Mean Difference (IV, Fixed, 95% CI)	418.94 [297.23, 540.65]
11.1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30 mg deferoxamine)	1	28	Mean Difference (IV, Fixed, 95% CI)	978.0 [544.71, 1411.29]
11.2 More than 3 to 7 mg Fe/g dw (10/35)	1	150	Mean Difference (IV, Fixed, 95% CI)	801.0 [572.53, 1029.47]
11.3 More than 7 mg Fe/g dw (20/41)	1	169	Mean Difference (IV, Fixed, 95% CI)	328.0 [124.94, 531.06]
11.4 More than 14 mg Fe/g dw (30/51)	1	216	Mean Difference (IV, Fixed, 95% CI)	77.0 [-303.18, 457.18]
11.5 Any iron overload	1	138	Mean Difference (IV, Fixed, 95% CI)	-64.16 [-354.62, 226.30]



Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12 Liver R2* (Hz): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
13 LIC (mg/g) evaluated by MRI (R2/R2*): mean change from baseline	2	217	Mean Difference (IV, Fixed, 95% CI)	0.36 [-1.01, 1.72]
14 LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline	1	541	Mean Difference (IV, Fixed, 95% CI)	2.37 [1.68, 3.07]
14.1 LIC 3 mg Fe/g dw or less (5/30)	1	28	Mean Difference (IV, Fixed, 95% CI)	4.3 [2.30, 6.30]
14.2 LIC more than 3 mg to 7 mg (10/35) Fe/g dw	1	143	Mean Difference (IV, Fixed, 95% CI)	3.80 [2.74, 4.86]
14.3 LIC more than 7 mg to 14 mg Fe/g dw (20/41)	1	164	Mean Difference (IV, Fixed, 95% CI)	1.5 [0.28, 2.72]
14.4 LIC more than 14 mg Fe/g dw (30/51)	1	206	Mean Difference (IV, Fixed, 95% CI)	-2.5 [-4.55, -0.45]
15 Responder analysis I (responder: fall in LIC > 10%)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
15.1 Response at 48 weeks (deferiasirox 10 mg/kg/day)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.2 Response at 48 weeks (deferiasirox 20 mg/kg/day)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
16 Responder analysis II (responder: LIC 1 to < 7 mg Fe/g dw)	1	553	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.69, 0.92]
16.1 Response at 1 year (LIC below 7 mg Fe/g dw)	1	172	Risk Ratio (M-H, Fixed, 95% CI)	0.48 [0.37, 0.64]
16.2 Response at 1 year (LIC at least 7 mg Fe/g dw)	1	381	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.84, 1.18]
17 Myocardial T2* (ms): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
18 Myocardial iron concentration derived from T2* value (mg Fe/g dw): change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
18.1 All participants	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
18.2 Participants with T2* <10 ms	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
18.3 Participants with T2* ≥10 ms	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
19 Myocardial T2* (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
19.1 Normalization	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
19.2 Improvement (from 6 - < 10 ms to 10 - ≤ 20 ms)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
19.3 Worsening (from 10- ≤ 20 ms to 6 - < 10 ms)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>20 Iron excretion-intake ratio</b>	1	541	Mean Difference (IV, Fixed, 95% CI)	-0.18 [-0.24, -0.12]
20.1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30 mg deferoxamine)	1	28	Mean Difference (IV, Fixed, 95% CI)	-0.37 [-0.54, -0.20]
20.2 More than 3 to 7 mg Fe/g dw (10/35)	1	143	Mean Difference (IV, Fixed, 95% CI)	-0.31 [-0.41, -0.21]
20.3 More than 7 mg Fe/g dw (20/41)	1	164	Mean Difference (IV, Fixed, 95% CI)	-0.11 [-0.21, -0.01]
20.4 More than 14 mg Fe/g dw (30/51)	1	206	Mean Difference (IV, Fixed, 95% CI)	0.23 [0.05, 0.41]
<b>21 Any serious AEs (# participants affected)</b>	2	773	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.42, 1.86]
<b>22 Serious AEs</b>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
22.1 Cardiac disorders - arrhythmia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.2 Endocrine disorders - hypogonadism	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.3 GI disorders abdominal abscess	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.4 GI disorders amoebiasis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.5 GI disorders - appendicitis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.6 GI disorders - colitis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.7 GI disorders - diarrhoea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.8 GI disorders - gastric haemorrhage	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.9 GI disorders - gastroenteritis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.10 GI disorders - ileus	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.11 GI disorders - upper abdominal pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.12 GI disorders - vomiting	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.13 GI disorders - GI infection	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
22.14 General disorders and administration site conditions - pyrexia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.15 General disorders and administration site conditions - local swelling	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.16 Hepatobiliary disorders - liver abscess	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.17 Hepatobiliary disorders - cholelithiasis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.18 Immune system disorders - face oedema	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.19 Infections and infestations - herpes zoster	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.20 Infections and infestations - tooth infection	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.21 Infections and infestations - urinary tract infection	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.22 Injury, poisoning and procedural complications - oesophageal rupture	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.23 Injury, poisoning and procedural complications - haemosiderosis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.24 Injury, poisoning and procedural complications - iron overload	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.25 Metabolism and nutrition disorders - hyperglycaemia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.26 Musculoskeletal and connective tissue disorders - back pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.27 Musculoskeletal and connective tissue disorders - pain in jaw	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.28 Nervous system disorders - grand mal convulsion	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.29 Nervous system disorders - meningitis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.30 Respiratory, thoracic and mediastinal disorders - acute tonsillitis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>23 Any AE (# participants affected)</b>	<b>2</b>	<b>258</b>	<b>Risk Ratio (M-H, Fixed, 95% CI)</b>	<b>0.94 [0.83, 1.08]</b>

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
24 AEs	5		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
24.1 Blood and lymphatic system disorder - agranulocytosis	2	657	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
24.2 Blood and lymphatic system disorder - leukopenia	1	138	Risk Ratio (M-H, Fixed, 95% CI)	7.0 [0.37, 133.02]
24.3 Blood and lymphatic system disorder - neutropenia	1	71	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
24.4 Blood and lymphatic system disorder - thrombocytopenia	2	209	Risk Ratio (M-H, Fixed, 95% CI)	4.0 [0.46, 34.88]
24.5 Cardiac disorders - cardiac AE	1	586	Risk Ratio (M-H, Fixed, 95% CI)	0.73 [0.38, 1.41]
24.6 Ear and labyrinth disorders - hearing loss	2	657	Risk Ratio (M-H, Fixed, 95% CI)	1.12 [0.41, 3.05]
24.7 Eye disorder - lens abnormality	2	657	Risk Ratio (M-H, Fixed, 95% CI)	0.39 [0.08, 2.00]
24.8 Eye disorder - retinal abnormality	1	71	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
24.9 GI disorders - abdominal pain	2	258	Risk Ratio (M-H, Fixed, 95% CI)	1.69 [0.93, 3.05]
24.10 GI disorders - abdominal pain upper	1	187	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.36, 3.60]
24.11 GI disorders - diarrhoea	2	258	Risk Ratio (M-H, Fixed, 95% CI)	1.65 [0.86, 3.16]
24.12 GI disorders - dyspepsia	1	71	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [0.25, 5.72]
24.13 GI disorders - GIT upset	1	60	Risk Ratio (M-H, Fixed, 95% CI)	3.0 [0.66, 13.69]
24.14 GI disorders - nausea	2	258	Risk Ratio (M-H, Fixed, 95% CI)	2.59 [0.90, 7.47]
24.15 GI disorders - vomiting	2	258	Risk Ratio (M-H, Fixed, 95% CI)	2.95 [0.91, 9.55]
24.16 General disorders and administration site conditions - asthenia	1	71	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [0.42, 3.42]
24.17 General disorders and administration site conditions - influenza-like illness	1	71	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [0.42, 3.42]
24.18 General disorders and administration site conditions - pyrexia	2	258	Risk Ratio (M-H, Fixed, 95% CI)	1.27 [0.66, 2.44]
24.19 Immune system disorders - allergic conjunctivitis	1	71	Risk Ratio (M-H, Fixed, 95% CI)	4.41 [0.25, 78.58]
24.20 Infections and infestations - bronchitis	1	71	Risk Ratio (M-H, Fixed, 95% CI)	2.40 [0.30, 19.35]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
24.21 Infections and infestations - upper respiratory tract infection	1	187	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.37, 2.42]
24.22 Infections and infestations - urinary tract infection	1	71	Risk Ratio (M-H, Fixed, 95% CI)	2.40 [0.30, 19.35]
24.23 Investigations - ALT increased	1	187	Risk Ratio (M-H, Fixed, 95% CI)	1.71 [0.59, 4.90]
24.24 Investigations - elevated ALT (>2 UNL)	1	586	Risk Ratio (M-H, Fixed, 95% CI)	4.90 [0.24, 101.60]
24.25 Investigations - AST increased	1	187	Risk Ratio (M-H, Fixed, 95% CI)	2.21 [0.59, 8.29]
24.26 Investigations - blood creatinine increased	1	187	Risk Ratio (M-H, Fixed, 95% CI)	3.79 [0.83, 17.38]
24.27 Investigations - isolated serum creatinine increase above upper limit of normal	2	657	Risk Ratio (M-H, Fixed, 95% CI)	2.57 [1.88, 3.51]
24.28 Investigations - platelet count increased	1	187	Risk Ratio (M-H, Fixed, 95% CI)	0.38 [0.08, 1.91]
24.29 Musculoskeletal and connective tissue disorders - arthralgia	2	258	Risk Ratio (M-H, Fixed, 95% CI)	1.31 [0.55, 3.13]
24.30 Musculoskeletal and connective tissue disorders - back pain	2	258	Risk Ratio (M-H, Fixed, 95% CI)	1.30 [0.73, 2.34]
24.31 Musculoskeletal and connective tissue disorders - osteoporosis	1	187	Risk Ratio (M-H, Fixed, 95% CI)	2.37 [0.47, 11.91]
24.32 Nervous system disorders - headache	2	258	Risk Ratio (M-H, Fixed, 95% CI)	1.44 [0.68, 3.05]
24.33 Nervous system disorders - vertigo	1	71	Risk Ratio (M-H, Fixed, 95% CI)	1.12 [0.32, 3.93]
24.34 Renal and urinary disorders - proteinuria	1	187	Risk Ratio (M-H, Fixed, 95% CI)	1.16 [0.50, 2.66]
24.35 Respiratory, thoracic and mediastinal disorders - cough	1	71	Risk Ratio (M-H, Fixed, 95% CI)	1.80 [0.67, 4.81]
24.36 Respiratory, thoracic and mediastinal disorders - influenza	2	258	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.52, 2.13]
24.37 Respiratory, thoracic and mediastinal disorders - nasopharyngitis	1	187	Risk Ratio (M-H, Fixed, 95% CI)	1.90 [0.59, 6.08]
24.38 Respiratory, thoracic and mediastinal disorders - oropharyngeal pain	1	187	Risk Ratio (M-H, Fixed, 95% CI)	2.84 [0.59, 13.73]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
24.39 Respiratory, thoracic and mediastinal disorders - pharyngitis	1	71	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.52, 2.00]
24.40 Respiratory, thoracic and mediastinal disorders - pharyngolaryngeal pain	1	71	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.37, 2.08]
24.41 Respiratory, thoracic and mediastinal disorders - rhinitis	1	71	Risk Ratio (M-H, Fixed, 95% CI)	1.28 [0.58, 2.83]
24.42 Skin and subcutaneous tissue disorders - Rash	1	60	Risk Ratio (M-H, Fixed, 95% CI)	2.67 [0.78, 9.09]
25 Any drug-related AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
26 Drug-related AEs	2		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
26.1 Blood and lymphatic system disorder - neutropenia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.2 Injury, poisoning and procedural complications - infusion site haemorrhage	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.3 Injury, poisoning and procedural complications - infusion site pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.4 Injury, poisoning and procedural complications - infusion site swelling	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.5 Injury, poisoning and procedural complications - injection site pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.6 Injury, poisoning and procedural complications - injection site reaction	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.7 Investigations - blood creatinine increased	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.8 Investigations - ALT increased	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.9 Investigations - AST increased	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.10 GI disorders - abdominal pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.11 GI disorders - abdominal pain upper	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.12 GI disorders - diarrhoea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.13 GI disorders - nausea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.14 GI disorders - vomiting	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
26.15 Immune system disorders - hypersensitivity	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.16 Immune system disorders - urticaria	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.17 Musculoskeletal and connective tissue disorders - arthropathy	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.18 Renal and urinary disorders - proteinuria	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.19 Skin and subcutaneous tissue disorders - alopecia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.20 Skin and subcutaneous tissue disorders - rash	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.21 Injury, poisoning and procedural complications - pulmonary toxicity	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.22 Eye disorders - Ophthalmological toxicity	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.23 Ear and labyrinth disorders - Audiological toxicity	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>27 Satisfaction with treatment (very satisfied or satisfied)</b>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
27.1 Week 4 - participants previously treated with DFO	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
27.2 Week 24 - participants previously treated with DFO	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
27.3 End of study (1 year) - participants previously treated with DFO	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
27.4 Week 4 - DFO-naive participants	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
27.5 Week 24 - DFO-naive participants	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
27.6 End of study (1 year) - DFO-naive participants	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>28 Convenience (good or very good)</b>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
28.1 Week 4 - participants previously treated with DFO	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
28.2 Week 24 - participants previously treated with DFO	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
28.3 End of study (1 year) - participants previously treated with DFO	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
28.4 Week 4 - DFO-naive participants	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
28.5 Week 24 - DFO-naive participants	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
28.6 End of study (1 year) - DFO-naive participants	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<a href="#">29 Willingness to continue treatment</a>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
29.1 Participants treated previously with DFO	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
29.2 DFO-naive participants	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<a href="#">30 Time lost from normal activities due to treatment (hours/month): participants treated previously with DFO</a>	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
30.1 week 4 - patients treated previously with DFO	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
30.2 week 24 - patients treated previously with DFO	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
30.3 end of study (1 year) - patients treated previously with DFO	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
30.4 week 4 - DFO-naive patients	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
30.5 week 24 - DFO-naive patients	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
30.6 end of study (1 year) - DFO-naive patients	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
<a href="#">31 Adherence (% of planned dose)</a>	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
<a href="#">32 Discontinuations</a>	8	1211	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.60, 1.50]
32.1 Deferasirox 10 mg/kg/day	1	35	Risk Ratio (M-H, Fixed, 95% CI)	0.16 [0.01, 3.64]
32.2 Deferasirox 20 mg/kg/day	2	174	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.10, 9.96]
32.3 Deferasirox 25 mg/kg/day	1	120	Risk Ratio (M-H, Fixed, 95% CI)	0.09 [0.01, 1.61]
32.4 Deferasirox 40 mg/kg/day	2	211	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.51, 2.05]
32.5 Deferasirox - variable dosage	2	646	Risk Ratio (M-H, Fixed, 95% CI)	1.39 [0.67, 2.85]
32.6 Deferasirox dosing unknown	1	25	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]




Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
33 Dose adjustments and dose interruptions	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
34 Dose interruptions (interrupted at least once)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
35 Dose reduction (at least once)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
36 Dose adjustments (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
37 Dose interruptions due to an AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
38 Haemoglobin (g/dL): mean change from baseline and at end of study	2	180	Mean Difference (IV, Fixed, 95% CI)	-0.52 [-0.82, -0.21]
38.1 At 8 months (change from baseline)	1	138	Mean Difference (IV, Fixed, 95% CI)	-0.46 [-0.81, -0.11]
38.2 At 1 year (at end of study)	1	42	Mean Difference (IV, Fixed, 95% CI)	-0.70 [-1.33, -0.07]
39 Transfusion index (mL/kg/year): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
40 Transferrin saturation (%): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
41 Platelet count (x10 <sup>3</sup> /mm <sup>3</sup> ): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
42 Absolute neutrophilic count (/mm <sup>3</sup> ): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

**Analysis 2.1. Comparison 2 Transfusion-dependent thalassaemia: deferasirox vs deferoxamine, Outcome 1 Mortality at any time point.**

Study or subgroup	Deferasirox n/N	Deferoxamine n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
<b>2.1.1 At 8 months</b>					
Molavi 2013	0/69	0/69			Not estimable
<b>Subtotal (95% CI)</b>	<b>69</b>	<b>69</b>			<b>Not estimable</b>
Total events: 0 (Deferasirox), 0 (Deferoxamine)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
<b>2.1.2 At 48 weeks (deferasirox 10 mg/kg/day)</b>					
Piga 2002	0/24	0/11			Not estimable
<b>Subtotal (95% CI)</b>	<b>24</b>	<b>11</b>			<b>Not estimable</b>

Favours deferasirox    0.01    0.1    1    10    100    Favours deferoxamine




**Analysis 2.2. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 2 LVEF (%): least squares mean change from baseline.**


Study or subgroup	Deferasirox		Deferoxamine		Mean Difference	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI	Fixed, 95% CI
Pennell 2014	91	-0.5 (4.5)	81	0 (4.4)		-0.5[-1.83,0.83]

Favours deferoxamine    -2    -1    0    1    2    Favours deferasirox


**Analysis 2.3. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 3 LVEF (# participants affected).**




**Analysis 2.4. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 4 Incidence of thyroid disease at end of study.**




**Analysis 2.5. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 5 ALT (# participants affected): improvement from abnormal to normal range.**



**Analysis 2.6. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 6 ALT (U/L) at end of study.**



**Analysis 2.7. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 7 AST (U/L) at end of study.**



**Analysis 2.8. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 8 Serum creatinine (mg/dL) at end of study.**


Study or subgroup	Deferasirox		Deferoxamine		Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
	N	Mean(SD)	N	Mean(SD)		
Hassan 2016	30	0.6 (0.2)	30	0.5 (0.2)		0.07[-0.03,0.17]

**Analysis 2.9. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 9 Blood urea (mg/dL): mean at end of study.**


Study or subgroup	Deferasirox		Deferoxamine		Mean Difference Fixed, 95% CI	Mean Difference Fixed, 95% CI
	N	Mean(SD)	N	Mean(SD)		
Hassan 2016	30	35.2 (6.5)	30	28.1 (5.7)		7.1[4.01,10.19]


**Analysis 2.10. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 10 Serum ferritin (ng/mL): mean change from baseline and at end of study.**

Study or subgroup	Deferasirox		Deferoxamine		Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
	N	Mean(SD)	N	Mean(SD)			
<b>2.10.1 Less than 3 mg Fe/g dw (median 5 mg deferasirox / 30mg deferoxamine)</b>							
Cappellini 2005b	15	1189 (700)	13	211 (459)		7.33%	978[544.71,1411.29]
<b>Subtotal ***</b>	<b>15</b>		<b>13</b>			<b>7.33%</b>	<b>978[544.71,1411.29]</b>
Heterogeneity: Not applicable Test for overall effect: Z=4.42(P<0.0001)							
<b>2.10.2 More than 3 to 7 mg Fe/g dw (10/35)</b>							
Cappellini 2005b	73	833 (817)	77	32 (585)		26.35%	801[572.53,1029.47]
<b>Subtotal ***</b>	<b>73</b>		<b>77</b>			<b>26.35%</b>	<b>801[572.53,1029.47]</b>
Heterogeneity: Not applicable Test for overall effect: Z=6.87(P<0.0001)							
<b>2.10.3 More than 7 mg Fe/g dw (20/41)</b>							
Cappellini 2005b	80	-36 (721)	89	-364 (614)		33.36%	328[124.94,531.06]
<b>Subtotal ***</b>	<b>80</b>		<b>89</b>			<b>33.36%</b>	<b>328[124.94,531.06]</b>
Heterogeneity: Not applicable Test for overall effect: Z=3.17(P=0)							
<b>2.10.4 More than 14 mg Fe/g dw (30/51)</b>							
Cappellini 2005b	115	-926 (1416)	101	-1003 (1428)		9.52%	77[-303.18,457.18]
<b>Subtotal ***</b>	<b>115</b>		<b>101</b>			<b>9.52%</b>	<b>77[-303.18,457.18]</b>
Heterogeneity: Not applicable Test for overall effect: Z=0.4(P=0.69)							
<b>2.10.5 Any iron overload</b>							
Elalfy 2015a	15	1507.3 (982.1)	30	1172.7 (590.3)		4.72%	334.66[-205.37,874.69]




**Analysis 2.11. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 11 Sensitivity analysis: serum ferritin (ng/mL): mean change from baseline.**







**Analysis 2.12. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 12 Liver R2\* (Hz): mean change from baseline.**




**Analysis 2.13. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 13 LIC (mg/g) evaluated by MRI (R2/R2\*): mean change from baseline.**




**Analysis 2.14. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 14 LIC (mg Fe/g dw) evaluated by biopsy or SQUID: mean change from baseline.**







**Analysis 2.15. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 15 Responder analysis I (responder: fall in LIC > 10%).**




**Analysis 2.16. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 16 Responder analysis II (responder: LIC 1 to < 7 mg Fe/g dw).**







**Analysis 2.17. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 17 Myocardial T2\* (ms): mean change from baseline.**




**Analysis 2.18. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 18 Myocardial iron concentration derived from T2\* value (mg Fe/g dw): change from baseline.**




**Analysis 2.19. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 19 Myocardial T2\* (# participants affected).**









**Analysis 2.20. Comparison 2 Transfusion-dependent thalassemia: deferferasirox vs deferoxamine, Outcome 20 Iron excretion-intake ratio.**





**Analysis 2.21. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 21 Any serious AEs (# participants affected).**




**Analysis 2.22. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 22 Serious AEs.**










**Analysis 2.23. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 23 Any AE (# participants affected).**





**Analysis 2.24. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 24 AEs.**























**Analysis 2.25. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 25 Any drug-related AE (# participants affected).**




**Analysis 2.26. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 26 Drug-related AEs.**









**Analysis 2.27. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 27 Satisfaction with treatment (very satisfied or satisfied).**




**Analysis 2.28. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 28 Convenience (good or very good).**







**Analysis 2.29. Comparison 2 Transfusion-dependent thalassemia: deferferasirox vs deferoxamine, Outcome 29 Willingness to continue treatment.**




**Analysis 2.30. Comparison 2 Transfusion-dependent thalassemia: deferferasirox vs deferoxamine, Outcome 30 Time lost from normal activities due to treatment (hours/month): participants treated previously with DFO.**







**Analysis 2.31. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 31 Adherence (% of planned dose).**




**Analysis 2.32. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 32 Discontinuations.**






**Analysis 2.33. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 33 Dose adjustments and dose interruptions.**



**Analysis 2.34. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 34 Dose interruptions (interrupted at least once).**



**Analysis 2.35. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 35 Dose reduction (at least once).**

Study or subgroup	Deferasirox		Deferoxamine		Risk Ratio		Risk Ratio	
	n/N	n/N	n/N	n/N	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Pennell 2014	15/96		18/91				0.79[0.42,1.47]	
					Favours deferasirox	0.01 0.1 1 10 100	Favours deferoxamine	

**Analysis 2.36. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 36 Dose adjustments (# participants affected).**

Study or subgroup	Deferasirox		Deferoxamine		Risk Ratio		Risk Ratio	
	n/N	n/N	n/N	n/N	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Piga 2002	27/48		4/23				3.23[1.28,8.16]	
					Favours deferasirox	0.01 0.1 1 10 100	Favours deferoxamine	

**Analysis 2.37. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 37 Dose interruptions due to an AE (# participants affected).**

Study or subgroup	Deferasirox		Deferoxamine		Risk Ratio		Risk Ratio	
	n/N	n/N	n/N	n/N	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Piga 2002	16/48		5/23				1.53[0.64,3.67]	
					Favours deferasirox	0.01 0.1 1 10 100	Favours deferoxamine	

**Analysis 2.38. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 38 Haemoglobin (g/dL): mean change from baseline and at end of study.**

Study or subgroup	Deferasirox		Deferoxamine		Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
	N	Mean(SD)	N	Mean(SD)			
<b>2.38.1 At 8 months (change from baseline)</b>							
Molavi 2013	69	-0.7 (1.2)	69	-0.2 (0.8)		76.27%	-0.46[-0.81,-0.11]
<b>Subtotal ***</b>	<b>69</b>		<b>69</b>			<b>76.27%</b>	<b>-0.46[-0.81,-0.11]</b>
Heterogeneity: Not applicable Test for overall effect: Z=2.56(P=0.01)							
<b>2.38.2 At 1 year (at end of study)</b>							
Elalfy 2015a	15	7.8 (1)	27	8.5 (1)		23.73%	-0.7[-1.33,-0.07]
<b>Subtotal ***</b>	<b>15</b>		<b>27</b>			<b>23.73%</b>	<b>-0.7[-1.33,-0.07]</b>
Heterogeneity: Not applicable Test for overall effect: Z=2.17(P=0.03)							
<b>Total ***</b>	<b>84</b>		<b>96</b>			<b>100%</b>	<b>-0.52[-0.82,-0.21]</b>
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =0.42, df=1(P=0.52); I <sup>2</sup> =0% Test for overall effect: Z=3.3(P=0) Test for subgroup differences: Chi <sup>2</sup> =0.42, df=1 (P=0.52), I <sup>2</sup> =0%							
					Favours deferoxamine	-1 -0.5 0 0.5 1	Favours deferasirox



**Analysis 2.39. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 39 Transfusion index (mL/kg/year): mean at end of study.**

Study or subgroup	Deferasirox		Deferoxamine		Mean Difference	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI	Fixed, 95% CI
Elalfy 2015a	15	219.6 (55.6)	27	203.5 (61.3)		16.1[-20.32,52.52]

**Analysis 2.40. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 40 Transferrin saturation (%): mean at end of study.**

Study or subgroup	Deferasirox		Deferoxamine		Mean Difference	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI	Fixed, 95% CI
Elalfy 2015a	15	61.1 (9.9)	27	62.1 (5.5)		-1[-6.42,4.42]

**Analysis 2.41. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 41 Platelet count (x10<sup>3</sup>/mm<sup>3</sup>): mean at end of study.**

Study or subgroup	Deferasirox		Deferoxamine		Mean Difference	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI	Fixed, 95% CI
Hassan 2016	30	345 (52)	30	337 (44)		8[-16.38,32.38]

**Analysis 2.42. Comparison 2 Transfusion-dependent thalassemia: deferasirox vs deferoxamine, Outcome 42 Absolute neutrophilic count (/mm<sup>3</sup>): mean at end of study.**

Study or subgroup	Deferasirox		Deferoxamine		Mean Difference	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI	Fixed, 95% CI
Hassan 2016	30	1980 (605)	30	2098 (554)		-118[-411.55,175.55]

**Comparison 3. Transfusion-dependent thalassemia: deferasirox vs deferiprone**


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at any time point	3	146	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.1 at 1 year	2	128	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 at 2 years	1	18	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 Incidence of thyroid disease at end of study	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
3 ALT (U/L): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4 AST (U/L): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5 Urea (mg/dL): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6 Creatinine (mg/dL): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
7 Neutrophil (count per mm <sup>3</sup> ): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
8 Serum ferritin (ng/mL): mean change from baseline and at end of study	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 All participants	2	83	Mean Difference (IV, Fixed, 95% CI)	229.99 [-403.14, 863.11]
8.2 Ferritin > 4000	1	11	Mean Difference (IV, Fixed, 95% CI)	1129.0 [-2226.18, 4484.18]
8.3 Ferritin 2000 - 4000	1	16	Mean Difference (IV, Fixed, 95% CI)	-151.0 [-743.80, 441.80]
8.4 Ferritin < 2000	1	11	Mean Difference (IV, Fixed, 95% CI)	388.0 [-255.71, 1031.71]
9 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
10 Myocardial T2* (ms): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
11 Any AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
12 AEs	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
12.1 GI disorders - diarrhoea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.2 GI disorders - nausea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.3 GI disorders - pain abdomen	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.4 GI disorders - vomiting	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
12.5 Musculoskeletal and connective tissue disorders - arthralgia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.6 Skin and subcutaneous tissue disorders - rash	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.7 Blood and lymphatic system disorder - agranulocytosis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.8 Blood and lymphatic system disorder - neutropenia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.9 Investigations - AST levels > 2x UNL	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.10 Investigations - ALT levels > 2x UNL	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.11 Investigations - serum creatinine 50% increase from baseline	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.12 Renal and urinary disorders - renal failure	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
13 Discontinuations (# participants affected)	3	179	Risk Ratio (M-H, Fixed, 95% CI)	0.16 [0.01, 2.99]
14 Discontinuation due to an AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
15 Transferrin saturation (%): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
16 Haemoglobin (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
17 Transfusion index (mL/kg/year): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
18 ALP (U/L): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

### Analysis 3.1. Comparison 3 Transfusion-dependent thalassaemia: deferasirox vs deferiprone, Outcome 1 Mortality at any time point.


Study or subgroup	Deferasirox n/N	Deferiprone n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
<b>3.1.1 at 1 year</b>					
			0.01   0.1   1   10   100		
			Favours deferasirox		Favours deferiprone




**Analysis 3.2. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 2 Incidence of thyroid disease at end of study.**




**Analysis 3.3. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 3 ALT (U/L): mean change from baseline.**




**Analysis 3.4. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 4 AST (U/L): mean change from baseline.**




**Analysis 3.5. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 5 Urea (mg/dL): mean change from baseline.**




**Analysis 3.6. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 6 Creatinine (mg/dL): mean change from baseline.**




**Analysis 3.7. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 7 Neutrophil (count per mm<sup>3</sup>): mean change from baseline.**




**Analysis 3.8. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 8 Serum ferritin (ng/mL): mean change from baseline and at end of study.**







**Analysis 3.9. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 9 LIC (mg/g) evaluated by MRI (R2\*): mean change from baseline.**




**Analysis 3.10. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 10 Myocardial T2\* (ms): mean change from baseline.**




**Analysis 3.11. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 11 Any AE (# participants affected).**




**Analysis 3.12. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 12 AEs.**







**Analysis 3.13. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 13 Discontinuations (# participants affected).**




**Analysis 3.14. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 14 Discontinuation due to an AE (# participants affected).**




**Analysis 3.15. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 15 Transferrin saturation (%): mean at end of study.**




**Analysis 3.16. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 16 Haemoglobin (g/dL): mean at end of study.**



**Analysis 3.17. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 17 Transfusion index (mL/kg/year): mean at end of study.**



**Analysis 3.18. Comparison 3 Transfusion-dependent thalassemia: deferasirox vs deferiprone, Outcome 18 ALP (U/L): mean change from baseline.**







**Comparison 6. Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at any time point	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
1.1 at 12 months	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Neutrophil (µg/L): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 ALT (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4 AST (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5 Serum ferritin: mean at end of study (ng/mL)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6 Discontinuations	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
7 Haemoglobin (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
8 ALP (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected

**Analysis 6.1. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 1 Mortality at any time point.**



**Analysis 6.2. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 2 Neutrophil (µg/L): mean at end of study.**



**Analysis 6.3. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 3 ALT (g/dL): mean at end of study.**

Study or subgroup	Deferasirox + DFO		DFO		Mean Difference		Mean Difference Fixed, 95% CI			
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI					
Molavi 2014	46	61.6 (29.8)	48	54.6 (20)			7.02[-3.27,17.31]			
Favours deferasirox + DFO					-10	-5	0	5	10	Favours DFO

**Analysis 6.4. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 4 AST (g/dL): mean at end of study.**

Study or subgroup	Deferasirox + DFO		DFO		Mean Difference		Mean Difference Fixed, 95% CI			
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI					
Molavi 2014	46	59.2 (21)	48	51.8 (18.6)			7.38[-0.66,15.42]			
Favours deferasirox + DFO					-10	-5	0	5	10	Favours DFO

**Analysis 6.5. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 5 Serum ferritin: mean at end of study (ng/mL).**

Study or subgroup	Deferasirox + DFO		DFO		Mean Difference		Mean Difference Fixed, 95% CI			
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI					
Molavi 2014	46	3529 (1540.4)	48	3441.2 (1910)			87.84[-612.23,787.91]			
Favours deferasirox + DFO					-1000	-500	0	500	1000	Favours DFO

**Analysis 6.6. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 6 Discontinuations.**

Study or subgroup	Deferasirox + DFO		DFO		Risk Ratio		Risk Ratio M-H, Fixed, 95% CI			
	n/N		n/N		M-H, Fixed, 95% CI					
Molavi 2014	0/46		0/48				Not estimable			
Favours deferasirox + DFO					0.01	0.1	1	10	100	Favours DFO

**Analysis 6.7. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 7 Haemoglobin (g/dL): mean at end of study.**

Study or subgroup	Deferasirox + DFO		DFO		Mean Difference		Mean Difference Fixed, 95% CI			
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI					
Molavi 2014	46	9.1 (0.9)	48	9.5 (0.8)			-0.36[-0.7,-0.02]			
Favours DFO					-0.5	-0.25	0	0.25	0.5	Favours deferasirox + DFO

**Analysis 6.8. Comparison 6 Transfusion-dependent thalassemia: deferasirox + deferoxamine vs deferoxamine, Outcome 8 ALP (g/dL): mean at end of study.**


Study or subgroup	Deferasirox + DFO		DFO		Mean Difference		Mean Difference			
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI			
Molavi 2014	46	431.8 (136)	48	334 (117.7)			97.78[46.27,149.29]			
Favours deferasirox + DFO					-200	-100	0	100	200	Favours DFO

**Comparison 7. Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine**


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at any time point	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
1.1 at 12 months	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Serum ferritin (ng/mL): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4 Myocardial T2* (ms): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5 Serious AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
6 Serious drug-related AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
6.1 Cholecystitis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Serious non-related drug AE	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
7.1 Appendicitis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
8 AEs	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
8.1 Blood and lymphatic system disorder - agranulocytosis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
8.2 Blood and lymphatic system disorder - neutropenia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
9 Drug-related AEs (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
10 Drug-related AEs	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
10.1 Blood and lymphatic system disorders - agranulocytosis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.2 Blood and lymphatic system disorders - neutropenia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.3 GI disorders - GI problems	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.4 Investigations - ALT increase (≥ 3 folds)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.5 Investigations - serum creatinine (≥ 33%) above baseline in 2 consecutive occasions	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.6 Musculoskeletal and connective tissue disorders - arthralgia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.7 Skin and subcutaneous tissue disorders - skin rash	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
11 Non-related drug AEs (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
12 Non-related drug AEs	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
12.1 Infections and infestations - infections	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.2 GI disorders	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.3 Skin and subcutaneous tissue disorders	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
13 Mild elevation of hepatic transaminases at start of therapy (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
14 Initial gastrointestinal manifestations (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
15 Quality of life (%) (measured by SF-36): mean change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
16 Adherence: actual dose/total prescribed dose	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
17 Discontinuations	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
18 Serious AE resulting in study discontinuation or interruption	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected


**Analysis 7.1. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 1 Mortality at any time point.**




**Analysis 7.2. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 2 Serum ferritin (ng/mL): mean change from baseline.**




**Analysis 7.3. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 3 LIC (mg/g) evaluated by MRI (R2\*): mean change from baseline.**




**Analysis 7.4. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 4 Myocardial T2\* (ms): mean change from baseline.**




**Analysis 7.5. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 5 Serious AE (# participants affected).**




**Analysis 7.6. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 6 Serious drug-related AE (# participants affected).**




**Analysis 7.7. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 7 Serious non-related drug AE.**




**Analysis 7.8. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 8 AEs.**




**Analysis 7.9. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 9 Drug-related AEs (# participants affected).**




**Analysis 7.10. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 10 Drug-related AEs.**







**Analysis 7.11. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 11 Non-related drug AEs (# participants affected).**




**Analysis 7.12. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 12 Non-related drug AEs.**




**Analysis 7.13. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 13 Mild elevation of hepatic transaminases at start of therapy (# participants affected).**




**Analysis 7.14. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 14 Initial gastrointestinal manifestations (# participants affected).**




**Analysis 7.15. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 15 Quality of life (%) (measured by SF-36): mean change from baseline.**



**Analysis 7.16. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 16 Adherence: actual dose/total prescribed dose.**



**Analysis 7.17. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 17 Discontinuations.**





**Analysis 7.18. Comparison 7 Transfusion-dependent thalassemia: deferasirox + deferiprone vs deferiprone + deferoxamine, Outcome 18 Serious AE resulting in study discontinuation or interruption.**

Study or subgroup	Deferasirox + deferiprone n/N	Deferiprone + DFO n/N	Risk Ratio	
			M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Elalfy 2015b	0/48	0/48	Not estimable	

**Comparison 8. Non-transfusion-dependent thalassemia: deferasirox vs placebo**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<b>1 Mortality at any time point</b>	1	148	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.1 Deferasirox 5 mg/kg/day: at 12 months	1	73	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Deferasirox 10 mg/kg/day: at 12 months	1	75	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>2 Serum ferritin (ng/mL): mean change from baseline</b>	1	154	Mean Difference (IV, Fixed, 95% CI)	-306.74 [-398.23, -215.24]
2.1 Deferasirox 5 mg/kg/day	1	78	Mean Difference (IV, Fixed, 95% CI)	-259.1 [-377.35, -140.85]
2.2 Deferasirox 10 mg/kg/day	1	76	Mean Difference (IV, Fixed, 95% CI)	-377.79 [-522.21, -233.37]
<b>3 LIC (mg Fe/g dw) evaluated by MRI R2: least squares mean change from baseline</b>	1	159	Mean Difference (IV, Fixed, 95% CI)	-3.27 [-4.44, -2.09]
3.1 Deferasirox 5 mg/kg/day	1	78	Mean Difference (IV, Fixed, 95% CI)	-2.33 [-4.00, -0.66]
3.2 Deferasirox 10 mg/kg/day	1	81	Mean Difference (IV, Fixed, 95% CI)	-4.18 [-5.83, -2.53]
<b>4 LIC (mg Fe/g dw) evaluated by MRI R2: mean change from baseline</b>	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 Non-transfusion-dependent $\beta$ -thalassemia 5 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Non-transfusion-dependent $\beta$ -thalassemia 10 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.3 $\alpha$ -thalassemia 5 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.4 $\alpha$ -thalassemia 10 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.5 HbE/ $\beta$ -thalassemia 5 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.6 HbE/ $\beta$ -thalassemia 10 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.7 < 18 years 5 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.8 < 18 years 10 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.9 $\geq$ 18 years 5 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.10 $\geq$ 18 years 10 mg/kg/day	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 LIC: decrease of $\geq$ 3 mg Fe/g dw (# participants affected)	1	166	Risk Ratio (M-H, Fixed, 95% CI)	4.16 [1.90, 9.11]
5.1 Deferasirox 5 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	3.05 [0.98, 9.50]
5.2 Deferasirox 10 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	5.26 [1.76, 15.71]
6 LIC: $\geq$ 30% reduction Fe/g dw (# participants affected)	1	166	Risk Ratio (M-H, Fixed, 95% CI)	14.17 [2.88, 69.74]
6.1 Deferasirox 5 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	15.02 [0.93, 242.87]
6.2 Deferasirox 10 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	13.75 [1.97, 95.97]
7 LIC: shift to lower iron burden range (# participants affected)	1	166	Risk Ratio (M-H, Fixed, 95% CI)	3.35 [1.62, 6.91]
7.1 Deferasirox 5 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	3.39 [1.10, 10.45]
7.2 Deferasirox 10 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	3.31 [1.28, 8.55]
8 LIC: achieve LIC < 5 mg Fe/g dw (# participants affected)	1	166	Risk Ratio (M-H, Fixed, 95% CI)	5.35 [1.30, 21.99]
8.1 deferiasirox 5mg/kg/d	1	83	Risk Ratio (M-H, Fixed, 95% CI)	4.07 [0.54, 30.96]
8.2 deferiasirox 10mg/kg/d	1	83	Risk Ratio (M-H, Fixed, 95% CI)	6.62 [0.91, 48.05]
9 Drug-related serious AEs (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
10 Drug-related serious AEs (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
10.1 GI disorders - abdominal pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.2 Infections and infestations - cellulitis	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.3 Skin and subcutaneous tissue disorders - pruritus	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.4 Skin and subcutaneous tissue disorders - rash	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.5 General disorders - pyrexia	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.6 Hepatobiliary disorders - hepatotoxicity	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
11 Any AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
12 Mild AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
13 Moderate AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
14 Severe AE (# participants affected)	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
15 AEs	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
15.1 Ear and labyrinth disorders - neurosensory deafness	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.2 Investigations - abnormal platelet count (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.3 Investigations - abnormal neutrophils count (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.4 Investigations - abnormal ALT (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.5 Investigations - abnormal AST (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.6 Investigations - abnormal serum creatinine (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.7 Investigations - abnormal creatinine clearance (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.8 Investigations - urinary protein/creatinine ratio (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.9 Investigations - abnormal (low) systolic blood pressure (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
15.10 Investigations - abnormal (high) systolic blood pressure (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.11 Investigations - abnormal (low) diastolic blood pressure (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.12 Investigations - abnormal (high) diastolic blood pressure (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.13 Investigations - abnormal (low) pulse rate (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.14 Investigations - abnormal (high) pulse rate (post-baseline)	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
15.15 Renal and urinary disorders - proteinuria	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>16 Drug-related AEs</b>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
16.1 GI disorders - abdominal pain	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
16.2 GI disorders - abdominal pain upper	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
16.3 GI disorders - diarrhoea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
16.4 GI disorders - nausea	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
16.5 Nervous system disorders - headache	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
16.6 Skin and subcutaneous tissue disorders - skin rash	1		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
<b>17 Adherence (# participants taking the planned study dose)</b>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
<b>18 Discontinuations</b>	1	166	Risk Ratio (M-H, Fixed, 95% CI)	1.32 [0.50, 3.52]
18.1 Deferasirox 5 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	1.19 [0.33, 4.25]
18.2 Deferasirox 10 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	1.53 [0.33, 7.08]
<b>19 Discontinuing study due to AE (# participants affected)</b>	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
<b>20 Dose increase</b>	1	166	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.63, 1.19]
20.1 Deferasirox 5 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.57, 1.38]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
20.2 Deferasirox 10 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.54, 1.33]
<a href="#">21 Dose interruption (at least once)</a>	1	166	Risk Ratio (M-H, Fixed, 95% CI)	1.10 [0.88, 1.39]
21.1 Deferasirox 5 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.73, 1.43]
21.2 Deferasirox 10 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	1.19 [0.87, 1.62]
<a href="#">22 Dose reduction</a>	1	166	Risk Ratio (M-H, Fixed, 95% CI)	1.46 [0.70, 3.06]
22.1 Deferasirox 5 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	1.53 [0.54, 4.30]
22.2 Deferasirox 10 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	1.4 [0.49, 4.00]
<a href="#">23 Dose reduction due to AE</a>	1	166	Risk Ratio (M-H, Fixed, 95% CI)	1.53 [0.69, 3.38]
23.1 Deferasirox 5 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	2.04 [0.63, 6.63]
23.2 Deferasirox 10 mg/kg/day	1	83	Risk Ratio (M-H, Fixed, 95% CI)	1.15 [0.39, 3.39]
<a href="#">24 Haemoglobin (g/L): mean change from baseline</a>	1	144	Mean Difference (IV, Fixed, 95% CI)	1.54 [-0.82, 3.90]
24.1 Deferasirox 5 mg/kg/day	1	71	Mean Difference (IV, Fixed, 95% CI)	1.00 [-2.31, 4.31]
24.2 Deferasirox 10 mg/kg/day	1	73	Mean Difference (IV, Fixed, 95% CI)	2.10 [-1.27, 5.47]
<a href="#">25 Transferrin saturation (%): mean change from baseline</a>	1	141	Mean Difference (IV, Fixed, 95% CI)	-7.10 [-11.71, -2.50]
25.1 Deferasirox 5 mg/kg/day	1	70	Mean Difference (IV, Fixed, 95% CI)	-7.16 [-12.95, -1.37]
25.2 Deferasirox 10 mg/kg/day	1	71	Mean Difference (IV, Fixed, 95% CI)	-7.01 [-14.59, 0.57]


**Analysis 8.1. Comparison 8 Non-transfusion-dependent thalassaemia: deferasirox vs placebo, Outcome 1 Mortality at any time point.**

Study or subgroup	Deferasirox n/N	Placebo n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% CI
<b>8.1.1 Deferasirox 5 mg/kg/day: at 12 months</b>					
Taher 2012	0/48	0/25			Not estimable
<b>Subtotal (95% CI)</b>	<b>48</b>	<b>25</b>			<b>Not estimable</b>
Total events: 0 (Deferasirox), 0 (Placebo)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
<b>8.1.2 Deferasirox 10 mg/kg/day: at 12 months</b>					
Taher 2012	0/49	0/26			Not estimable


Favours deferasirox    0.01    0.1    1    10    100    Favours placebo




**Analysis 8.2. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 2 Serum ferritin (ng/mL): mean change from baseline.**




**Analysis 8.3. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 3 LIC (mg Fe/g dw) evaluated by MRI R2: least squares mean change from baseline.**







**Analysis 8.4. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 4 LIC (mg Fe/g dw) evaluated by MRI R2: mean change from baseline.**



**Analysis 8.5. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 5 LIC: decrease of  $\geq 3$  mg Fe/g dw (# participants affected).**




**Analysis 8.6. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 6 LIC:  $\geq 30\%$  reduction Fe/g dw (# participants affected).**







**Analysis 8.7. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 7 LIC: shift to lower iron burden range (# participants affected).**




**Analysis 8.8. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 8 LIC: achieve LIC < 5 mg Fe/g dw (# participants affected).**




**Analysis 8.9. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 9 Drug-related serious AEs (# participants affected).**




**Analysis 8.10. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 10 Drug-related serious AEs (# participants affected).**




**Analysis 8.11. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 11 Any AE (# participants affected).**




**Analysis 8.12. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 12 Mild AE (# participants affected).**




**Analysis 8.13. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 13 Moderate AE (# participants affected).**




**Analysis 8.14. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 14 Severe AE (# participants affected).**




**Analysis 8.15. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 15 AEs.**






**Analysis 8.16. Comparison 8 Non-transfusion-dependent thalassaemia: deferasirox vs placebo, Outcome 16 Drug-related AEs.**



**Analysis 8.17. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 17 Adherence (# participants taking the planned study dose).**

Study or subgroup	Deferasirox n/N	Placebo n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Taher 2012	104/110	54/56		0.98[0.92,1.05]
		Favours placebo	1	Favours deferasirox


**Analysis 8.18. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 18 Discontinuations.**




**Analysis 8.19. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 19 Discontinuing study due to AE (# participants affected).**

Study or subgroup	Deferasirox n/N	Placebo n/N	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
Taher 2012	6/110	2/56		1.53[0.32,7.32]
		Favours deferasirox	0.01    0.1    1    10    100	Favours placebo


**Analysis 8.20. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 20 Dose increase.**




**Analysis 8.21. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 21 Dose interruption (at least once).**




**Analysis 8.22. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 22 Dose reduction.**




**Analysis 8.23. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 23 Dose reduction due to AE.**



**Analysis 8.24. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 24 Haemoglobin (g/L): mean change from baseline.**



**Analysis 8.25. Comparison 8 Non-transfusion-dependent thalassemia: deferasirox vs placebo, Outcome 25 Transferrin saturation (%): mean change from baseline.**





## APPENDICES

### Appendix 1. Search strategies August 2015

MEDLINE (via OvidSP)	
#1	deferasirox*.mp.
#2	(ICL670* or ICL 670*).mp.
#3	(CGP72670* or CGP 72670*).mp.
#4	exjade*.mp.
#5	desirox*.mp.
#6	jadenu*.mp.
#7	2-hydroxyphenyl.mp.
#8	triazol-1-yl.mp.
#9	benzoic acid.mp.
#10	7 and 8 and 9
#11	1 or 2 or 3 or 4 or 5 or 6 or 10
#12	(2010* or 2011* or 2012* or 2013* or 2014* or 2015*).ed,ep,dc. or ("2010" or "2011" or "2012" or "2013" or "2014" or "2015").yr.
#13	11 and 12
#14	randomized controlled trial.pt.
#15	controlled clinical trial.pt.
#16	randomi#ed.ab.
#17	placebo.ab.
#18	drug therapy.fs.
#19	randomly.ab.
#20	trial.ab.
#21	groups.ab.
#22	14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
#23	exp animals/ not humans.sh.
#24	22 not 23
#25	13 and 24

(Continued)

**Notes**

date searched: August 06, 2015

Time-span: 2010-2015

**MEDLINE Daily Update (via OvidSP)**

#1	deferasirox*.mp.
#2	(ICL670* or ICL 670*).mp.
#3	(CGP72670* or CGP 72670*).mp.
#4	exjade*.mp.
#5	desirox*.mp.
#6	jadenu*.mp.
#7	2-hydroxyphenyl.mp.
#8	triazol-1-yl.mp.
#9	benzoic acid.mp.
#10	7 and 8 and 9
#11	1 or 2 or 3 or 4 or 5 or 6 or 10

**Notes**

date searched: August 06, 2015

**MEDLINE In-Process and Other Non-Indexed Citations (via OvidSP)**

#1	deferasirox*.mp.
#2	(ICL670* or ICL 670*).mp.
#3	(CGP72670* or CGP 72670*).mp.
#4	exjade*.mp.
#5	desirox*.mp.
#6	jadenu*.mp.
#7	2-hydroxyphenyl.mp.
#8	triazol-1-yl.mp.
#9	benzoic acid.mp.

(Continued)

#10	7 and 8 and 9
#11	1 or 2 or 3 or 4 or 5 or 6 or 10

**Notes**

date searched: August 06, 2015

**Embase (via OvidSP)**

#1	deferasirox/
#2	DEFERASIROX*.mp.
#3	(ICL670* or ICL 670*).mp.
#4	(CGP72670* or CGP 72670*).mp.
#5	desirox*.mp.
#6	exjade*.mp.
#7	jadenu*.mp.
#8	2-HYDROXYPHENYL.mp.
#9	TRIAZOL-1-YL.mp.
#10	BENZOIC ACID.mp.
#11	8 and 9 and 10
#12	1 or 2 or 3 or 4 or 5 or 6 or 7 or 11
#13	limit 12 to yr="2010 -Current"
#14	(RANDOM* or PLACEBO* or DOUBLE-BLIND*).mp.
#15	13 and 14
#16	limit 15 to medline
#17	15 not 16

**Notes**

date searched: August 06, 2015

Time-span: 2010-2015

**PubMed –subset “supplied by publisher”**

#1	Search <b>deferasirox*[tw]</b>
#2	Search <b>(ICL670*[tw] OR ICL 670*[tw])</b>

(Continued)

#3 Search **(CGP72670\*[tw] OR CGP 72670\*[tw])**

#4 Search **exjade\*[tw]**

#5 Search **desirox\*[tw]**

#6 Search **jadenu\*[tw]**

#7 Search **2-hydroxyphenyl[tw]**

#8 Search **triazol-1-yl[tw]**

#9 Search **benzoic acid[tw]**

#10 Search **(#7 AND #8 AND #9)**

#11 Search **(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #10)**

#12 Search **(# 11 AND publisher[sb])**

**Notes**

date searched: August 06, 2015

**Cochrane Library (via Wiley: [www.thecochranelibrary.com](http://www.thecochranelibrary.com))**

#1 deferasirox\*

#2 ICL670\* or (ICL next 670\*)

#3 CGP72670\* or (CGP next 72670\*)

#4 exjade\*

#5 desirox\*

#6 jadenu\*

#7 2 next hydroxyphenyl

#8 triazol next 1 next yl

#9 benzoic next acid

#10 (#7 and #8 and #9)

#11 (#1 or #2 or #3 or #4 or #5 or #6 or #10)

#12 #11 Publication Year from 2010 to 2015 (Word variations have been searched)

**Notes**

date searched: August 06, 2015

Time-span: 2010-2015

**Biosis Previews (via Thomson Reuters)**

(Continued)

#1	ts=deferasirox*
#2	ts=(ICL670* or "ICL 670*")
#3	ts=(CGP72670* or "CGP 72670*")
#4	ts=exjade*
#5	ts=desirox*
#6	ts=jadenu*
#7	ts="2-hydroxyphenyl"
#8	ts="triazol-1-yl"
#9	ts="benzoic acid"
#10	#7 AND #8 AND #9
#11	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #10
#12	ts=(rando* or placebo or trial or "single-blind*" or "double-blind*" or groups)
#13	#11 AND #12

**Notes**

date searched: August 06, 2015

Time-span: 2010-2015

**Web of Science Core Collection (via Web of Science, Thomson Reuters)**

#1	ts=deferasirox*
#2	ts=(ICL670* or "ICL 670*")
#3	ts=(CGP72670* or "CGP 72670*")
#4	ts=exjade*
#5	ts=desirox*
#6	ts=jadenu*
#7	ts="2-hydroxyphenyl"
#8	ts="triazol-1-yl"
#9	ts="benzoic acid"
#10	#7 AND #8 AND #9
#11	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #10

(Continued)

#12	ts=(rando* or placebo or trial or "single-blind*" or "double-blind*" or groups)
-----	---

#13	#11 AND #12
-----	-------------

**Notes**

date searched: August 06, 2015

Time-span: 2010-2015

**Appendix 2. Search strategies June 2010**
**MEDLINE and Medline In-Process (via Ovid)**

#1	deferasirox*.mp
#2	(ICL670* or ICL 670*).mp
#3	(CGP72670* or CGP 72670*).mp
#4	exjade*.mp
#5	2-hydroxyphenyl.mp
#6	triazol-1-yl.mp
#7	benzoic acid.mp
#8	and/5-7
#9	or/1-4,8
#10	remove duplicates from 9

**Notes**

.mp = title, original title, abstract, name of substance word, subject heading word, unique identifier

The chemical substance name "4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl) benzoic acid" was searched by splitting it up in searchable terms (2-hydroxyphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #8).

searched Medline 1950 to June Week 3 2010, Medline in Process and Other Non-Indexed Citations to June 25, 2010

date searched: June 28, 2010

**EMBASE (via Ovid)**

#1	deferasirox*.mp
----	-----------------

(Continued)

#2	(ICL670* or ICL 670*).mp
#3	(CGP72670* or CGP 72670*).mp
#4	exjade*.mp
#5	2-hydroxyphenyl.mp
#6	triazol-1-yl.mp
#7	benzoic acid.mp
#8	and/5-7
#9	or/1-4,8
#10	remove duplicates from 9

**Notes**

.mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name

The chemical substance name "4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl) benzoic acid" was searched by splitting it up in searchable terms (2-hydroxyphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #8).

searched 1980 to 2010 Week 24

date searched: June 24, 2010

**BIOSIS Previews (via Ovid)**

#1	deferasirox*.mp
#2	(ICL670* or ICL 670*).mp
#3	(CGP72670* or CGP 72670*).mp
#4	exjade*.mp
#5	2-hydroxyphenyl.mp
#6	triazol-1-yl.mp
#7	benzoic acid.mp
#8	and/5-7
#9	or/1-4,8
#10	remove duplicates from 9

**Notes**

(Continued)

.mp = abstract, biosystematic codes, original language book title (non-english), book title (english), chemicals & biochemicals, concept codes, diseases, geopolitical locations, gene name, major concepts, miscellaneous descriptors, methods & equipment, organisms, parts, structures & systems of organisms, sequence data, super taxa, title, time, taxa notes

The chemical substance name "4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl) benzoic acid" was searched by splitting it up in searchable terms (2-hydroxyphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #8).

searched 1969 to 2010 Week 29

date searched: June 28, 2010

---

### Cochrane Library (via Wiley Interscience)

#1	deferasirox*
#2	ICL670* or ICL next 670*
#3	CGP72670* or CGP next 72670*
#4	exjade*
#5	2-hydroxyphenyl
#6	triazol-1-yl
#7	benzoic acid
#8	(#5 AND #6 AND #7)
#9	(#1 OR #2 OR #3 OR #4 OR #8)

### Notes

The chemical substance name "4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl) benzoic acid" was searched by splitting it up in searchable terms (2-hydroxyphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #8).

Issues searched: Cochrane Database of Systematic Reviews 2010, Issue 6; other Cochrane Library Databases 2010 Issue 2

date searched: June 29, 2010

---

### Web of Science (via Thomson Reuters)

#1	ts=deferasirox*
#2	ts=(ICL670* or "ICL 670*")
#3	ts=(CGP72670* or "CGP 72670*")
#4	ts=exjade*
#5	ts="2-hydroxyphenyl"



(Continued)

#6	ts="triazol-1-yl"
#7	ts="benzoic acid"
#8	#5 AND #6 AND #7
#9	#1 OR #2 OR #3 OR #4 OR #8

**Notes**

ts = topic

The chemical substance name "4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl) benzoic acid" was searched by splitting it up in searchable terms (2-hydroxyphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #8).

searched 1945 to June 26, 2010

date searched: June 30, 2010

**Derwent Drug File and XTOXLINE (via DIMDI)**

#1	deferasirox* (text field)
#2	ICL670* or ICL 670* (text field)
#3	CGP72670* or CGP 72670* (text field)
#4	exjade* (text field)
#5	2-hydroxyphenyl (text field)
#6	triazol-1-yl (text field)
#7	benzoic acid (text field)
#8	#5 and #6 and #7
#9	#1 or #2 or #3 or #4 or #8

**NOTES**

The chemical substance name "4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl) benzoic acid" was searched by splitting it up in searchable terms (2-hydroxyphenyl, triazol-1-yl, benzoic acid) and combining those by AND (lines #5 - #8).

searched Derwent Drug File January 1, 1983 - June 23, 2010, XTOXLINE January 1, 1965 - June 29, 2010

date searched: July 1, 2010

**WHAT'S NEW**

Date	Event	Description
20 July 2017	New search has been performed	<p>Inclusion criteria adapted to people with thalassaemia intermedia.</p> <p>The search strategy was expanded and 12 new studies (1103 participants) were included (Chirico 2013; Elalfy 2015a; Elalfy 2015b; Habibian 2014; Hassan 2016; Kakkar 2014; Molavi 2013; Molavi 2014; Peng 2013; Pennell 2014; Sanjeeva 2015; Taher 2012;).</p> <p>Five additional comparisons were included for people with thalassaemia major:</p> <ul style="list-style-type: none"> <li>• deferasirox versus deferiprone;</li> <li>• deferasirox versus deferasirox + deferiprone;</li> <li>• deferasirox + deferiprone versus deferiprone;</li> <li>• deferasirox + deferoxamine versus deferoxamine;</li> <li>• deferasirox + deferiprone versus deferiprone + deferoxamine.</li> </ul> <p>One comparison was included for people with thalassaemia intermedia:</p> <ul style="list-style-type: none"> <li>• deferasirox versus placebo.</li> </ul>
20 July 2017	New citation required but conclusions have not changed	The inclusion of new trials did not significantly alter the conclusions of the review.

## HISTORY

Protocol first published: Issue 4, 2008

Review first published: Issue 2, 2012

Date	Event	Description
22 July 2016	Amended	Contact details updated.
22 May 2012	Amended	Contact details updated.
12 August 2009	Amended	Contact details updated.
10 January 2008	New citation required and major changes	Substantive amendment

## CONTRIBUTIONS OF AUTHORS

Joerg Meerpohl: conception, design and coordination of the review. Data collection and data management as well as analysis and interpretation of the data. Writing of the review and approval of the final version.

Claudia Bollig: coordination of the review update. Conduct of the search in August 2015. Data collection and data management as well as analysis and interpretation of the data (update). Writing of the review and approval of the final version (update).

Lisa Schell: data collection and data management (update). Analysis and interpretation of data (update). Approval of final version (update).

Gerta Rücker: statistical advice and methodological support. General advice on the review and approval of the final version.

Roman Allert: data collection (update). Approval of final version.

Edith Motschall: advice on search strategy and conduct of search in June 2010. Approval of final version.

Charlotte Niemeyer: interpretation of the data and clinical expertise. General advice on the review and approval of the final version.

Dirk Bassler: data collection and data management for the previous version. Analysis and interpretation of data. Involvement in writing the review and approval of the final version.

## DECLARATIONS OF INTEREST

Joerg Meerpohl enrolled two adolescents with thalassaemia and one with Diamond-Blackfan anaemia in a post-marketing surveillance study on deferasirox and participated once in a Novartis advisory board meeting on paediatric iron overload prior to 2010.

For the remaining authors: none known.

## SOURCES OF SUPPORT

### Internal sources

- Cochrane, Germany.

### External sources

- National Institute for Health Research, UK.

This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Although these outcomes were not defined a priori, we also extracted: Blood urea, platelet count, neutrophilic count, urinary b-2 microglobulin, urinary N-acetyl-beta-glucosaminidase levels, serum copper, serum zinc, growth and development, transfusion index, haemoglobin, transferrin saturation, ALP levels.

Inclusion criteria adapted to people with non-transfusion dependent thalassaemia.

We defined the number of patients who discontinued treatment as a form of adherence in our 'summary of findings' table.

## INDEX TERMS

### Medical Subject Headings (MeSH)

Administration, Oral; Benzoates [administration & dosage] [adverse effects] [\*therapeutic use]; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine [administration & dosage] [therapeutic use]; Erythrocyte Transfusion [adverse effects]; Ferritins [blood]; Iron Chelating Agents [administration & dosage] [adverse effects] [\*therapeutic use]; Iron Overload [blood] [\*drug therapy] [etiology]; Patient Satisfaction; Pyridones [administration & dosage] [therapeutic use]; Randomized Controlled Trials as Topic; Thalassemia [\*complications] [mortality] [therapy]; Triazoles [administration & dosage] [adverse effects] [\*therapeutic use]

### MeSH check words

Humans